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ABSTRACT 
South Africa has the largest ARV treatment programme in the world, wherein highly active 
antiretroviral treatment (HAART) has improved the health related quality of life (HRQoL) in 
HIV/AIDS patients. On the contrary, cancers not previously associated with HIV/AIDS (non-
Aids defining cancers; NADCs) have been shown to be increasing, compared to the AIDS 
defining cancers (ADCs). Lung cancer, as a NADC has been documented in the HIV/AIDS 
population as a leading malignancy. The poor understanding of the association between ARV 
drugs and lung cancer places a burden on public health, both globally and in South Africa 
(SA). Furthermore, the deregulation of the cell-cycle is one of the hallmarks of cancer, 
including lung cancer. The main aim of this study was to elucidate the effects of HAART 
components Efavirenz (EFV) and Lopinavir/ritonavir (LPV/r) on cell-cycle related genes in an 
in vitro lung cancer model. To achieve this, cellular based, molecular and Bio-Informatics 
approaches were employed. First, the cytotoxic effects of EFV (at 4, 13, 26, 50 µM) and 
LPV/r (at 10, 32, 50, 80 µM), for 24h, 48h and 72h on normal lung fibroblasts (MRC-5)  and 
lung adenocarcinoma (A549) cells, were evaluated using the  Alamar Blue (AB) assay. This 
was then followed by cell-impedance “xCELLigence” real-time cell analysis (RTCA) assay. 
This was done to determine the effects of EFV (at 4, 13, 50 µM) and LPV/r (at 10, 32, 80 µM) 
on cell viability, cell death and proliferation. Cell-cycle analysis using propidium iodide (PI) 
by Fluorescence-activated cell sorting (FACS) was done to quantify DNA present at each of 
the cell-cycle stages of the cell-cycle in response to ARV treatment. Subsequently, an 
apoptosis assay using Annexin V FITC and Propidium iodide (PI) dual staining by FACS was 
carried out to confirm and quantify the ARVs potential apoptotic effects. Then, 4′,6-
diamidino-2-phenylindole (DAPI) staining was used to assess changes in nuclear morphology 
exerted by the ARVs’ effects. A more in depth interrogation of the cell-cycle was performed 
using a focussed gene array panel of some 84 human cell-cycle related genes. First, total RNA 
was isolated from   both treated and untreated MRC-5 and A549 cells and reverse transcribed 
to cDNA for use as template in the PCR array reactions. From the array gene expression 
results, by convention a ±2 fold up-or-down-regulation was used as the basis of target 
selection. Following this, a real-time quantitative PCR (RT-qPCR) validation of selected 
genes of interest was done to quantify and confirm the PCR array results. This was followed 
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by in-silico Bio-informatics analysis to map the molecular pathways regulated by the 
identified targets. For this purpose, STRING, Database for Annotation, Visualization and 
Integrated Discovery (DAVID), Reactome and Ingenuity Pathway Analysis (IPA) databases 
were used.  
Interestingly, double-edged oncogenic properties of both EFV and LPV/r at different 
concentrations were identified. The proliferative effects of EFV at 4, 13µM and LPV/r at10 
µM, were elucidated, while 26, 50µM of EFV, and 32µM of LPV/r had slight inhibitory 
effects on cell proliferation. LPV/r at concentrations of 50 and 80µM exerted cytotoxic effects 
on the cells, as demonstrated by the AB and xCELLigence RTCA assays. Cell-cycle analysis 
using PI staining, particularly showed cell-cycle arrest at 32µM LPV/r, and a shift to G2/M by 
13µM EFV, plasma relevant doses, compared to the untreated cells. An increasing apoptosis 
percentage was observed with increasing LPV/r concentrations, that is, 80µM LPV/r raised   
the apoptosis percentage almost two-fold compared to 32µM. This was coupled by necrosis, 
observed in a time-dependant manner. DAPI staining confirmed loss of nuclear integrity post 
ARV exposure, suggesting that both EFV and LPV/r impose damage to the genomic DNA. To 
further assess the observed changes in nuclear morphology, the effects of EFV and LPV/r on 
the expression of an arrayed panel of human cell-cycle genes in cancer and normal lung cells 
was determined. Significantly differentially expressed targets were identified and further 
quantified and confirmed by RT-qPCR. Such  targets included ATM, p53, cyclin-dependant 
kinase inhibitors (CDKIs), such as, p21, aurora kinase B (AURKB), Mitotic Arrest Deficient-
Like 2 (MAD2L2) and the apoptosis related gene, caspase 3 (CASP3). Bio-Informatics 
analyses revealed close and direct protein-protein interactions (PPIs) between these targets, 
notably, with change in interaction between the gene products involved in DNA repair 
mechanisms, observed between ARV treated and untreated groups, as illustrated by STRING 
interactions. DAVID, Reactome and IPA analysis showed changes in expression of genes 
related to stress and toxicity and DNA damage response genes. In particular, ATM, p53 and 
its downstream targets such as GADD45A (growth arrest and DNA damage inducible alpha) 
gene were up-regulated by ARV treatment, while cyclin/CDK activity was down-regulated, 
resulting in reduced cell proliferation. Thus in summary, both EFV and LPV/r altered the 
expression levels of cell-cycle related genes, influencing overall cellular health, acting to 
either inhibit or stimulate cell proliferation. This suggests EFV’s and LPV/r’s proliferative and 
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inhibitory roles in the proliferation of lung cells. Moreover, future directions can include the 
transfection of lung cells with HIV provirus followed by treatment of the cells with the same 
ARVs under study. This could be substantiated by including HIV positive patient samples on 
and off ARV drug treatment with lung cancer, including HIV negative patients with cancer as 
one of the controls.  
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CHAPTER 1: INTRODUCTION AND 
LITERATURE REVIEW 
 
1.1 INTRODUCTION  
Currently, human immunodeficiency virus/ acquired immunodeficiency syndrome 
(HIV/AIDS) and lung cancer are arising as colliding epidemics and urgent interventions are 
necessary to combat these leading causes of morbidity and mortality. In addition, cancer 
incidence rates are also shown to be increased in people living with HIV/AIDS (PLWA) 
compared to the general population (reviewed in Corti, 2016). To date, there is no cure for 
HIV/AIDS and the highly active antiretroviral treatment (HAART) is the most effective 
regimen. Additionally, there has been a decline in cancers previously associated with 
HIV/AIDS, also known as the AIDS defining cancers (ADCs): including Kaposi’s sarcoma, 
primary central nervous system lymphoma, non-Hodgkin lymphoma, and cervical cancer. On 
the contrary, non-ADCs have been documented to be on the rise in the HAART era, with lung 
cancer emerging as a leading NADC ((reviewed in Corti, 2016), (Rubinstein et al., 2014)). In 
addition, when compared to the same age group in the general population, the risk of 
developing non-small cell lung carcinoma (NSCLC), the most predominant form of lung 
cancer, is higher in HIV positive patients. Furthermore, South Africa has the largest HIV 
epidemic and HAART programme in the world. The poor understanding between the use of 
HAART and tumourigenesis especially lung cancer has placed a burden on public health, 
globally and in South Africa.  
HIV infection accompanied by low CD4 count, smoking and aging, have been eliminated as 
the main risk factors to HAART associated carcinogenesis ((Koegelenberg et al., 2016), 
(Rubinstein et al., 2014)). This has led to the conclusion that lung carcinogenesis in the 
HAART era is a multifactorial process. The deregulation of the cell-cycle is a hallmark of all 
cancers, including lung cancer ((Walter et al., 2015), (Eymin and Gazzeri, 2010)). A few 
previous reports have demonstrated the potential of efavirenz (EFV), (Hecht et al., 2015) and 
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lopinavir/ritonavir (LPV/r), (Chow et al., 2009) to either influence or inhibit cell proliferation 
and alter gene expression (Adefolaju et al., 2014). With no clear evidence as yet, in the 
present study, such recent studies raised the query as to whether the cell-cycle related genes 
controlling cell proliferation and cell death can be targeted as either potential bio-markers or 
HAART associated lung cancer therapeutics. Molecular profiling of lung cancer is a 
promising diagnostic and therapeutic tool in the fight against lung cancer, which still has a 
poor survival rate of 14% (Corti, 2016). The synergic effect of both HIV infection and 
HAART on lung tumourigenesis is not covered in this study. Therefore, in the context of the 
NADCs epidemic and the rising/increasing prevalence of NSCLC, the present study focused 
on investigating the effects of EFV and LPV/r on cell-cycle related genes in lung cancer.  
      
1.2 LITERATURE REVIEW  
1.2. 1 HIV epidemic and prevalence 
It has been more than 55 years since the first proven case of HIV infection and HIV/AIDS 
continues to be a deadly epidemic. Despite medical and social interventions made, the number 
of people living with HIV and AIDS (PLWHA) remains on the rise in the general population. 
To date, there is no cure for HIV/AIDS. However, the highly active antiretroviral treatment 
(HAART) is the most effective regimen against HIV/AIDS (UNAIDS, 2016).  
According to the 2016 Joint United Nations Programme on HIV/AIDS report, 18.2 million 
people had access to the antiretroviral therapy by June 2016, and 36.7 million people 
worldwide were living with HIV by the end of 2015, while 1.1 million people died from 
AIDS-related illnesses in 2015. Since the beginning of the epidemic, 78 million people have 
become infected with HIV, and, almost 46% of all people living with HIV had access to 
treatment by the end of 2015. In 2015, some 77% of pregnant women living with HIV had 
access to antiretroviral (ARV) medicines to prevent mother-to-child transmission of HIV. This 
has resulted in a 50% decline in new HIV infections since 2010. Every year since 2010, about 
1.9 million adults have become newly infected with HIV. Nevertheless, AIDS-related deaths 
since they peaked in 2005 have fallen by 45%, by end of 2015. In East and Southern Africa, 
there were 19 million people living with HIV by the end of 2015, with women accounting for 
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more than half the total number of people living with HIV in this region. Even though in 2015, 
there were an estimated 960000 new HIV infections in Eastern and Southern Africa, there was 
a 14% drop in new HIV infections between 2010 and 2015. Furthermore, Eastern and 
Southern Africa accounts for 46% of the global total of new HIV infections. From 2010 to 
2015, the number of AIDS-related deaths in Eastern and Southern Africa fell by 38%, also 
with 66% decline in HIV infection in children in this region. In sub-Saharan Africa, about 54 
% of HIV positive people accessed HAART. South Africa has the highest burden of HIV 
epidemic in the world, with an estimated 7 million people living with HIV in 2015, Figure 1.1 
(sanac.org.za).   
 
Figure 1.1: The prevalence of HIV/AIDS in South Africa by the year 2015 (adopted from 
UNAIDS Gap Report 2016). 
In the same manner, South Africa has the largest antiretroviral treatment (ART) programme in 
the world. However, HIV prevalence remains high (19.2%) among the general population, 
although it varies significantly between regions, with Kwa-Zulu Natal being highest (40%) 
and Northern Cape being lowest (18 %).   
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1.2.2 Introduction to Highly Active Anti-Retroviral Treatment (HAART) 
Currently, there is no drug capable of curing HIV infections. The Highly Active Antiretroviral 
Therapy (HAART) also known as the combined antiretroviral therapy (cART) is a treatment 
against HIV and consists of three ARV drugs, each from a different class of drugs. These 
classes include; Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Nucleotide/ 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), the Protease Inhibitors (PI’s), Integrase 
or Integrase Strand Transfer Inhibitors (INSTIs), Chemokine Receptor Antagonists (CRAs) 
and  Fusion Inhibitors (FIs) (Karanja et al., 2016). These are summarized diagrammatically 
(Figure 1.2) and each category is further discussed below.    
 
Figure 1.2: Different classes of the ARV drugs, which make up HAART when combined as 
first-line, second-line or third-line of treatment.   
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1.2.2.1 Classes of ARV drugs and mode of action  
There are a number of categories of antiretroviral drugs and these are described below. 
 i) Nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs)  
Nucleoside reverse transcriptase inhibitors (NRTIs), also known as nucleoside analogs or 
“nukes,” contain faulty forms of the building blocks (nucleotides) used by reverse 
transcriptase (RT) enzyme. This enzyme reverse transcribes the viral RNA into 
complementary DNA. RT incorporates the faulty NRTI building blocks, disrupting the DNA 
synthesis of the virus ( reviewed in (Berretta et al., 2016),(Torres and Mulanovich, 2014)).  
ii) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) also called the “non-nukes” bind to 
the RT enzyme. The binding occurs allosterically in a hydrophobic pocket located around 10 
angstroms (Å) from the catalytic site of the p66 subunit of the enzyme all at the equivalent site 
in the RT, in spite of their chemical diversity. In the NNRTI binding site (NNIBP), every 
NNRTI interacts with different amino acid residues (Mounier et al., 2009).  
iii) Protease inhibitors (PIs) 
Protease Inhibitors (PIs) selectively bind to HIV-1 protease and block the proteolytic cleavage 
of protein precursors necessary for the production of new infectious viral particles. The HIV 
protease contains a binding pocket into which drugs bind to inhibit its activity. As HIV 
replicates, mutations occur changing this conformation. This may then prevent or inhibit the 
binding of one or more PIs to the HIV protease. All of the resistance mutations differ with PIs, 
but are all located near the substrate-binding gap of the enzyme. These primary mutations 
cause simultaneous resistance to multiple PIs ((Shafer, 2006), (Kiser et al., 2008)).  
iv) Integrase strand transfer inhibitors (INSTIs) 
Integrase inhibitors also known as Integrase strand transfer inhibitors (INSTIs) block the 
activity of the integrase enzyme. Integrase is a viral enzyme that enables the insertion and 
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integration of the viral genome into the host DNA (Berretta et al., 2016). The INSTIs block 
the integration of viral DNA with host DNA, thus interrupting with the HIV’s spread.   
v) Chemokine receptor type 5 (CCR5) receptor antagonists 
Chemokine (CCR5) receptor antagonists block the CCR5 receptor. The C-C pattern 
chemokine receptors CCR5 and Chemokine receptor type 4 (CXCR4) are the most important 
chemokine receptors implicated in the entry of HIV into host cells (Berretta et al., 2016). The 
virus uses CCR5 mostly during initial infection, while CXCR4 is used in the later HIV 
infection stages (Barmania and Pepper, 2013). These receptors form part of the seven 
transmembrane G-protein-coupled receptor (GPCR) family and are mainly expressed on 
macrophages, T-cells, dendritic cells, and Langerhans cells. They cooperate as co-receptors 
that HIV-1 uses to bind cells before viral fusion and entry (Ritchie et al., 2006). 
vi) Entry/Fusion inhibitors (FIs) 
Fusion inhibitors (FIs) are a class of drugs intended to disrupt the HIV-1 fusion protein 
equipment at the final stage of fusion with the host cell, to prevent the infection of non-
infected cells (Beumer et al., 2014). Fusion inhibitors bind to and block the HIV gp41 
fusogenic protein, thereby inhibiting the viral entry into healthy cells. Enfuvirtide (T20) has 
been used in therapy as FI, and binds to gp41, preventing the fusion of the viral and cellular 
membranes (Harman et al., 2012).  
1.2.2.2 Approved WHO ARV guidelines, 2013-2016 
It is recommended by WHO, with South Africa also adhering to these HAART guidelines, 
that the first-line ART should consist of two nucleoside reverse transcriptase inhibitors 
(NRTIs) and a non-nucleoside reverse-transcriptase inhibitor (NNRTI) (WHO 2015). 
Tenofovir and lamivudine or emtricitabine and efavirenz (TDF + 3TC (or FTC) + EFV) as a 
fixed-dose combination is recommended as the preferred option to initiate ART. While 
second-line ART for adults should consist of two nucleoside reverse-transcriptase inhibitors 
(NRTIs) + a ritonavir-boosted protease inhibitor (PI). It is important to note that in 2016, a 
new ARV based regimen has been launched globally. This treatment includes dolutegravir-an 
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integrase inhibitor based combination that includes the ARVs abacavir and lamivudine 
(DTG/ABC/3TC). It is a three-in-one pill that has been proven to outperform South Africa’s 
current EFV three-in-one combination ARV in effectiveness and tolerability. Patients on the 
dolutegravir-based combination treatment also had been shown to have a lower incidence of 
side effects, for example, psychiatric, skin and gastrointestinal disorders. This new pill can be 
taken with or without food, and patients would still retain the drug concentrations high enough 
in the blood even 72h post their previous dose. This has been proven to be highly effective 
and helps protect patients against the development of drug resistance ((Taha et al., 2015), 
(Barnhart and Shelton, 2015), (Gubavu et al., 2016)).  Furthermore, DTG has all the potential 
to be used as a first-line drug in combination with other nucleoside backbones, especially in 
the form of a single tablet in combination with abacavir (ABC) and lamivudine (3TC) 
((Cottrell et al., 2013), (Taha et al., 2015)). Table 1.1 below shows the ARV drugs under 
different ARV classes.   
 
Table 1.1: The WHO 2016 approved ARV drugs 
NRTIs NNRTIs PIs INSTIs 
3TC lamivudine 
ABC abacavir 
AZT zidovudine 
d4T stavudine 
ddI didanosine 
FTC emtricitabine 
TAF tenofovir 
alafenamide fumarate 
 
EFV efavirenz 
ETV etravirine 
NVP nevirapine 
RIL rilpivirine   
ATV atazanavir 
DRV darunavir 
FPV fosamprenavir 
IDV indinavir 
LPV/r lopinavir/ritonavir 
RTV ritonavir 
SQV saquinavir 
TPV tipranavir  
DTG dolutegravir 
EVG elvitegravir  
RAL raltegravir  
 
 
1.2.3 The use of ARV drugs as chemotherapeutic agents  
The use of anti-HIV drugs as cancer regimes is not new. For instance, 
Azidothymidine/zidovidine (AZT) was studied as an anti-cancer (AC) drug in the 1990s. 
However, this drug demonstrated insignificant anti-tumour activity in clinical trials, even 
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though it was promising with in vitro models. On the other hand, PIs have been documented 
to significantly treat HIV-related Kaposi's sarcoma. The anti-tumorigenic activities of PIs 
were further shown by their ability to inhibit tumour-cell invasion and angiogenesis, inhibition 
of inflammatory cytokine production, proteasome activity, cell proliferation and survival, and 
induction of apoptosis as reviewed in (Chow et al., 2009). The potential anti-cancer properties 
of ARVs are considered below. 
i) Efavirenz and Nevirapine 
NNRTIs such as nevirapine (NVP) and efavirenz (EFV) have been shown to reduce cell 
proliferation, induce morphological differentiation, and reprogram gene expression in 
transformed melanoma and prostate carcinoma cells without inducing apoptosis. Additionally, 
efavirenz was shown to inhibit the growth of xenografted melanoma, prostate, colon, and 
small-cell lung carcinoma tumours in nude mice. Furthermore, NVP and EFV were illustrated 
to significantly retard growth of thyroid cancer cells. In addition, Hetch et al., (2015) 
demonstrated that EFV has the highest anti-proliferative activity as an NNRTI, against 
pancreatic cancer cells.  
ii) Ritonavir 
The anti-tumour activity of ritonavir (like saquinavir and indinavir) was first shown in vitro 
for Kaposi's sarcoma and in vivo for a xenograft mouse model (Pati et al., 2002). Ritonavir 
was shown to inhibit proliferation of primary endothelial cells and induced apoptosis in 
Kaposi's sarcoma cell-lines by inhibiting the production of cytokines that contribute to 
neovascularisation (including TNFα, interleukin 6 (IL6), and vascular endothelial growth 
factor-VEGF) and inhibiting the transcriptional activation of nuclear factor kappa B (NFκB) at 
clinically relevant concentrations (3–15 μM). Similarly with saquinavir, the anti-tumorigenic 
effects of ritonavir seem to be concentration dependent. At lower concentrations (~2.5–μM), 
ritonavir was demonstrated to induce apoptosis and inhibit activation of NFκB in primary 
adult T-cell leukaemia (ATL) cells (Dewan et al., 2006). In a similar manner, breast 
carcinoma is sensitive to ritonavir. The increased sensitivity of oestrogen-receptor-positive 
breast carcinoma cells could be partly explained by ritonavir-mediated downregulation of 
oestrogen-receptor expression. Furthermore, in cell lines both negative and positive for 
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oestrogen receptors, ritonavir induced G1 arrest, reduced expression of cyclin-dependent 
kinases (CDK) 2, 4, and 6 and cyclin D1, induced apoptosis independent of G1 arrest, 
inhibited Akt-phosphorylation, and inhibited the chaperone function of heat shock protein 90 
(Hsp90) (Laurent et al., 2004). In addition, at high concentrations of ritonavir (50–100 μM), 
proliferation of glioma cells was inhibited by blocking G1 and inducing apoptosis. Finally, 
ritonavir inhibited growth of HEP2 head and neck carcinoma in nude mice at high 
concentrations (20–2000 μM). Despite the toxicity of RTV at high concentrations, this drug 
could still be used as an AC drug at low concentrations (Chow et al., 2009). 
iii) Lopinavir 
When administered alone, Lopinavir has insufficient anti-HIV viral activity. However, like 
other HIV protease inhibitors, its blood concentrations are significantly increased by low-dose 
ritonavir boost. Lopinavir was illustrated to inhibit the growth of cervical carcinoma cell lines 
infected with human papilloma virus (HPV) 16. This was achieved by inhibiting the viral E6-
activation of proteasomal degradation of nuclear p53 and followed by induction of apoptosis 
(Chow et al., 2009). 
 
1.2.4 The effect of HAART on cancer: ADCs and NADCs.  
Like any other treatment components, HAART agents are associated with a number of 
adverse effects including; hepatotoxicity, hypersensitivity rash, lactic acid, osteoporosis, 
lipodystrophy, macular disorders, cardiovascular disorders, neurological disorders, liver 
disorders and metabolic abnormalities (Hima Bindu and Naga Anusha, 2011). A rise in 
malignancies both related to and unrelated to HIV-infection and HAART has been 
documented.  
 
1.2.4.1 HAART and ADCs and NADCs 
Even though there’s a decline in the incidence of AIDS-defining cancers (ADCs), including 
Kaposi’s sarcoma, primary central nervous system lymphoma, non-Hodgkin lymphoma, and 
cervical cancer following the introduction of (HAART), this incidence rate is still greater in 
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PLWHA compared to the general population (Rubinstein et al., 2014). The non-AIDS-
defining cancers (NADCs) include those associated with viral infections (such as anal cancer 
caused  by the Human Papilloma Virus (HPV), liver cancer caused by the Hepatitis C (HCV) 
and Hepatitis B Viruses (HBV), head and neck cancer caused by (HPV) and those cancers not 
associated with viral infections (such as  lung and melanoma). NADCs are a leading cause of 
morbidity and mortality for PLWHA ((Clifford et al., 2005), (Herida et al., 2003), (Powles et 
al., 2009), (Lewden et al., 2008), (Rodger et al., 2013)). Longevity and immune status may be 
the associated risk factors. However, these alone are insufficient to fully explain these trends 
in cancer epidemiology. For PLWHA, even those with normal CD4+ T cell counts, the risk 
for many NADCs remains greater than for their age-matched HIV-negative counterparts  
(Powles et al., 2009). Furthermore, compared to the general population, PLWHA present with 
more aggressive and advanced disease at the time of cancer diagnosis. These changes in 
cancer epidemiology are poorly understood. Furthermore, the risk of cancer in PLWHA can 
be defined by the standard incidence ratio (SIR) ((Jones and Swerdlow, 1998), (Rubinstein et 
al., 2014)). For malignancies in HIV, the SIR compares the rate of cancers in the HIV/AIDS 
population to the number expected in the general population at any given time (Shiels et al., 
2011). In the HAART era, the SIR has decreased for all ADCs, with the exception of invasive 
cervical carcinoma (Powles et al., 2009). When PLWHA are compared to recipients of solid 
organ transplants, both populations have similar risks for KS and NHL as well as certain 
NADCs including HL, anal, liver and lung cancer (Grulich et al., 2007). However, in the case 
of lung cancer, even when correcting for cigarette smoking, the incidence remains greater in 
PLWHA than in the general population, although no correlation between low CD4+ T cell 
count and lung cancer risk has been identified (Kirk et al., 2007). The etiological factors that 
contribute to both ADCs and NADCs are multifactorial. PLWHA are susceptible to infection 
by oncogenic viruses. Kaposi sarcoma-associated herpes virus (KSHV) or human herpes virus 
8 (HHV-8), Epstein Barr Virus (EBV), HPV, and hepatitis B and C viruses are implicated in 
various ADCs and NADCs and are more prevalent in PLWHA than the general population 
((El-Serag, 2012)), (Guech-Ongey et al., 2010). These viruses can alter apoptosis and cell-
cycle regulation, activate oncogenes, and inhibit the activity of tumor suppressor genes. In 
addition, viruses associated with ADCs and NADCs can also express micro-ribonucleic acids 
(miRNAs), which are small non-coding RNAs that act as negative regulators of protein 
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synthesis by covalently binding to single-stranded mRNA ((Bartel, 2009), (Qi et al., 2006)). 
Interestingly, HIV has also been implicated in inhibiting the p53 tumour suppressor gene, 
altering cell-cycle regulation, and activating proto-oncogenes that can lead to cellular 
transformation (Amini et al., 2004).  
 
1.2.5 Cancer 
According to the World Health Organization (WHO) 2015, cancer remains one of the leading 
causes of morbidity and mortality globally, with approximately 14 million new cases and 8.2 
million cancer related deaths by the end of 2012. The WHO estimates that the number of new 
cases is expected to rise by about 70% over the next 2 decades, from 14 million in 2012 to 22 
million. In men, the 5 most common sites of cancer diagnosed in 2012 were lung, prostate, 
colorectum, stomach, and liver cancer (WHO 2015). Among women, breast, colorectum, lung, 
cervix, and stomach cancers were the most diagnosed types of cancer.  Around one third of 
cancer deaths are due to the 5 leading behavioral and dietary risks, which are high body mass 
index (BMI), low fruit and vegetable intake, lack of physical activity, tobacco use and alcohol 
use (WHO 2015), while cancer causing viral infections such as HBV/HCV and HPV are 
responsible for up to 20% of cancer deaths in low- and middle-income countries. It has also 
been documented by WHO (2015) that more than 60% of the world’s total new annual cases 
occur in Africa, Asia, Central and South America. In addition, these regions account for 70% 
of the world’s cancer deaths.  
1.2.5.1 Causes of cancer 
Cancer arises from one single cell. The transformation from a normal cell into a tumour cell is 
a multistep process, progression from a pre-cancerous lesion to malignant tumours (Hashim et 
al., 2016). The acquired changes  are a result of the interaction between a person's genetic 
factors and external factors which include physical carcinogens, such as ultraviolet and 
ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, 
aflatoxin (a food contaminant), arsenic (a drinking water contaminant); and biological 
carcinogens, such as infections from certain viruses, bacteria or parasites.   
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Cancer remains a leading cause of mortality in South Africa as well. According to the Cancer 
Association of South Africa (CANSA) 2016, one in four South Africans are affected by 
cancer through diagnosis of family, friends or self. More than 100 000 South Africans are 
diagnosed with cancer every year, and the survival rate of South African cancer patients is 6 
out of 10. Globally and in South Africa, lung cancer is prevalent in both men and women and 
remains the leading cause of mortality ((WHO 2016), (CANSA 2016), (Hashim et al., 2016)).   
1.2.5.2 The hallmarks of cancer 
The hallmarks of cancer, acquired during the multistage tumour developmental process 
include;  sustained proliferative signaling, evasion of growth suppressors, enabling replicative 
immortality, induction of angiogenesis, and activation of invasion and metastasis, resisting 
cell-death and deregulating the cell-cycle.  ((Hanahan and Weinberg, 2000), (Hanahan and 
Weinberg, 2011)).  
 
1.2.6 Cell division and the cell-cycle  
An adult human is built from about 10
13
 cells which were generated through cell divisions 
from a single cell, the fertilized egg. The proper regulation of cell division is essential towards 
producing large number of cells and also generating distinct cell types. Thus the cell division 
processes can either be symmetric or asymmetric. A diversity of cell types is generated 
through asymmetric cell division, during which daughter cells inherit different cellular 
components such as proteins, RNAs and organelles ((Noatynska et al., 2013), (Barnum and 
O'Connell, 2014)). Cells divide through a series of stages (events) known as the cell-cycle.  
1.2.6.1 Introduction to the cell-cycle 
The cell-cycle is the series of events in which cellular components are doubled, and then 
segregated accurately into the daughter cells. The replication of DNA forms part of this 
fundamental process. In eukaryotes, DNA is replicated during the Synthesis or S-phase, and 
then chromosome segregation occurs during Mitosis or M phase. Two Gap phases separate S 
phase and M phase, known as Gap 1(G1) and Gap 2 (G2) (Noatynska et al., 2013). 
Furthermore, the gap phases are not periods of inactivity, but rather phases where cells obtain 
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mass, integrate growth signals, organize a replicated genome, and prepare for chromosome 
segregation, Figure 1.3. The progression of the cell-cycle is tightly regulated by its 
checkpoints, the G1/S, G2/M and the mitotic spindle assembly checkpoint (SAC).  
 
Figure 1.3: Diagrammatic representation of the cell-cycle.  The cell-cycle is divided into the 
G1, G2, S and the M phases. The numbers denote the cell-cycle checkpoints with (1) 
representing the G1/S checkpoint, (2) indicating the G2/M checkpoint and (3) showing the 
mitotic spindle assembly checkpoint (SAC) (Own figure).  
 
The progression of the cell-cycle is driven by the cyclin-dependent kinases (CDKs). These are 
serine/threonine protein kinases that phosphorylate key substrates to promote DNA synthesis 
and mitotic progression ((Fisher et al., 2012), (Malumbres and Barbacid, 2009)). The CDKs 
are active when bound to cyclins, to form the cyclin/CDK complexes. Contrarily, the activity 
of CDKs can also be negatively regulated by the binding of small inhibitory proteins, known 
as the CDK-inhibitors (CKIs), or by inhibitory tyrosine phosphorylation which blocks 
phosphate transfer to substrates (Coudreuse and Nurse, 2010).  
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1.2.6.2 Cyclins and CDK complexes 
In higher eukaryotes, multiple CDKs and cyclins exist, but only five types CDKS (CDK1, 2, 
3, 4, 6) are generally associated with cell-cycle control (Malumbres and Barbacid, 2009). 
Usually, CDK1 is activated by A- and B-type cyclins, CDK2 by E- and A-type cyclins, 
CDK3by C-type cyclins, while CDK4 and CDK6 are activated by D-type cyclins (Homem 
and Knoblich, 2012). Cyclin E/CDK2 complex is required for S phase (Knoblich et al., 1994), 
and cyclin A and B/CDK1 complexes regulate M phase (Knoblich and Lehner, 1993). 
Although CDK4 and cyclin D are not critical for cell proliferation, they are required for cell 
growth (Emmerich et al., 2004). The cell-cycle regulation and the fidelity of checkpoints are 
crucial for the maintenance of genome integrity.  
 
1.2.6.3 The cell-cycle and its regulation 
The cell-cycle checkpoints are surveillance mechanisms that monitor the order, integrity, and 
fidelity of the cell-cycle process. These control measures include cell growth to the 
appropriate size, the replication and integrity of the chromosomes, as well as the timely and 
accurate segregation at mitosis. These mechanisms are highly conserved and of ancient origin. 
Cell-cycle checkpoints can be activated by damage to DNA ((Barnum and O'Connell, 2014), 
(Casimiro et al., 2012)). Depending on the severity of the cell-cycle defect, checkpoint 
dysfunction can result in outcomes ranging from cell-death to cell-cycle reprogramming, 
which can lead to cancer (Barnum and O'Connell, 2014).  
 
1.2.6.4 The Mitotic Spindle Checkpoint 
Prior to sister-chromatid segregation, it is essential that spindle attachment of sister-
chromatids occurs in a bi-oriented fashion such that they are under tension at metaphase, and 
attached to both poles of the spindle (Wittmann et al., 2001). Once all kinetochores are 
attached and properly aligned at the metaphase plate, anaphase can proceed. This process is 
promoted by the activity of Anaphase-Promoting Complex or Cyclosome (APC/C), an E3 
ubiquitin ligase. This ligase targets a number of proteins which include the mitotic cyclins. 
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Furthermore, APC activity is controlled by the cell-division-cycle protein (CDC20), which 
functions up to the metaphase–anaphase.  Once sister chromatid cohesion is released, spindle 
tension and the associated motor proteins enable sister chromatids to dissociate and move 
apart to form identical daughter nuclei (McLean et al., 2011). 
The spindle checkpoint functions to prevent activation of APC and CDC20, for example,  
where kinetochores are not occupied by spindle microtubules, or are attached but not under 
tension. Under these conditions, the spindle checkpoint protein Mad2 (Mitotic Arrest 
Deficient) inhibits the activity of CDC20 activity both at unattached kinetochores, where it 
forms a mitotic checkpoint complex, resulting in the inactivation of CDC20 and APC, and 
hence, cells cannot enter anaphase ((McLean et al., 2011), (Barnum and O'Connell, 2014)). 
Additionally, the spindle checkpoint includes a number of other proteins, such as the Polo 
kinases, Aurora kinases (AURKs), and never in mitosis gene (NIMA)- a related (Nek) kinase 
((O'Connell et al., 2003), (Barnum and O'Connell, 2014)). In a similar manner, the spindle 
checkpoint shares the basic principles as those controlling DNA integrity discussed above, 
that is, to prevent a cell-cycle progression while other effectors correct a genome altering 
defect. Contrarily, the mitotic checkpoint functions to maintain CDK activity, while the 
interphase checkpoints maintain CDK inactivity. Among mitotic kinases, Aurora kinases’ 
(AURKs) dysregulation have been previously associated with loss of p53 activity, and 
implicated in many cancers. Thus, Aurora kinases (AURKs) are emerging as potential targets 
in cancer therapeutics (Barnum and O'Connell, 2014).  
 
1.2.6.5 Aurora kinases and tumourigenesis.  
Aurora kinases belong to a family of conserved serine/ threonine kinases, with three types of 
these kinases in mammals, AURKA, AURKB and AURKC (Sasai et al., 2016). Although 
very close in protein sequence and structure (70% identity in the catalytic domain), Aurora A 
and B have distinct localizations and functions during mitosis. Aurora B is a component of the 
chromosomal passenger complex (CPC) interacting with inner centromere protein (INCENP), 
survivin and borealin, and is essential for chromosome segregation and cytokinesis. 
Furthermore, Aurora B localizes at centromeres in prophase and metaphase, at the cortex and 
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spindle midzone in anaphase, and at the mid-body in telophase (Carmena et al., 2012). Aurora 
C has a similar localization but is specifically expressed in mammalian germ cells and has not 
been found in other organisms (Carmena et al., 2009). Aurora A localizes at centrosomes and 
at the spindle poles, and is required for mitotic entry, centrosome maturation and spindle 
formation. In addition, the mammalian Aurora A promotes mitotic entry by phosphorylating 
and activating cell-division-cycle 25B (CDC25B). Activation of Aurora kinases occurs by 
autophosphorylation of the T-loop. This is promoted by the interaction with cofactors such as 
the microtubule-associated protein TPX2 for Aurora A and INCENP for Aurora B (Bishop 
and Schumacher, 2002). In addition, AURKs have been shown to interact with p53. In 
particular, AURKB phosphorylates p53 at serine 269 and threonine 284, thus inhibiting p53 
transactivation activity (Wu et al., 2011). Furthermore, phosphorylations at serine 183, 
threonine 211, and serine 215 drives the degradation of p53 through polyubiquitination-
mediated proteasome pathway (Gully et al., 2012). Additionally, the abnormal expression of 
the Aurora kinases interacting with p53 signaling protein family has been shown to be critical 
in nullifying p53 protein family mediated tumor suppressor pathways (Sasai et al., 2016). P53 
signaling protein family has been shown to play a significant role in the DNA damage 
response pathways (Zhang et al., 2009).  
 
1.2.6.7 DNA Damage Responses (DDR) and the tumour suppressor P53 
Throughout interphase, DNA damage stimulates a cell-cycle arrest that permits sufficient time 
for repair pathways to be activated and allow for DNA repairs before progression to following 
phases (Barnum and O'Connell, 2014).  DNA can be damaged by intrinsic and/or extrinsic 
agents. Intrinsic factors may include; intermediates of metabolism, wearing down of telomeric 
activity, oncogene overexpression, and DNA replication errors. Extrinsic sources such as 
exposure to; sunlight, ionizing radiation or other anticancer therapeutics. Different lesions in 
genomic DNA activate common checkpoint pathways. These pathways when activated 
maintain CDKs in an inactive state until repairs are done. P53 located on chromosome 17p13 
encodes a nuclear phosphoprotein of 53 kDa (TP53) that identifies and binds to regions of 
damaged DNA and acts as a transcription factor controlling the expression of a multitude of 
different downstream genes. Furthermore, damaged DNA or carcinogenic stress induces TP53 
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leading to cell-cycle arrest by inducing expression of cyclin dependent kinase inhibitors to 
enable DNA repair, through DNA damage response (DDR) pathways or apoptosis ((Barnum 
and O'Connell, 2014), (Goodman and Woodgate, 2013)).  
P53 is a critical component of DNA damage response and is regulated by various 
posttranslational modifications, which include N-terminal phosphorylation on serine-15, 
which is catalyzed by ATR and its relatives ATM (Ataxia Telangiectasia Mutated) and DNA-
PKcs (DNA-dependent protein kinase, catalytic subunit). Similar to ATR, these kinases 
(ATM) are targeted to double-strand DNA breaks by interacting proteins: the MRN (Mre11-
Rad50-Nbs1) complex, interacting with ATM. Activated p53 is then stabilized through 
protection from Mdm2, its E3 ubiquitin ligase. Then p53 trans-activates the expression of a 
large number of genes, including the cyclin-dependent kinase inhibitor (CKI) p21. By this 
mechanism, the G1 CDKs activity is inhibited, and DNA damage is repaired prior to DNA 
replication. Moreover, p53 can also repress the expression of genes, and is also required for 
G2 arrest in case of persistent DNA damage ((Carvajal et al., 2012), (St Clair et al., 2004)). 
The deregulation of the p53 pathway has been implicated in tumourigenesis.  
Once stabilised, the replisome may stay in position until the blockade is removed or deoxy-
nucleotide-triphosphates (dNTPs) restored. Otherwise, the cell can employ post-replication 
repair pathways to bypass the lesion, either by recruiting mutagenic bypass polymerases, or 
switching templates by recombination and then replicate using the other nascent strand as a 
template (Lee and Myung, 2008). In either event, checkpoints must be employed to prevent 
the onset of mitosis until the completion of replication. Translesion DNA synthesis is one of 
the mechanisms employed by cells to bypass DNA lesions and continue with DNA replication 
until the replication process is completed (Lange et al., 2016).  
 
1.2.6.8 DNA repair and tolerance: Translesion DNA synthesis (TLS) 
To avoid the damaging effects of a stalled replication fork, cells use specialized polymerases 
to bypass the damage. This process is known as “translesion DNA synthesis” (TLS), and 
grants the cell additional time to repair the damage before the replicase returns to complete 
genome duplication. Generally, this damage-tolerance mechanism is error-prone, and cell 
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survival often leads to an increased risk of mutations and tumourigenesis (Ohmori et al., 
2001). Furthermore, the error-prone TLS polymerases also gain access to undamaged DNA, 
where their inaccurate synthesis is beneficial towards genetic diversity and evolutionary 
fitness (Goodman and Woodgate, 2013).  
DNA damage interferes with DNA replication and hinders transcription, thereby affecting 
gene expression and cellular physiology. An estimated 30,000 lesions are generated 
spontaneously in a mammalian cell per day (Lindahl and Barnes, 2000). Usually DNA lesions 
cannot be used as a template by the high–fidelity replicative DNA polymerases, which are 
optimized to replicate the entire genome with high accuracy, efficiency and integrity (Baker 
and Bell, 1998). However, TLS polymerases can use damaged DNA as templates and insert 
nucleotides opposite lesions, irrespective of the conformational constraints that many 
modified bases may impose (Baker and Bell, 1998). Most TLS polymerases are members of 
the Y family of DNA polymerases. These polymerases have specialized structures to allow 
replication on damaged DNA substrates. In addition, other classes of DNA polymerases, such 
as the A and X polymerase families, can demonstrate the TLS activity. Another eukaryotic 
DNA polymerase, polymerase zeta (Pol ζ), is a member of the B family of DNA polymerases. 
This family, includes replicative DNA polymerases, and is also capable of TLS (Waters et al., 
2009).  
The action of the TLS polymerases has been shown to be crucial to limit cancer. This was 
demonstrated by (Lange et al., 2016) in mice, where the complete deletion of DNA pol zeta 
(ζ) leads to embryonic lethality and conditional deletion augmented tumorigenesis. In 
mammalian cells, Reversionless (REV) 3L is a large protein with over 3000 aa and multiple 
functional domains. The DNA polymerase domain occupies only the last third of the protein. 
The structural integrity of REV3L may be required in DNA processing complexes and for 
protein-protein interactions necessary to maintain cell viability and DNA integrity. The central 
region of REV3L has two adjacent binding domains for REV7 (also known as MAD2L2). 
REV7 is essential for pol ζ activity in vitro and functions as a bridge protein for interaction 
with the REV1 protein ((Kikuchi et al., 2012), (Hanafusa et al., 2010), (Wojtaszek et al., 
2012b)). REV1 in turn interacts with the Y-family DNA polymerases that insert bases 
opposite the sites of DNA damage and work together with pol ζ ((Guo et al., 2003), 
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(Wojtaszek et al., 2012a), (Pozhidaeva et al., 2012)). REV7/MAD2L2 also has other cellular 
functions in the maintenance of chromatin assembly and structure (Lange et al., 2016). The 
dysregulation of MAD2L2 has been documented in solid tumours such as colon and lung 
cancers (Rimkus et al., 2007). 
 
1.2.7 Lung cancer  
1.2.7.1 Biology of lung cancer 
Lung cancer is highly heterogeneous and can arise in many different sites in the bronchial 
tree. The symptoms and signs may differ, depending on the anatomic location.  Lung cancer is 
a highly invasive and rapidly metastasizing prevalent cancer. Seventy-percent of patients 
diagnosed with lung cancer are diagnosed at already advanced stages (III or IV). Lung cancer 
is divided into non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), which 
comprise 85% and 15% of all cases, respectively (Wu et al., 2013).  Deregulation of the cell-
cycle and the cell-cycle related components such as p53 and RB have been implicated in lung 
cancer (Eymin and Gazzeri, 2010). Furthermore, the deregulation of the pRB pathway through 
p16 (CDKI) loss and overexpression of cyclin D1 during the G1 phase is a crucial event 
during lung carcinogenesis, in both NSCLC and SCLC. The deregulation of the p53 pathway 
particularly during the S-phase also plays a key role in lung carcinogenesis (Zhang et al., 
2009).  The transformation from a normal to malignant lung cancer phenotype arises in a 
multistep manner, involving a series of genetic and epigenetic alterations, consequently 
evolving into invasive cancer by clonal expansion (Nowell, 1976).  Following the 
development of the primary cancer, continued accumulation of genetic and epigenetic 
abnormalities, acquired during clonal expansion, effects contribute to the processes of 
invasion, metastasis, and resistance to cancer therapy (Lemjabbar-Alaoui et al., 2015).    
1.2.7.2 Molecular pathology of lung cancer 
Although tobacco consumption remains the primary risk factor for the development of lung 
cancer, it has been documented that only 10% of smokers develop lung cancer. Thus, lung 
cancer is a multi-step and a multi-factorial process. Molecular diagnostics tools may be used 
to distinguish tumour cells on the basis of the presence or the absence of receptor proteins, 
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driver mutations, or oncogenic fusion rearrangements. In NSCLC, EGFR, ALK, KRAS, 
HER2, MET, BRAF, PIK3CA, MEK1, NRAS, AKT1 and ROS1 have been identified as 
molecular markers. Furthermore, multiple mutations may occur in variable oncogenes leading 
to transcription of mutated signals. These mutations lead to changes in protein structure and 
copy number (Pendharkar et al., 2013). Furthermore, kinase genes have been shown to have 
these driver mutations, and such mutations may be seen in all subtypes of non-small cell lung 
cancer. For example, females, and non-smokers are more likely to harbor EGFR mutations. In 
addition, the more common and most studied mutations include EGFR, ALK, HER2, RET and 
ROS1. Biomarker status is rapidly becoming an important tool based on which treatment is 
decided (Nana-Sinkam and Powell, 2013). Furthermore, the majority of oncology research 
today is directed towards molecular profiling of lung cancer. Receptor tyrosine kinases are 
emerging as major molecular markers and targets (Pendharkar et al., 2013).   
 
1.2.7.3 Lung cancer in HIV positive compared to HIV negative population 
It has been documented that the risk of developing lung cancer, especially non-small cell lung 
carcinoma (NSCLC), seems to be higher in HIV infected patients compared to the same age 
group in the general population (Suneja et al., 2013). Furthermore, lung cancer in HIV-
infected individuals is frequently diagnosed at younger ages than in the general population 
((Louie et al., 2002); (Makinson et al., 2011)), with a median age at diagnosis of 47 years 
compared to 70 years in the general population ((Hessol et al., 2007), (Sigel et al., 2013)). 
Additionally, it has been documented that the majority of lung cancers in HIV-infected 
patients are diagnosed at advanced stages, with more than half of the cases being diagnosed at 
stage III or IV ((Lavole et al., 2009). Adenocarcinoma is the most common histological type, 
followed by squamous cell carcinoma, large-cell carcinoma and small-cell lung carcinoma 
(Bearz et al., 2014). Bronchogenic lung cancer in HIV/AIDS patients presents different 
characteristics in comparison with the general population (Worm et al., 2013). In regard to 
prognosis and survival, Biggar et al. (2005) reported a 2-year survival rate of only 10% in 
patients with HIV, compared with 31% in the general population. Similarly, the 5-year 
survival rate for lung cancer was 10% in HIV-infected patients compared to HIV negative 
counterparts ((Biggar et al., 2005), (Marcus et al., 2015)). Contrarily, Rengan et al. (2012) 
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found that the survival rates were similar for both HIV-positive and HIV-negative patients 
diagnosed with non-small-cell lung cancer (NSCLC) between 2000 and 2005. Similarly, 
Hakimian et al. (2007) reported comparable survival rates in patients with advanced non-
small-cell lung cancer (NSCLC) between HIV-positive patients with CD4 cell counts >200 
cells/mm3 and HIV negative patients.  Therefore, these data suggest that, although HIV 
infection could have been a significant contributory factor in the pre-HAART era, this effect 
alone does not account for lung cancer epidemiology in PLWHA in the HAART era ((Rengan 
et al., 2012), (Hakimian et al., 2007), (Moltó et al., 2015)).  
 
1.2.8 HAART and Chemotherapy drug-drug interactions (DDIs) 
With increasing incidence rates of the NADCs in PLWHA, a better understanding towards an 
integrated approach in treating both HIV/AIDS and cancer is needed.  In most cases, the drug-
drug interactions (DDIs) are frequently encountered in the therapy of cancer patients with 
HIV. For example, all PIs are inhibitors of CYP3A, which is a central route in the metabolism 
of almost 50% of all anti-cancer (AC) drugs, with, ritonavir being the strongest inhibitor of 
CYP3A activity. On the other hand, NNRTIs can induce metabolism and potentially reduce 
the efficacy of AC drugs ((King et al., 2004), (Moltó et al., 2015)). Ritonavir is also an 
inhibitor of P-glycoprotein, which leads to increased exposure to many AC drugs. Table 1.2 
outlines the low, moderate and high risk DDIs between HAART components and AC drugs.  
Table 1.2: The outline of potential high, moderate and low DDIs between HAART 
components and AC drugs  
High risk Moderate risk Low risk 
-Boosted protease inhibitors 
(PIs): 
Atazanavir/ritonavir 
Atazanavir/cobicistat 
Darunavir/ritonavir 
Darunavir/cobicistat 
-Nucleoside reverse 
transcriptase inhibitors 
(NRTIs):  
Tenofovir 
 
-Non-nucleoside reverse 
-Nucleoside reverse 
transcriptase inhibitors 
(NRTIs): 
Abacavir 
Lamivudine 
Emtricitabine 
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Lopinavir/ritonavir 
 
-Non-nucleoside reverse 
transcriptase inhibitors 
(NNRTIs): 
Nevirapine 
Efavirenz 
Etravirine 
 
-Integrase inhibitors 
(INSTIs): 
Elvitegravir/cobicistat 
 
transcriptase inhibitors 
(NNRTIs): 
Rilpivirine 
 
 
-Integrase inhibitors 
(INSTIs): 
Raltegravir 
Dolutegravir 
 
-Entry inhibitors 
Maraviroc 
Enfuvirtide 
 
 
Contrarily, integrase inhibitors are considered to be among the most preferred options for 
HAART in HIV patients with cancer. This is due to their favourable drug interaction profile 
with antineoplastic drugs (Cottrell et al., 2013) . For instance, raltegravir and dolutegravir are 
mainly metabolized by glucuronidation through UGT1A1 and they do not have any inducer or 
inhibitor effect on either P450 enzymes or drug transporters, thus minimizing their potential 
for drug interactions (Liedtke et al., 2014).  
 
1.2.9 Integrated approach for combating the colliding epidemics-HIV/AIDS 
and lung cancer 
The optimum health care for PLWHA and with cancer, lung cancer in particular may be 
complex, but is very similar to treating lung cancer patients with other treatment agents, such 
as those used for cardiovascular or chronic respiratory diseases, avoiding DDIs ((Sparano et 
al., 2004), (Moltó et al., 2015)). Currently, a multidisciplinary approach in the treatment of 
lung cancer is a preferred option and it involves thoracic surgeons, pulmonary specialists, 
radiologists, and medical and radiotherapy oncologists. In the context of treating HIV patients 
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with lung cancer, the participation of a physician with expertise in treating HIV infection is 
critical. Importantly, the therapeutic approach for lung cancer in PLWHA should not differ 
from that of the general population, although with a consideration that DDIs between HAART 
and chemotherapeutic drugs may occur resulting in overlapping toxicity (Moltó et al., 2015) . 
Furthermore, PLWHA should still be maintained on HAART when concurrently treated for 
lung cancer. Thus, multidisciplinary collaboration between oncologists and HIV specialists is 
crucial for the optimal treatment for PLWHA and lung cancer.  
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CHAPTER 2: AIMS AND OBJECTIVES 
2.1 INTRODUCTION  
 
The molecular basis of lung cancer is heterogeneous and complex. Understanding the genetic 
and molecular alterations and their functional significance is rapidly influencing the potential 
impact molecular markers have on lung cancer diagnosis, prognosis and treatment (Cooper et 
al., 2013). Furthermore, the numbers of HIV-positive patients with lung cancer as a leading 
NADC will most likely increase over the next 2 decades. This highlights the importance of 
further research on lung cancer, and HIV epidemic as well as the potential interactions 
between the two diseases as the number of individuals with both diseases increases 
(Koegelenberg et al., 2016).  
The South African (SA) healthcare system has to deal with the largest HIV burden in the 
world, has the largest HAART programme globally, one of the highest incidences of TB, and 
a high prevalence of NADCs in the HAART era. Additionally, lung adenocarcinoma has been 
shown to be the most common form (Koegelenberg et al., 2016). To date, the relationship 
between the use of HAART and lung carcinogenesis is poorly understood. While the 
deregulation of the cell-cycle is one of the hallmarks of lung cancer, this study aimed at 
elucidating the effects ARV drugs have on lung cancer in in vitro cell-line models.  
 
2.2 HYPOTHESIS 
Antiretroviral treatment (ART) modulates the expression of cell-cycle related genes, leading 
to lung tumourigenesis.   
 
2.3 AIM  
The broad aim of this study was to investigate the effect of antiretroviral drug treatment 
(ART) in the regulation of the cell-cycle related genes in lung cancer.  
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2.3.1 Objectives  
a) To determine the cytotoxic effect (s) of antiretroviral drug treatment (ART) on lung cancer. 
For this purpose, the Alamar Blue (AB) assay was used to measure effects of EFV and LPV/r 
on cell viability and cell death, pre-and-post ARV treatment.   
 
b) To investigate the ARVs’ pro-or-anti-oncogenic properties. To achieve this, effects of EFV 
and LPV/r on cell proliferation and cell death/apoptosis were monitored in real-time, using the 
real time cell impedance (xCELLigence) assay.  
c) To determine the ARVs’ regulatory effects on the cell-cycle in lung cells. Propidium iodide 
(PI) staining together with FACS analysis was used to quantify the DNA present at each of the 
cell-cycle stages before and after ARV treatment. Furthermore, the cytotoxic effects of the 
ARVs were confirmed by the Annexin V FITC/PI apoptosis assay, using FACS analysis. 
d) To assess the ARVs’ effects on nuclear morphology. Nuclear changes including DNA 
fragmentation and chromatin condensation in response to ARV treatment were evaluated with 
DAPI staining.  
e) To investigate which cell-cycle related genes are targeted by the ARV drugs. Effects of 
these drugs at gene expression level were evaluated using focused human gene arrays. In 
addition, RT-qPCR was performed to validate selected PCR array targets.  
f) To map the molecular pathways involved in response to the ARV treatments. In silico Bio-
informatics analyses were employed. 
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CHAPTER 3: MATERIALS AND 
METHODS 
3.1 MATERIALS 
For the proposed use of MRC-5 and A549 cell-lines, an ethics waiver was applied for and 
obtained for this study (see Appendix A).  
 
3.1.1 ARV drugs 
The ARV drugs for this study were purchased from Toronto Research Chemicals (Toronto, 
Ontario, Canada), and dissolved as stock solutions in methanol (see Appendix B1). The two 
ARVs selected for this study were the non-nucleoside reverse transcriptase inhibitor (NNRTI) 
Efavirenz (EFV) and the conjugate protease inhibitor (PI) Lopinavir/ritonavir (LPV)/r). The 
chemical structures of EFV, LPV and RTV (r) are shown in Table 3.1.  
 
Table 3.1: Chemical structures of EFV, LPV and RTV   
NNRTI-EFV PI-LPV PI-RTV 
 
 
 
[Adapted from Arts and Hazuda, 2012 (Arts and Hazuda, 2012)].  
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The choice of ARVs was based on the approved WHO 2013 ART guidelines, the South 
African 2013 ART guidelines, and potential oncogenic properties from in vitro reports 
((Sikora et al., 2010) ; (Batman et al., 2011), (Srirangam et al., 2011), (Hecht et al., 2013), 
(Hecht et al., 2015), (Grossman et al., 2014)).  
 
3.1.2 Cell culture 
The lung cell lines MRC-5 ((normal lung fibroblast (ATCC CCL171)) and A549 ((lung 
adenocarcinoma (ATCC CCL185)) were purchased from the American Type Culture 
Collection (ATCC). These cell lines are adaptable to a single growth medium and they have 
been previously demonstrated to show reproducible profiles for growth and drug sensitivity. 
MRC-5 and A549 cell lines were treated with a range of concentrations including the plasma 
level ARV concentrations at 24h, 48h and 72h time intervals, for screening purposes. Cells 
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM):F12, 10% serum, 1% 
pen/strep and 5% CO2 in air and left to grow to 70-80% confluency in a humid chamber at 
37°C for 48 to 72h. This was followed by trypsinization, to detach cells from the flask, 
centrifuging to pellet the cells and to remove the supernatant, washing with PBS and re-
suspending the cells in 5ml of fresh DMEM media. The cells were split in a 1:2 ratio and sub-
cultured.  Cell culture medium containing 10% FBS and 1% pen/strep was replaced every 2-3 
days until cells reached 70-80% confluency. Cells were then serum-starved for 24h to 
synchronise the cell-cycle. The following day, the cells were pharmacologically treated with 
the ARV drugs, EFV (4, 13, 26, 50µM, respectively) and LPV/r (10, 32, 50, 80µM, 
respectively) for 24h to 72h. Vehicle control cells were exposed to growth medium and 
vehicle only (methanol 0.1% v/v). 
 
3.2 Alamar Blue (AB) cell viability assay 
Alamar Blue, also known as resazurin, is a water soluble dye stable in a cell culture medium 
environment, non-toxic to cells and is permeable through cell-membranes. Because of its 
stability and non-toxicity, continuous monitoring of cell cultures over time is permitted.  
Alamar Blue has been shown to act as an intermediate electron acceptor in the electron 
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transport chain without interfering with the normal transfer of electrons ((Page et al., 1993); 
(Rampersad, 2012)).  
Alamar Blue (AB) can be reduced by NADPH, FADH, FMNH, NADH and cytochromes. As 
it accepts electrons, AB changes from the oxidized, non-fluorescent, blue substrate resazurin 
to the reduced, fluorescent, pink product, resorufin. This alteration from the oxidized to the 
reduced state can be quantified fluorometrically or colorimetrically indicating the presence or 
absence of viable cells, as only viable cells reduce AB (Byth et al., 2001). The latter was used 
in this study.  Spectrophotometric absorbance is measured at two wavelengths 570nm and 600 
nm or 540nm and 630 nm. AB can be used in various aspects of monitoring cellular health 
including cell proliferation, cell death, cell-cycle function and control (Rampersad, 2012). In 
this study AB (Sigma Aldrich) powder was dissolved in aqueous solution to make up stock 
solution as described in appendix B2, and was employed to examine the viability of MRC-5 
and A549 lung cells pre- and- post  ARV drug treatment, with  reference to the untreated 
(vehicle control) group. To achieve this, the following protocol was carried out: 
Confluent cells were trypsinised, harvested by centrifuging at 800rpm for 3 minutes; the 
supernatant was discarded and cell pellets were re-suspended in 1ml of cell culture medium. 
An aliquot of cells was then counted using an automated cell counter (Bio-Rad) and 2 X 10
3 
cells were seeded in triplicate in a 96-well plate. Cells were allowed to grow and attach 
overnight at 37°C with 5% CO2 in air. The following morning, cells were serum-starved (to 
synchronize the cell-cycle) for 24h. Next, the cells were treated with each of methanol (0.1%; 
v/v), vehicle control), EFV (4, 13, 26, 50 µM) and LPV/r (10, 32, 50, 80 µM), for 24h, 48h 
and 72h, respectively. The first column on the 96-well plate was always the blank that is, 
containing cell culture medium and AB without cells. The subsequent columns were seeded 
with cells and exposed to methanol, EFV and LPV/r at the above mentioned concentrations 
for 24h, 48h and 72h, with a final volume of 200µl (180µl medium + 20µl AB). The 
absorbance of control and test wells was measured at 540nm and 630nm using a microplate 
reader (Biotek), where the number of viable cells is directly proportional to the intensity of the 
reduced dye and was expressed as AB reduction percentage, using the following formula 
derived by Willard et al., (1965):  
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% Reduction  =                     ᵋoxid 630nm (sample A540nm) - ᵋoxid 540nm(sample A630nm) 
                              ᵋred 540nm (oxidised control A630nm) - ᵋred 630nm (oxidised control A540nm)       ×100 
 
The molar extinction coefficients of AB for the oxidised and reduced controls are:  
Ɛoxid 630 nm = 34.798, Ɛoxid 540 nm = 47.619, Ɛred 630 nm = 5.494, and                                              
Ɛred 540 nm = 104.395 (Willard et al., 1965).    
The percentage AB reduction values were corrected for the background values of the blank 
control wells containing medium only.   
The AB assay was however limited by the fact that EFV is primarily metabolized by 
CYP2B6. To account for a possible drug-drug (EFV-AB) interaction, the AB assay was 
followed by a label free real-time-cell-analysis (RTCA) xCELLigence assay. Due to the high 
costs of conducting a RTCA, the AB assay was a useful indicator of cell viability in response 
to ARV drug treatment over a period of 24h, 48h and 72h, these time periods being similar to 
the RTCA analysis. 
 
3.3 xCELLigence RTCA cell proliferation and cytotoxicity assay 
Measuring cell viability is an essential step in cell biology. There are many ways to quantify 
cell viability, including the 3-4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide 
(MTT) reduction and Trypan Blue assays. With modern technology, new alternative viability 
methods with increased sensitivity and specificity have been developed. The xCELLigence 
System Real-Time Cell Analyser (RTCA) is one of these newly developed methods. Cellular 
biological events, such as cell proliferation, cell viability, cell morphology and migration can 
be analyzed in real time by the xCELLigence system without labeling.  
The xCELLigence system uses custom-designed plates, which have a high-density gold 
electrode array on which the target cells adhere and grow. Cells adhere to the plate surface and 
influence the electrical impedance across the array. This electrical impedance is monitored 
and measured by the xCELLigence software. The impedance values are then converted by the 
xCELLigence software into the Cell Index (CI). The CI is used as a measure of cell adhesion, 
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that is, in the absence of cells, the CI will be zero. However, as cells adhere to the electrode 
array, the CI increases. It thus follows, the greater the CI values, the greater the level of cell 
adhesion. On contrary, the decreasing CI values signify a net decrease in cell adhesion. 
Primarily, xCELLigence measures the net cell adhesion within the well. As a result, any 
responses that triggers change in cell morphology, which includes cell size, volume, shape, 
movement (migration), cell proliferation or cell death can be investigated by the xCELLigence 
technology (Kho et al., 2015). It is advantageous that data from the xCELLigence assay 
provides continuous quantitative information about the biological status of cells in real-time. 
This system was employed in this study to determine the effects of ARV drugs (EFV and 
LPV/r) in MRC-5 and A549 cells in real-time.  
The xCELLigence Real-Time Cell Analyser System was used according to the manufacturer’s 
instructions (ACEA Biosciences). The seeding density of both the MRC-5 and the A549 cells 
were first optimized using cell titration curves. Briefly, 100µl of cell culture medium was 
added to each of the sixteen E-plate wells and an automatic scan was performed to verify 
proper contact between the E-plate and the RTCA analyzer.  After this, the background 
impedance was measured for each well.  A 2× dilution series was prepared, that is, 50 000, 
25 000, 12500, 6250, 0 cells/ml, and 100µl of each cell suspension was added to duplicate 
wells. The E-plate was left for 30min to allow the cells to settle in an evenly distributed 
manner at the bottom of the wells. Following on this, a scanning program was initiated that 
consisted of measuring the CI every 30min for 200 repetitions. This allowed for the 
continuous monitoring of cells for up to 100h. During or after the experiment, respective wells 
were selected in the software analysis page (Plot Page), to determine the Cell Index of a well 
as a function of time, these being plotted and represented as averages.  
3.3.1 Real time evaluation of cytotoxicity  
 
The optimum cell number for each cytotoxicity experiment was determined from the Cell 
Titration assay as described above. Thirty thousand cells/ml for the MRC-5 cell line and fifty 
thousand cells/ml for A549 cells were shown to be optimal.  The seeding procedure was 
followed as described above for the cell titration assay. After cells were grown for 24h, cells 
in appropriate wells were washed with PBS and treated with EFV at concentrations of 4, 13 
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and 50µM, respectively; or with LPV/r at concentrations of 10, 32 and 80µM, respectively, 
for up to a time period of 72h. This was relative to the 0.1% (v/v) methanol/ (vehicle) control. 
The cells were monitored every 15min (instead of 30min as described in the Titration assay).  
It is important to note that here the Normalized Cell Index (NCI) instead of the CI was plotted 
against time. NCI was used following cell treatment with either EFV or LPV/r, being useful to 
study the change in cell adhesion, selected from a specific time point of 24h. NCI is 
proportional to cell adhesion and proliferation.  
The RTCA data was useful in indicating the optimum and appropriate drug treatments and 
time-periods for subsequent experiments. Furthermore, changes in cell proliferation patterns 
in response to ARV treatment were then assessed on the cell-cycle stages using FACS.  
  
3.4 Cell-cycle Analysis by Fluorescence-activated cell sorting 
(FACS) 
Flow cytometry allows for the measurement of physical and chemical characteristics of 
individual cells rapidly and with high accuracy. For this reason, flow cytometry is widely used 
in cell-cycle analysis, utilizing a fluorescent compound such as propidium iodide which 
intercalates within nuclear DNA allowing for its quantification. When PI is bound to nucleic 
acids, the fluorescence excitation maximum is 535nm and the emission maximum is 617nm, 
from red to blue. PI has little to no sequence preference and does also bind to double stranded 
(ds) RNA and thus was used in conjunction with RNAse to remove RNA.  
For the purposes of this study, the BD Accuri C6 system (BD Biosciences) was used to 
quantify the DNA present at each of the stages of the cell-cycle.  This was done to examine 
the effects of ARV drugs on different cell-cycle stages. Single cells with propidium iodide-
stained DNA pass in front of a laser beam in the flow cytometer. Each cell absorbs light and 
emits fluorescence that is proportional to the DNA content of the cell. This measured 
fluorescence is digitally converted to an electric pulse and the data is visualized as DNA 
histograms (Dey, 2004). The cells were harvested and stained as follows: 
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1. Drug treated and control cells were trypsinised at 70-80% confluency, harvested by 
centrifuging and the cell pellet was re-suspended in 250µl of PBS at room temperature (Rt) 
for 10min 
2. One ml of ice cold absolute ethanol was added drop-wise to the cells while vortexing 
3. The fixed cells were stored at -20°C for 1h 
4. The cells were centrifuged at 800rpm and the supernatant was discarded 
5. The pellets were then re-suspended in 500µl of PBS and allowed to rehydrate at RT for 
15min 
6. Two µl of 10mg/ml RNAse (Sigma) was added to the resuspended cells and incubated at 
37°C to eliminate RNA  
7. The cells were centrifuged and resuspended in 500µl of PBS  
8. The cells were then stained with 25µl of PI (1mg/ml), (Sigma) and incubated at 4°C 
overnight in the dark 
9. The following morning, stained cells were analysed on the BD Accuri C6 and results were 
generated and analysed as histogram by the BD C6 Accuri software.  
The histograms generated by cell-cycle FACS analysis together with the RTCA data were 
indicators of ARVs (LPV/r in particular) apoptotic effects and this lead to ARVs (LPV/r) 
apoptosis evaluation by FACS analysis.  
 
3.5 Dual Staining Annexin V-FITC/ Propidium Iodide (PI) 
Apoptosis Assay  
Apoptosis is a normal physiologic process which is important in the maintenance of tissue 
homeostasis.  Loss of plasma membrane integrity, condensation of the cytoplasm and nucleus, 
and internucleosomal cleavage of DNA are characteristic features of cells undergoing 
apoptosis, with loss of plasma membrane being one of the earliest features. An early indicator 
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of apoptosis is the rapid translocation of the membrane phospholipid phosphatidylserine (PS) 
from the inner to the outer surface of the plasma membrane (Leventis and Grinstein, 2010). 
Due to the exposure of the PS membrane to the extracellular surface, Annexin V, a calcium 
dependent phospholipid binding protein that has a high affinity for PS, and binds to cells with 
exposed PS can be used to monitor cells undergoing apoptosis.  Annexin V may be conjugated 
to fluorochromes such as Fluorescein isothiocyanate (FITC) and used in conjunction with 
DNA binding dyes such as Propidium Iodide (PI).  This dual staining procedure allows the 
investigator to distinguish between early apoptotic cells, late apoptotic cells and dead cells. 
For example, viable cells are Annexin V-FITC and PI negative; early apoptotic cells are 
Annexin V-FITC positive and PI negative; and cells that are in late apoptosis or already dead 
are both Annexin V-FITC and PI positive (Sawai and Domae, 2011).  
The MRC-5 and A549 cells were cultured and treated with LPV/r at a concentration of 32 and 
80µM, respectively for 24h, 48h and 72h. Camptothecin (CPT) (Sigma) treatment (50µM) 
was used as a positive control. The cells were then rinsed with PBS, trypsinized and 
centrifuged at 1500g for 5min to collect the cell pellet. The cell pellet was then washed twice 
in PBS.     
The apoptosis kit (Annexin V FITC/PI) from Santa Cruz Biotechnology was used to assess 
LPV/r apoptotic effects on lung cells. The following protocol was carried out to stain cells for 
apoptosis as per manufacturer’s instructions (Santa Cruz Biotechnology):  
Staining 
1. Cells were re-suspended in 1× binding buffer at a concentration of 1 x 10
6
 cells/ml. 
2. One hundred μl of the cell suspension (1 x 105 cells) was transferred to a sterile 1.5ml 
micro-centrifuge tube.  
3. Five μl of Annexin V-FITC and 5μl of PI were added to the tube with the cell suspension. 
4. The tube containing cells was gently vortexed and incubated for 15min at RT (25°C) in the 
dark. 
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5. Four hundred μl of 1× binding buffer was added to each tube, and the cells were then 
analyzed within one hour by flow cytometry using the BD Accuri C6 Flow Cytometer, and 
results were generated as cytograms.   
This was then followed by the assessment of changes in nuclear morphology following ARV 
drug treatment using DAPI staining.  
 
3.6 DNA staining using 4, 6-diamidino-2-phenylindole (DAPI) 
A variety of fluorescent dyes are available to label DNA and allow for easy visualization of 
the nucleus in interphase cells and chromosomes in mitotic cells. These stains include 
Hoechst, 4,6-diamidino- 2-phenylindole (DAPI), ethidium bromide, propidium iodide, and 
acridine orange. Compared to the Hoechst DNA staining, DAPI has greater photostability 
(Chazotte, 2011). It is assumed that DAPI associates with the minor groove of double-
stranded DNA, with a preference for the adenine-thymine clusters. For DAPI to enter the cell 
and intercalate into DNA, cells must be first permeabilized with a detergent before or after 
fixation. Fluorescence increases approximately 20-fold when DAPI is bound to double-
stranded DNA. Here, cells (MRC-5 and A549) were treated for 48h with EFV (13 and 50µM) 
and LPV/r (32 and 80µM). The two concentrations for each drug were selected as plasma 
relevant and anti-proliferative or cytotoxic, as indicated by preceding experiments. DAPI was 
used to assess the effects of the ARVs on the cellular DNA using the following protocol: 
 
1. 1×10
4
 cells were seeded on the coverslips and allowed to grow overnight in 6-well plates. 
 
2. Cells were rinsed with PBS and serum-starved for 24h. 
 
3. Cells were then treated with 13µM and 50µM of EFV; and with 32µM and 80µM of LPV/r.  
 
4. The DAPI (Sigma) solution was diluted 1:5000 in PBS. 
5. The cell culture medium was aspirated from the cells grown on the coverslips, followed by 
three PBS washes.  
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6. The cells were fixed for 10min in 3.7% formaldehyde in PBS. 
7. The fixative was aspirated and cells were rinsed three times, 5min each, in PBS. 
8. The cells were then permeabilized in 0.2% Triton X-100 in PBS for 5min. 
9. Triton-X was then aspirated, and the cells were rinsed three times, 5min each, in PBS. 
10. The cells were incubated for 10min at room temperature (Rt) with 100µl of DAPI labeling 
solution (from Step 4). 
11. DAPI was aspirated off and cells were rinsed three times in PBS. 
12. The coverslips were then mounted with aqueous FluoroMount mounting medium (Sigma) 
and allowed to dry. 
13. The cells were viewed on the Zeiss LSM 780 confocal microscope.   
Following assessment of ARVs (EFV and LPV/r) on cellular health, gene expression studies 
were done to investigate ARVs role on the expression of cell-cycle related genes. 
 
3.7 Human Cell-Cycle Gene (PCR) Arrays 
A gene array panel was used to analyze the cell-cycle response pre- and post- antiretroviral 
treatments of each cell-line. This method provides for a highly reliable and sensitive gene 
expression profiling of focused panels of genes in signal transduction, biological processes, or 
disease research pathways using real-time PCR methodology.  
In this study, RT² Profiler Human Cell-cycle PCR Arrays were used (Qiagen). This pathway-
focused array consists of 84 genes related to the cell-cycle, in a 96-well plate format as 
illustrated in Appendix C, Figure C5.1. Aside from the pathway-focused genes, the panel 
contains 5 housekeeping (reference) genes and additionally a panel of proprietary controls that 
monitor genomic DNA contamination (GDC), first strand synthesis (RTC) and real-time PCR 
efficiency (PPC).  
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Use of such a panel requires the isolation of high quality cellular RNA and sufficient cDNA 
synthesis to provide for the PCR amplification and analysis of gene expression. These steps 
are described below. 
3.7.1 RNA Extraction 
RNA was extracted from cells treated for 48h at drug plasma levels (13µM EFV and 32µM 
LPV/r); and from untreated cells, using the RNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions. Briefly, cells were washed with PBS twice, and then lysed 
directly by adding 350µl of Buffer RLT, to T25 cell culture flasks (for A549 cells) and adding 
600µl of Buffer RLT to T75 cell culture flasks (for MRC-5 cells).  Cell scrapers (Lonza) were 
used to detach the cells, the lysate was then transferred into sterile 2ml micro-centrifuge tubes. 
The tubes were then briefly vortexed before equal volumes (350µl or 600µl) of 70% ethanol 
were added to the lysate. Up to 700µl of the sample was transferred into an RNeasy Mini spin 
column placed in a 2ml collection tube. These were centrifuged for 15s at 8000g. The flow-
through was then discarded and 700µl of Buffer RW1 was added to the RNeasy spin column 
and centrifuged for 15s at 8000g. Once again the flow through was discarded and 500µl of 
Buffer RPE was added to the RNeasy spin column, which was centrifuged for 15s at 8000g. 
The flow through was discarded again, and 500µl of Buffer RPE was added and the tubes 
were centrifuged for 2min at 8000g. The flow-through was discarded and the RNeasy spin-
column was centrifuged at 8000g for 1min. The RNeasy spin column was inserted into a new 
1.5ml collection tube and 30µl of RNase-free water was added directly to the spin column 
membrane. This was incubated at room temperature (Rt) for 1min to allow the RNase free 
water to cover the spin column membrane. Total RNA was eluted by centrifuging at 8000 x g 
for 1min. The quality and quantity of RNA was measured using a Nanodrop (Nanodrop ND-
1000 spectrophotometer (Nanodrop Technologies)).  For highly pure RNA, the 260/280 
absorption ratio is ~2, and the 260/230 ratio is 2.0-2.2. 
3.7.2 cDNA synthesis 
cDNA was synthesized using the  RT
2
 First Strand cDNA synthesis kit (Qiagen) following the 
manufacturer’s instructions. Briefly, two mixtures were prepared separately, firstly the 
Genomic DNA (gDNA) elimination mixture (Table 3.2) for each RNA sample and secondly, 
the reverse transcription (RT) cocktail (Table 3.3).  
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Table 3.2: gDNA elimination mixture 
Reagent  Volume (µl) 
Total RNA 1µg
*
  
GE (5x gDNA Elimination Buffer) 2 
RNase-free water to a final volume  10 
*The volume in µl depends on concentration of the RNA in ng/µl 
The gDNA mixture was incubated at 42°C for 5min and immediately placed on ice for 1min.  
 
Table 3.3: Reverse transcription (RT) cocktail 
Reagent Volume (µl)  
BC3 4 
P2 1 
RE3 2 
RNase-free water 3 
Final volume 10 
 
The RT cocktail was briefly centrifuged and added to the gDNA mixture to provide a final 
volume of 20µl. This mixture was then incubated at 42°C for 15min, 95°C for 5min and then 
at 4°C for 5min. cDNA was diluted to 111µl by adding nuclease-free water, according to the 
manufacturer’s instructions.  The cDNA was used immediately for the PCR Arrays or stored 
at -20°C for future use.   
 
3.7.3 PCR Array plates 
The synthesized cDNA was mixed with the Qiagen RT
2
 SYBR Green/ROX qPCR master 
mix, to which nuclease-free water was also added. Thereafter, 25µl per well was loaded in 96-
well plates with pre-dispensed primer sets of the RT
2
 Profiler PCR Array, as indicated in 
Table 3.4.   
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Table 3.4: The RT-qPCR master mix for PCR Arrays 
Reagent  Volume (µl) 
2× SYBR Green/ROX master mix 1350 
cDNA 102 
Nuclease-free water 1248 
 
The PCR Array plates were centrifuged briefly (Boeco) before they were loaded on the ABI 
7500 RT PCR instrument (Applied Biosystems). The following cycling conditions were used:                    
10min at 95°C, followed by 40 cycles of 15s at 95°C and 1min at 60°C. Data (CT values) was 
exported as Excel files to (Qiagen, www.qiagen.com) GeneGlobe Database for analysis.   
 
3.7.4 Data Analysis using GeneGlobe 
The online GeneGlobe (Qiagen) analysis tool was used to analyse the PCR array data of all 
treated and untreated samples. A cycle threshold (Ct) of 35 was set as the cut-off value for 
gene expression. Thus genes with Ct values greater than 35 cycles were considered non-
detectable. Five house-keeping genes, including (ACTB-Beta Actin (ACTB); Beta-2-
microglobulin (BM2); Glyceraldehyde-3-phosphate dehydrogenase (GAPDH); HPRT1-
Hypoxanthine phosphoribosyltransferase (HPRT1); RPLP0-Ribosomal protein, large, P0 
(RPLP0)) were used to obtain the change in cycle threshold (ΔCT) value for each gene of 
interest, where ΔCT is calculated as: CT value of gene of interest less the CT value of 
reference gene. The difference between the ΔCT of the treatment group and that of the vehicle 
control group is represented by ΔΔCT value, where the fold-change is calculated by 2(-ΔΔCT). 
(Livak and Schmittgen, 2001). This value represents the level of the expression of each gene 
in the drug-treated (EFV or LPV/r) sample versus that in the vehicle control sample. By 
convention, the fold difference of ±2 up-or-down regulation was used as a basis of target 
selection. Due to the costs of running PCR gene arrays, these were confirmed by RT-qPCR.  
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3.8 Validation of Cell-cycle Array Data   
Real-Time quantitative Polymerase Chain Reaction (RT-qPCR) has been proven to be a more 
sensitive method for gene expression studies, compared to the conventional method 
(Sanguinetti et al., 2003). To validate the PCR Array data, Real-Time quantitative PCR (RT-
qPCR) was performed at least three independent times in triplicate. Three representative genes 
of the array were rationally selected according to their level of expression (above or below 
two-fold expression).   
3.8.1 Primer Design 
The Primer 3 tool (http://primer3.wi.mit.edu/) was used to design primers for the selected 
gene targets, including the house-keeping gene (HKG) GAPDH, based on NCBI accession 
numbers provided by Qiagen (for all three selected targets), following PCR Array analysis. 
The target genes selected included MAD2L2 (accession number NM_001127325), CASP3 
(accession number NM_004346), AURKB (accession number NM_001256834) and (HKG) 
GAPDH (accession number NM_002046). The amplicons’ sizes were as follows; 157bp for 
MAD2L2, 149bp for CASP3, 150bp for AURKB and 87bp for GAPDH. Primer sequences of 
the selected gene targets and GAPDH as a reference gene (one of the internal controls’ panel 
in the PCR Array) are shown in Figure 3.1.   
MAD2L2 
MAD2L2-Forward:  5'-CGA GTT CCT GGA GGT GGC TGT GCA TC-3'   
MAD2L2-Reverse:  5'-CTT GAC GCA GTG CAG CGT GTC CTG GAT A-3'  
  
Caspase 3 (CASP3) 
CASP3- Forward:  5’-GCT CAT ACC TGT GGC TGT GTA-3’     
CASP3- Reverse: 5’-ATG AGA ATG GGG GAA GAG GCA -3’    
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AURKB 
AURKB- Forward: 5‘-AGC AGC GAA CAG CCA CG-3’       
AURKB- -Reverse: 5‘-GCC GAA GTC AGC AAT CTT CA-3’ 
 
GAPDH 
GAPDH- Forward: 5‘-TGCACCACCAACTGCTTAGC-3’ 
GAPDH- Reverse: 5’-GGCATGGACTGTGGTCATGAG-3’ 
Figure 3.1: The forward and reverse primer sequences of the selected gene targets and 
GAPDH reference gene used to perform Real-Time quantitative PCR (RT-qPCR) in order to 
validate the PCR Array data. 
 
Total RNA from treated and untreated cells for 24h and 48h was extracted using the RNeasy 
mini kit (Qiagen), as described in section 3.7.1. The extracted RNA (treated and untreated) 
samples were used for reverse transcription in RT-qPCR experiments. Briefly, RNA was 
reverse transcribed to cDNA using the Maxima First Strand cDNA synthesis kit for RT-qPCR 
with dsDNase (Thermo Scientific), following the manufacturer’s instructions as shown in 
Table 3.5 and Table 3.6.  
Table 3.5: Digestion of gDNA 
Reagent  Volume (µl) 
10× dsDNase Buffer 1 
dsDNase 1 
Template RNA 1µg
* 
Nuclease-free water Up to 10 
Total volume 10 
 *Added volume of RNA template varies, to amount to 1µg.  
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The contents were gently mixed and centrifuged. This was followed by incubation at 37°C for 
2 min, chilling on ice, another brief centrifuge and then placed on ice. Components of Table 
3.5 were added to those listed in table 3.6. The two cocktails were gently mixed and briefly 
centrifuged. The reactions were incubated at 25°C for 10min and 50°C for 15min. The 
reactions were terminated by heating at 85°C for 5 min. This was followed by 4°C hold for 
5min. The cDNA was ready to use, as per table 3.7 or was stored at -20°C for future use.  
Table 3.6: Reverse Transcription Components  
Reagent  Volume (µl)  
5X reaction mix 4 
Maxima enzyme mix 2 
Nuclease-free water 4 
Total volume 10 
 
Table 3.7: RT-qPCR master mix cocktail 
Reagent  Volume (µl) 
Fwd Primer
*
  0.4 
Rv Primer
* 
0.4 
2X SYBR Green master mix 5 
cDNA 0.8
# 
Nuclease-free water 3.4 
Total volume 10 
*10µM of each primer (for all different gene targets) was used.  
# No template reactions were also included, for negative control(s).  
The reactions each consisting of a total volume of 10µl were then loaded into a 96-well PCR 
plate, which was centrifuged at 1000rpm for 20s, (Boeco) before loading onto the ABI 7500 
RT-qPCR Instrument (ABI,) The following thermal profile was used: denaturation at 95°C for 
10min; followed by 40 cycles of 95°C for 15s, then  60°C for 1min (data collection point); and 
finally the dissociation stage, which is pre-set on the ABI 7500 system at 95 °C for 15s, 
Reps1, 60°C for 1min, 95°C for 15s.  
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3.8.2 RT-qPCR data analysis 
 
Following the RT-qPCR experimental run on the ABI 7500 light cycler, the CT values were 
exported as an Excel file to create a table of CT values. This table was then uploaded on to the 
data analysis web portal at http://www.qiagen.com/geneglobe. Samples were assigned to 
controls and test groups. CT values were then normalized based on a manual selection of the 
GAPDH reference gene. The data analysis web portal calculates fold change/regulation using 
the delta delta CT method ((Livak and Schmittgen, 2001), (Schmittgen and Livak, 2008)) in 
which delta CT is calculated between genes of interest, (GOI) and HKG, followed by delta-
delta CT calculations (delta CT (test/experiment)-delta CT (control/calibrator)). Fold Change 
is then calculated using 2^ (-delta delta CT) formula, shown below. 
ΔCT = CT (Test target-Test HKG)  
ΔCT = CT (Calibrator target-Calibrator HKG)  
= 2
-[ΔCT (test) – ΔCT (calibrator)] 
To map the disease and molecular pathways influenced by the selected up-and-down regulated 
targets, Bio-informatics tools were employed.  
 
3.9 Bio-informatics for Pathway analysis 
In silico analyses using various Bio-informatics tools provide an important means for  
analyzing genes, their products and the (disease) pathways they are involved in (Bechtel, 
2016) . For this purpose, Bio-informatics tools were employed to identify complexes formed 
by the identified targets and how these interact with other cell-cycle related genes. Next, Bio-
Informatics tools were used to identify and map other biological and molecular pathways, 
except for the cell-cycle, the identified targets are involved in.  
Four different Bio-Informatics tools were used: STRING, DAVID, Reactome and IPA 
databases. The gene-lists represented by the GenBank accession numbers of selected gene 
targets (from the gene array data) were up-loaded on the databases. Each tool is briefly 
described below. 
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1. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (v10.0) was 
used to establish the protein-protein interactions (PPIs) of the up-or-down regulated genes 
involved in cell-cycle regulation whose transcription levels were analysed using the RT² 
Profiler Human Cell-cycle PCR Array panel before and after ARV treatment. The PPIs were 
constructed before and after ARV treatment.  
2. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to 
perform a functional enrichment analysis of the target genes in order to identify those genes of 
interest involved in cell-cycle regulation and progression pre- and post- EFV and LPV/r drug 
treatment. The functional annotation tool from DAVID database was used. Gene names of the 
up-and-downregulated groups were uploaded into the database and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway was selected for visualization.  Figure 3.2 below 
annotates the KEGG pathway.    
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Figure 3.2: The annotation of the KEGG pathway (Own figure)  
 
3. Reactome is an open-source, open access, manually curated and peer-reviewed pathway 
database. This database is an all-inclusive resource of human pathways for basic research, 
genome analysis, pathway modelling, systems biology and education. In this study Reactome 
version (V58) was used to map and analyse biological and molecular pathways other than the 
focused cell-cycle pathway, which may be influenced by the identified targets 
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4. Qiagens’s Ingenuity Pathway Analysis (IPA) has been widely used to model, analyse and 
understand the complex biological and chemical systems by the scientific community. In this 
study, IPA was used to help build a more complete regulatory picture and gain a better 
understanding of the biology underlying the studied gene expression profiles. To achieve this, 
the core analysis function of IPA was used. The z core was primarily used to indicate the 
degree of expression levels, with positive z score denoting upregulation, negative z core 
representing down-regulation, while zero (0) z core illustrates unchanged gene expression. 
Figure 3.3 below represent the IPA core-analysis annotation.  
  
Figure 3.3: The annotation of IPA (Own figure) 
RM. Marima: PhD Thesis 
46 
 
3.10 Statistical analysis 
 
Results for this study were analysed using Graph-Pad Prism 5 and expressed as means ± 
standard error of the mean (SEM) for at least three independent experiments. Significant 
differences were determined using one-way analysis of variance (ANOVA) followed by 
Tukey’s Post Hoc test. A probability level of p <0.05 was considered significant.  
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3.11 Diagrammatic summary of the research approach 
 
Figure 3.4: The flow-chart summarizing the research approach.   
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CHAPTER 4: RESULTS 
4.1 Introduction 
This chapter is presented in two sections, firstly describing the cellular analyses, followed by 
the molecular and Bio-informatics analyses. The cellular based approach was employed to 
elucidate the potential cytotoxic effects of ARVs in lung cancer, using in vitro cell culture 
models. To achieve this, Alamar blue (AB) assay, xCELLigence RTCA assay, FACS analysis 
of the cell-cycle and apoptosis and DAPI staining demonstrated that EFV and LPV/r drug 
treatment affected cellular health  by stimulating either proliferative effects at low doses or 
anti-proliferative and cytotoxic effects at high doses. These changes in cellular homeostasis 
post-ARV treatment led to an investigation of the underlying associated molecular and bio-
informatics basis of these effects. For this purpose, an evaluation of a focused panel of human 
cell-cycle related genes pre-and-post ARV treatment showed up-regulation of proliferation 
inhibitory genes, such as p21 and down-regulation of cyclin/CDK complexes, which drive the 
cell-cycle progression. The interrogation of gene expression using in silico bioinformatics 
analysis tools, including STRING, DAVID, Reactome and IPA, indicated this to be coupled 
with the induction of DNA damage response pathways in response to ARV treatment. This 
proposed DNA damage correlates with the observed changes in nuclear morphology, cell 
proliferation and death. These results are presented in detail below.   
 
4.2 The Effects of Efavirenz (EFV) and Lopinavir/Ritonavir 
(LPV/r) on Lung Cancer 
4.2.1 Alamar blue (AB) cell viability assay 
As previously described, the physiological reduction of the Alamar Blue (AB) dye was used 
here to quantitatively measure both cell proliferation and viability of MRC-5 and A549 cells 
pre- and post ARV (EFV and LPV/r) drug treatments.  
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(i) Efavirenz (EFV) treatment 
The reduction of AB was monitored in real-time at 24h intervals (24h, 48h and 72h) and 
measured spectrophotometrically at 540nm and 630nm. Figure 4.1 and Figure 4.2 illustrate 
percentage reduction of AB in response to EFV for MRC-5 and A549 cells, respectively. As 
represented in Figure. 4.1, 4µM EFV did not significantly change cell viability over a 24h to 
72h treatment period. However, at 13µM, indicated by the blue box, both cell proliferation 
and viability increased over 24 to 72h. In contrast, at higher doses, both 26µM and 50µM EFV 
treatments had anti-proliferative effects on the MRC-5 cells, as indicated by a decline in the 
percentage reduction of AB over 24 to 72h. Based on this analysis, 13µM EFV would seem to 
be the most physiologically relevant dose.  
 
Figure 4.1: The percentage (%) of AB reduction representing the MRC-5 cell viability. The 
results indicate treated relative to vehicle treated or control cells. Following EFV treatment, 
1% (at 24h), 2% (at 48h) and 5% (at 72h) increase in AB % reduction was observed. There is 
no statistical significance observed, with p> 0.05. The blue box indicates the most relevant 
physiological dose.  
With regards to the A549 cells (see Figure. 4.2) a concentration of 4µM EFV had no 
significant change in AB % reduction at 24h and 72h; but with a slight decrease at 48h. An 
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increase in cell proliferation was demonstrated by the 13µM EFV treated cells across all three 
time periods. This was then followed by a slight decline in cell viability at 26 and 50µM EFV 
at 24h to 72h. A further decrease in cell viability (AB % reduction) was observed irrespective 
of the time period. 
 
Figure 4.2: The A549 cell viability in response to the EFV drug treatment. The percentage 
(%) of AB reduction indicates treated relative to vehicle treated or control cells over 24h, 48h 
and 72h. Three percent (at 24h), 4% (at 48h) and 2% (at 72h) increase in cell proliferation was 
seen. The increase was not statistically significant with p> 0.05. The blue box indicates the 
most relevant physiological dose. 
 
(ii) Lopinavir/ritonavir (LPV/r) treatment 
Cell proliferation and viability following LPV/r treatment is shown in Figure 4.3 and Figure 
4.4 for each of the MRC-5 and A549 cell lines, respectively. When compared to the vehicle 
(veh) control cells, the 10µM LPV/r treatment, was shown to have an increased proliferation, 
while at 32µM there was a slight but insignificant drop in cell proliferation. At each of 50µM 
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and 80µM LPV/r, there was an evident decline in cell viability in MRC-5 cells (see Figure 
4.3). 
 
 
Figure 4.3: The MRC-5 cell viability in response to LPV/r drug treatment relative to vehicle 
treated cells. This is indicated by AB % reduction over a time period of 24h, 48h and 72h. An 
overall decrease of ~3% in AB% reduction is observed from 24h to 72h. This decrease is 
however, statistically insignificant, with p> 0.05. The blue box indicates the most relevant 
physiological dose.  
 
A change in AB % reduction was observed following treatment with a range of LPV/r 
concentrations (see Figure 4.4). At 10µM, LPV/r treatment was observed to exert an apparent 
proliferative effect on the cells, compared to the (veh control) cells. A decline in AB % 
reduction was observed on the 32µM LPV/r treated cells at all three time points. Treatment 
with both 50µM and 80µM LPV/r had an anti-proliferative effect on the A549 cells, as 
indicated by the decreased AB % reduction.  
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Figure 4.4: The representation of the A549 cell viability in response to the LPV/r cytotoxic 
effects, at 24h, 48h and 72h. The blue box indicates the most relevant physiological dose, and 
effects on cell viability are statistically insignificant, with p> 0.05.  
 
The mean steady-state peak plasma concentration (Cmax) is the most physiologically relevant 
concentration for the ARVs because it represents naturally occurring concentrations of the 
drugs following their intake (Drug Information SUSTIVA® Gilead Sciences 2010); (Drug 
information, KALETRA® Abbott laboratories, 2010), hence, Cmax was used for subsequent 
experiments.  
 
4.2.1.1 EFV and LPV/r drug treatment affect cell viability 
AB was used to evaluate MRC-5 and A549 cell viability treated with EFV and LPV/r relative 
to vehicle control cells. The experiment was conducted three independent times in triplicate 
and the results were spectrophotometrically analysed. The percentage (%) reduction (which is 
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proportional to cell viability) quantified in treated versus vehicle control cells varied with 
different drug concentrations, but not in a time-dependent manner. In particular, EFV at 13µM 
was shown to drive cell proliferation in both normal and cancerous cells at all three time 
points (Figure 4.1 and Figure 4.2). However 4µM EFV did not have significant effects on cell 
growth and proliferation. On the contrary, at higher concentrations of either 26µM or 50µM, 
EFV had anti-proliferative effects on the cells at 24h, 48h and 72h, respectively. Thus, the 
plasma relevant doses (4 and 13µM) of this NNRTI seem to favor cell proliferation, while 
raised levels (26 and 50µM) EFV exhibited anti-proliferative effects on the cells. 
Interestingly, similar pro- and anti-proliferative effects were observed with LPV/r treatment. 
At 10µM, LPV/r favoured cell proliferation, while at higher doses (32, 50 and 80µM) cell 
proliferation was inhibited, (Figure 4.3 and Figure 4.4). Overall, LPV/r treatment was 
demonstrated to exert significant anti-proliferative effects, not only on normal lung epithelial 
cells, but also on the A549 cancerous cells. Both EFV and LPV/r effects on lung cell viability 
was not statistically significant, with p> 0.05.   
 
4.2.2 Real Time Cell Impedance Analysis (RTCA) of EFV and LPV/r 
Treatment on MRC5 and A549 cells 
 
In the present study, the RTCA xCELLigence (ACEA Biosciences) instrument was used to 
assay in real time the cytotoxic effects of EFV and LPV/r on MRC-5 and A549 cell 
proliferation, cell viability and cell death. Prior to assessing drug effects, the optimum seeding 
cell density was determined for each cell line, (see Figure 4.5 and Figure 4.6). Once this was 
optimized, ARV drug treatment was administered 24h post seeding.   
 
4.2.2.1 Cell titration assays for optimal seeding densities 
This was done to determine the optimum cell density to seed prior to ARV drug treatment. 
Different titration curves were plotted for MRC-5 cells and for A549 cells, as these are two 
different cell lines in regard to size, shape and morphology. The cell index (CI) value, which 
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increases with increasing (attached) cell proliferation, was predetermined using the titration 
assays for both MRC-5 and A549 cells. For comparison purposes in response to ARV drug 
cytotoxicity, the CI values for both the cell-lines were plotted in a similar range.    
 
Figure 4. 5: MRC-5 cell titration, represented by Cell Index versus Time. A series of 2 fold 
dilutions was performed, wherein 30 000 cells/ml were selected as optimal for seeding, as 
recommended by the manufacturer. Cell index (y-axis) should at least be between 0.5 and 1, 
24h after seeding, prior to drug treatment.  
 
 
Figure 4.6: A549 cell titration, represented by the Cell Index versus Time. A series of 2 fold 
dilutions was done. Since the cell index should be between 0.5 and 1 post 24h seeding, 50 000 
cells/ml were demonstrated to be the optimum seeding density for the A549 cells.    
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4.2.2.2 RTCA analysis of cytotoxicity  
The potential cytotoxic effects of EFV and LPV/r on the MRC-5 and A549 cells were 
determined using RTCA assays. This was achieved by plotting the growth curves as a function 
of cell index (normalized to 1) versus time (h) over a period of approximately 100h. Since the 
cell index is proportional to cell viability, the greater the cell index the greater the cell 
viability. Based on the AB preceding data, three of the four ARV concentrations were further 
selected for cytotoxic, cell viability and proliferation using RTCA. Both cell lines were treated 
with EFV (4, 13, 50µM) and LPV/r (10, 32, 80µM).  
 To further analyse the effects of EFV and LPV/r on cell proliferation and cell death in a time 
dependent manner, the slope function of the curve was used. This function  describes the 
steepness, incline, gradient or changing rate of a curve within the given time period; and 
provides a measure for parameters of cell proliferation, cell adhesion, receptor activation, 
cytotoxicity or other cell based assays. Here, the slope function was used to determine the rate 
of change of the cell index (CI) or normalized cell index (NCI) for the cells following drug 
treatment. The slope incline is proportional to the cell index.  
4.2.2.3 Dose response profile of MRC-5 and A549 cells to EFV and LPV/r drug treatment 
i) EFV treatment response in MRC5 and A549 cells. 
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a) MRC5 cell response to EFV 
 
Figure 4. 7: MRC-5 cell growth curves treated with each of 4µM, 13µM and 50µM EFV. The 
curves were plotted relative to the vehicle control. 
With reference to Figure 4.7, following treatment at 24h, all MRC5 cells whether treated or 
vehicle control with EFV continued to proliferate. In addition, cells treated either with 4µM or 
13µM EFV proliferated and grew more than vehicle control cells. In contrast, 50µM treated 
cells, had a decreased cell proliferation.  
In plotting the slope function, an indication of cell detachment/cell death, in MRC-5 cells, an 
increase in cell proliferation and growth was observed for EFV at 4µM, and particularly for 
13µM, after 24h of treatment (see Figure. 4.8). A steady decline in cell proliferation was noted 
at 48h and was more evident at 72h. On the contrary, for 50µM EFV, a slight increase in cell 
proliferation and growth was observed at 24h, with further growth at 48h; and a steep decline 
in cell proliferation at 72h (Figure 4.8). 
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Figure 4.8: The slope function of MRC-5 cells representing the response to EFV treatment, 
Over 24h time intervals, this plot represents the rate of cell detachment, and thus cell death for 
each of the three drug concentrations. 
(b) A549 cell response to EFV 
After 24h of growth, the vehicle control A549 cells grew and proliferated steadily, compared 
to the treated cells, which continued to proliferate and grew for a further 40h prior to a 
decrease in cell viability (see Figure. 4.9 below). Conversely, cells treated with 50µM EFV 
proliferated slowly compared to the vehicle control cells, indicating an anti-proliferative effect 
of 50µM EFV on the A549 cells (Figure 4.9).  
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Figure 4.9: Growth curves representative of A549 cells treated with 4µM, 13µM and 50µM 
EFV, respectively. The curves were monitored and plotted relative to the vehicle control. 
The slope function plot for cell response to EFV reflected a slight increase in cell proliferation 
for 4µM after 24h of treatment (see Figure 4.10). However, a steady increase in cell 
proliferation and growth was shown for each of the 13µM and 50µM treatments after 24h. At 
48h there was decreased cell proliferation, with a sharp decline at 72h in cell viability for the 
three drug concentrations (Figure 4.10).  
 
Figure 4.10: The slope function representing the response of A549 cells to EFV drug 
treatment at 24h time intervals.  
 
 
RM. Marima: PhD Thesis 
59 
 
ii) LPV/r treatment response  
a) MRC-5 cell response to LPV/r  
Cell growth and proliferation of LPV/r treated cells relative to vehicle control was monitored 
over a 72h period. The MRC-5 vehicle control cells continued to grow and proliferate 
steadily, compared to 10µM treated cells which proliferated at an increased rate (see Figure. 
4.11). However, at a concentration of 32µM the cells neither increased nor decreased their 
proliferation, this being a particular characteristic of cell-cycle arrest. On the other hand, 
80µM of LPV/r was clearly cytotoxic to the cells, indicated by an abrupt peak of the 
normalized CI immediately after drug treatment, followed by a rapid decline in cell viability 
(see Figure. 4.11 below).   
 
 
Figure 4.11: MRC-5 growth curves representing cells treated with 10µM, 32µM and 80µM 
LPV/r. The curves represent the normalized cell index (NCI) which is proportional to cell 
viability versus time (hours). 
The slope-function plot reflected the growth trends of the real time growth curves (refer to 
Figure 4.12 below). With drug treatment, the cells continued to grow steadily after 24h and 
48h periods, followed by a decline in cell viability after 72h for 10µM LPV/r. At 32µM, a 
slight decrease in cell viability subsequent to drug treatment was observed at 24h, followed by 
a slight incline in cell proliferation at 48h; and this remained steady even after 72h of culture.  
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At 24h following 80µM LPV/r treatment, a marked decline in cell viability was observed, 
with decreased cell viability persisting at 48h and 72h.  
 
Figure 4.12: The slope function demonstrating MRC-5 cell response to LPV/r drug treatment, 
monitored at 24h intervals.   
b) A549 cell response to LPV/r  
The A549 cells were monitored before and after drug treatments at 24h post seeding (refer to 
Figure 4.13). When compared to the control cells, 10µM and 80µM treated cells showed a 
proliferative effect, followed by a rapid decline in cell viability. The 32µM treated cells in 
contrast, displayed a cell-cycle arrest (observed from the time point of treatment), after which 
there was decreased cell viability (Figure. 4.13).  
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Figure 4.13: Growth curves for A549 cells treated with 10µM, 32µM and 80µM LPV/r in 
relation to the vehicle control cells. The curves were plotted as a function of normalized CI 
versus time.  
The slope function plot for cell response to LPV/r revealed an apparent increase in A549 cell 
proliferation for 10µM LPV/r at 24h, while there is a decline for 32µM LPV/r and an increase 
in proliferation for 80µM LPV/r (figure 4.14). There is a consistent decrease in cell viability 
for 32µM treatment even after 48h and 72h. An abrupt decline in cell viability is observed at 
48h and 72h, for 32µM LPV/r treated cells, and particularly observed in 80µM treatment.   
 
Figure 4.14: A slope function bar graph representing A549 cells treated with LPV/r at 24h 
intervals. 
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4.2.2.4 RTCA demonstrates the pro-and-anti-proliferative effects of EFV and LPV/r  
The label-free RTCA analysis as measured by the xCELLigence instrument corroborated the 
results of the Alamar Blue assays. The RTCA very precisely, evaluated the cytotoxic effects 
of EFV and LPV/r on MRC-5 and A549 cells, assessing cell viability in real-time. This assay 
was particularly sensitive to and indicative of the window period of the drug efficacy. This 
was reflected by the growth curves and further analysed by the slope function, showing the 
associated decline in CI, and therefore in cell viability.  
At lower concentrations EFV had the effect of stimulating cell proliferation in both the MRC-
5 and A549 cells, this relative to vehicle control cells. Subsequently, proliferation (CI) 
decreased at higher concentrations with cellular detachment from the culture substrate 
occurring.   
However, notably, while there was no clear distinction here in the growth and proliferation 
patterns between treated and vehicle control cells, there were nevertheless observed decreases 
and increases in the proliferation rates between the vehicle control and treated cells. This 
finding suggests that although EFV treatment does seem to influence cell proliferation it does 
not necessarily alter cellular health.  
Similar to EFV, LPV/r at low concentrations stimulated cell proliferation in both MRC-5 and 
excessively in A549 cells, followed by cell death. An intermediate dose, caused cell-cycle 
arrest in both cell types, while high concentrations led to an increase in cell death, preceded by 
increased cell proliferation. 
The following research approach further interrogates the effects of ARVs on the cell-cycle by 
fluorescence activated cell sorting (FACS).  
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4.2.3 Cell-cycle Analysis by Fluorescence-Activated Cell Sorting (FACS) 
 
Since RTCA analysis demonstrated some effects of ARVs on the cell-cycle, flow cytometry 
was next employed to quantify DNA content and thus the particular cell-cycle stage of treated 
cells, relative to vehicle control cells. Here, the scope of this analysis was to determine the 
regulatory effects of ARV’s on the cell-cycle in lung cells.  
 
4.2.3.1 Cell-cycle analysis of EFV and LPV/r treated cells by flow cytometry 
Prior to ARV (EFV and LPV/r) drug treatment and cell-cycle analysis, cells were serum-
starved overnight to synchronise the cell-cycle at G0/G1. Results are a representation of at 
least three (3) independent experiments, represented as histograms and bar graphs. Data is 
expressed as mean ± SEM. (For supplementary data, see appendix C3).   
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(a) Cell-cycle analysis of MRC-5 cells treated with EFV 
 
Figure 4.15: PANEL A- FACS analysis of the cell-cycle stages in MRC-5 cells treated with 
(4, 13 and 50 µM) EFV for 24h (A to D) and 48h (E to H), respectively. Vehicle control and 
drug treated cells (4, 13 and 50µM EFV) were stained with propidium iodide and their DNA 
content measured using flow cytometry An increase in S-phase is observed with 13µM EFV 
(C and G) and 50µM EFV (D and H), while there was a slight increase in the percentage of 
cells in G2/M in 4µM EFV treated cells (B and F), compared to vehicle control cells (A and 
E). 
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PANEL B- Bar graphs representing cell-cycle distribution relative to drug concentration at 
24h and 48h, respectively. The increase in the proportion of cells in S-phase is evident from 
these graphs, this increasing with raised EFV concentrations, with p < 0.01 at both 24h and 
48h compared to vehicle control cells. Error bars denote SEM.  
 
(i) FACS analysis of EFV treated MRC-5 cells 
About 73% of the control cells (vehicle control) were located in the G0/G1 phase of the cell-
cycle, at both 24h and 48h. Relative to this, the percentage of cells in G0/G1 decreased with 
increased drug concentration at 24h, reducing to about 60% (4μM), 10.5% (13µM) and 21% at 
50µM. At 48h however, 54% cells treated with 4µM were in G0/G1, before decreasing to 
10% (13µM) and 16.4% (50µM). In association with this, the percentage of cells undergoing 
DNA synthesis in S-phase, began to increase, from 3% in (normal) control cells, to 7 to 10% 
(4μM), 60% (13μM) and peaking at about 70% (50μM), at both the 24h and 48h time points. 
While about 20% of control cells were in G2/M at 4µM EFV, this percentage increased to 
approximately 28 to 30% at 4μM EFV; and decreased again to 18-19% of cells at 13μM and 
further to about 5-6% of cells at 50μM EFV (see Figure 4.15). 
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(b) Cell-cycle analysis of A549 cells treated with EFV 
 
Figure 4.16: PANEL A- Histograms representing cell-cycle analysis of A549 cells treated 
with EFV. A to D represent 24h treatment, while E to H show 48h treatment.  A clear 
induction of the S-phase is observed with 13µM and 50µM EFV treatments (C and G, D and 
H), while an increase in the G2/M is seen with 4µM EFV (B and F), compared to the vehicle 
control  cells (A and E).  
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PANEL B- Bar graphs representing cell-cycle distribution in A549 cells relative to drug 
concentration at 24h and 48h, respectively. Vehicle control and drug treated cells (4, 13 and 
50µM EFV) were stained with propidium iodide and their DNA content measured using flow 
cytometry. The concentration of the drug is proportional to the increase in S-phase, with p< 
0.05 for 13µM and 50µM EFV treated at both time points. Error bars indicate SEM.     
 
(ii) FACS analysis of EFV-treated A549 cells 
Some 80% of the control cells (vehicle control) were located in the G0/G1 phase of the cell-
cycle, at both 24h and 48h. Relative to this, the percentage of cells in G0/G1 decreased with 
increased drug concentration at 24h, reducing to about 58% (4μM), 33% (13µM) and 13% at 
50µM. At 48h however, 80% cells treated with 4µM remained in G0/G1, before decreasing to 
30% (13µM) and 22% (50µM). In relation to this, an increase in S-phase with increasing EFV 
dose is observed. This S-phase incline ranges from 11% (vehicle control) to 15% (4µM), to 
40% (13µM), to 55 % (50µM) at 24h. This pattern is also seen at 48h, with an exception of 
4µM treatment, with 80% of cells remaining at G0/G1. In addition, an increase of G2/M 
population at 4µM is observed at both time points, from 4.6% to 16.1% at 24h and 2.7% to 
10% at 48h (see Figure 4.16).   
 
 
 
 
 
 
 
 
 
RM. Marima: PhD Thesis 
68 
 
(c) Cell-cycle analysis of MRC-5 cells treated with LPV/r 
 
Figure 4.17: PANEL A- Histograms representing cell-cycle analysis in MRC-5 cells treated 
with LPV/r for 24h (A to D) and 48h (E to H). Vehicle control and drug treated cells (10, 32 
and 80µM LPV/r) were stained with propidium iodide and their DNA content measured using 
flow cytometry. An induction of the S-phase arrest is seen at 32µM LPV/r treatment (C and 
G), with an increase in the percentage of cells in G2/M at 10µM LPV/r treatment (B and F); 
and a sub-G0/G1 population is observed with 80µM treatment (D and H).  
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PANEL B- Bar graphs representing cell-cycle distribution in MRC-5 cells relative to LPV/r 
concentration at 24h and 48h, respectively.  Distinct interphases of the cell-cycle in response 
to LPV/r treatment in MRC-5 cells are represented here. S-phase arrest is observed at 32µM 
with p< 0.01 at 24h and p< 0.01 at 48h.  LPV/r treatment, while 10µM LPV/r increased G2/M 
and decreased bars of 80µM LPV/r being attributed to the Sub-G0/G1 population, at 24h and 
48h, this observation was not statistically significant. Error bars represent SEM.  
 
(iii) FACS analysis of LPV/r treated MRC-5 cells 
At 24h and 48h some 60-70% of the control cells (vehicle control) were located in the G0/G1 
phase of the cell-cycle. Relative to this, the percentage of cells in G0/G1 decreased with 
increased drug concentration at both 24h and 48h, then reducing to about 51 to 52% (10μM) 
and 16-23% (32µM). However at the highest concentration (80μM), the percentage of cells in 
G0/G1 increased in the range of 45-57%.  The percentage of cells in S-phase increased from 
approximately 3% at 24h and 48h in control cells to 65 and 72%, respectively at 32μM LPV/r. 
At 80μM LPV/r, the percentage of cells synthesizing DNA decreased markedly to 26% at 24h 
and 8% at 48h. For G2/M, the proportion of cells increased marginally from about 30% to 
about 20% at 24h and 48h at 10μM. After this at the higher concentrations, the cell 
percentages decreased to below those at the control levels, (see Figure 4.17).  
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(d) Cell-cycle analysis of A549 cells treated with LPV/r 
 
Figure 4.18: PANEL A- Histograms representing cell-cycle analysis in A549 cells treated 
with LPV/r at 24h (A to D) and 48h (E to H). Vehicle control and drug treated cells (10, 32 
and 80µM LPV/r) were stained with propidium iodide and their DNA content measured using 
flow cytometry. An increase in the G2/M phase is seen with 10µM treatment (B and F), while 
32µM (C and G) and 80µM LPV/r (D and H) induced S-phase arrest. A sub-G0/G1 
population was observed with the 80µM LPV/r treatment.  
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PANEL B- Bar graphs representing distinct cell-cycle phases in A549 cells treated with 
LPV/r. The increase in S-phase was observed with increasing LPV/r concentrations, 
particularly with 32µM with p< 0.05. Ten micromolar LPV/r treatment in particular increased 
the G2/M populations, at both of the 24h (p< 0.01) and 48h (p< 0.05) time periods. Error bars 
denote SEM.  
 
(iv) FACS analysis of A549 cells treated with LPV/r 
After drug treatment, the percentage of cells in G0/G1 decreased from 78 and 82 %, to 19 and 
24%, and increased in G2/M from 8 and 4% to 42 and 22% at 10μM LPV/r for the 24h and 
48h time points, respectively; then at 32μM increasing again to about 49 and 32%, 
respectively; but with these percentages remaining in a similar range at 80μM for both time 
periods. The relative stability of these proportions at the upper concentrations of LPV/r 
signifies an S-phase arrest. A sub-G0/G1 population was detected in response to 80μM LPV/r, 
indicating cell-death (see Figure 4.18).  
 
4.2.3.2 Both EFV and LPV/r alter the cell-cycle stages 
FACS analysis more precisely determined the effects of the ARV drugs, EFV and LPV/r on 
cell-cycle stages. In summary, at low concentrations and at both time points the ARVs 
effectively stimulated an increased G2/M percentage in normal and cancerous cells. At higher 
concentrations, an S-phase arrest, which usually follows DNA damage, occurred.  This results 
in cells with damaged DNA being unable to proceed to the G2 phase. Thus it would seem that 
at higher concentrations LPV/r causes irreparable DNA damage, potentially leading to 
apoptosis. At the maximum ARV concentrations used here, cell viability was reduced, leading 
to the detection of a sub-G0/G1 cell population. This ability of ARVs (LPV/r) to induce 
programmed cell death is further investigated below. 
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4.2.4 The effect of ARVs on apoptosis  
Prior analyses in the present study demonstrated that of the two ARVs tested, LPV/r had 
cytotoxic effects on both the normal MRC-5 and cancerous A549 cells, whereas EFV in 
comparison did not seem to predispose cells to apoptosis. Further to this, the demonstration of 
a sub-G0/G1 population after LPV/r treatment prompted additional investigation of the 
cytotoxic/ apoptotic effects of LPV/r.    
 
4.2.4.1 Induction of apoptosis by LPV/r 
Following 32 and 80µM LPV/r drug treatments, FACS analysis using Annexin FITC and PI 
staining was used to quantify and analyse apoptosis in the lung cell lines. The experiment was 
done three times in triplicate (see appendix C for supplementary data); vehicle control and 
treated cells were labeled with both Annexin FITC and PI. The vehicle control -unstained cells 
were used as blank, vehicle control and stained cells (negative control), while Annexin-FITC 
single staining and PI single staining were used for compensation and setting up of quadrants. 
These results are represented in histograms and bar-graphs depicted below:  
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(a) Apoptosis in MRC-5 cells  
 
Figure 4.19: PANEL A- FACS analysis of MRC-5 cells treated with LPV/r at 24h and 48h. 
Histograms A to D represent 24h treatment, while E to H denote treatment at 48h. A and E 
represent vehicle (negative) control stained cells; B and F, camptothecin (CPT) (50μM) 
treated cells (positive control), C and G, cells treated with 32µM LPV/r; and D and H, cells 
treated with 80µM LPV/r. The apoptotic quadrant depicted at the lower right of each 
histogram denotes the percentage of cells undergoing early apoptosis, relative to the viable 
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population of cells (lower left) and the late apoptotic and/or necrotic cells (upper right 
quadrant).  
PANEL B- Bar graphs representing percentage of apoptosis induction relative to drug dose in 
MRC-5 cells. The left panel represents apoptosis analysis at 24h; while the right panel 
represents apoptosis analysis at 48h.  ANOVA and Tukey’s multiple comparison tests were 
used to evaluate the significance of apoptosis in treated versus vehicle control cells. All three 
treatments show a significant increase in apoptosis percentage (%) compared to the negative 
(veh) control. Cells treated with 80µM displayed double and triple fold increases in apoptosis 
%, respectively [p<0.001 (***)], compared to 32µM LPV/r treated [p<0.01 (**)]; and CPT 
treated [ p<0.05 (*)] cells. Error bar denotes SEM; *p<0.05; **p<0.01; ***p<0.001.   
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(a) A549 cells (apoptosis)  
 
Figure 4. 20: PANEL A- FACS analysis of A549 cells treated with LPV/r at 24h and 48h. 
Histograms A to D represent 24h treatment, while E to H show treatment at 48h. A and E 
represent vehicle (negative) control stained cells; B and F, CPT (50µM) treated cells (positive 
control), C and G, cells treated with 32µM LPV/r; and D and H, cells treated with 80µM 
LPV/r. The apoptotic quadrant depicted at the lower right of each histogram  denotes the 
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percentage of cells undergoing apoptosis, distinguished from a viable population of cells 
(lower left) and the late apoptotic and/or necrotic cells (upper right quadrant).   
PANEL B- Bar graphs representing percentage apoptosis induction relative to drug treatment 
in A549 cells. The left panel represents apoptosis analysis at 24h; the right panel represents 
apoptosis analysis at 48h.  Camptothecin (CPT) at 50μM was used as a positive control. Using 
ANOVA and Tukey’s multiple comparison test, all three treatments effected a significant 
increase in apoptosis percentage (%) compared to the negative (veh) control. The 80µM 
treated cells demonstrated a consistent apoptosis percentage after 24h and 48h, (p<0.001). 
CPT and 32µM LPV/r showed a similar apoptotic effect, especially after 48h (p<0.01).  Error 
bar denotes SEM; *p<0.05; **p<0.01; ***p<0.001.  
 
4.2.4.2 LPV/r drug treatment induces cell death (apoptosis and necrosis) in a dose dependent 
manner  
Both LPV/r concentrations, 32 and 80µM, induced apoptotic effects on normal and cancerous 
lung cells. The raised apoptotic percentage rate increased with LPV/r concentration. However, 
there was also a significant coupled cellular necrosis observed in both MRC-5 and A549 cells. 
Thirty-two µM LPV/r effected a slightly higher degree of apoptosis, compared to CPT treated 
cells (in both MRC-5 and A549 cells). At 80µM LPV/r treated cells had double the apoptosis 
percentage rate, compared to 32µM treated cells (Figure 4.19 and 4.20). Nevertheless the 
necrotic cell-death did not seem to increase with increasing LPV/r concentrations.  
 
4.2.5 Evaluation of Nuclear Morphology before and after ARV treatment, 
using DAPI staining 
 
To determine morphological and nuclear changes such as DNA fragmentation and chromatin 
condensation in MRC-5 and A549 cells in response to EFV and LPV/r, DAPI staining was 
used. This analysis is presented below, Figures 4.21 and 4.22. 
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Figure 4.21: DAPI staining of MRC-5 cells. Changes in morphology were assessed in ARV 
drug treated relative to vehicle control cells.  A represents vehicle control  cells, B and C show 
MRC-5 cells treated with 13µM and 50µM EFV. D and E illustrate LPV/r treatment at 32µM 
and 80µM.  
Green arrows point to changes in the nucleus such as DNA fragmentation and chromatin 
condensation in ARV drug treated (B to E)  relative to vehicle control cells (A) (Original 
Magnification, 63X).  
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Figure 4.22: DAPI staining of the A549 cells. Nuclear morphology was evaluated before and 
after EFV and LPV/r treatment. Compared to the vehicle control, (A) 13µM (B) and 50µM 
(C) EFV treatment, and 32µM (D) and 80µM (E) LPV/r show changes in nuclear morphology 
as demonstrated by the green arrows (Original Magnification, 63X).      
 
Green arrows point to changes in the nucleus. Such changes may include DNA fragmentation 
and chromatin condensation in ARV drug treated (B to E) relative to vehicle control cells (A) 
(Original Magnification, 63X).  
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4.2.6 Synopsis 
 
In summary, the effects of these ARV drugs on the normal and cancerous lung cells was  
monitored in  real-time, with  real time cell impedance assays  (xCELLigence system), which 
particularly served to  elucidate the timing and nature of any relevant physiological responses 
by living cells. In particular, the curves representing cell growth/proliferation over time 
identified the window period during which these drugs were either pro- or anti-proliferative, 
where the Cmin of both EFV and LPV/r promoted cell growth and proliferation, while the 
Cmax and higher concentrations inhibited cell proliferation, leading to cell death. It was 
interesting to note that the proliferative effects of EFV were effective for at least 40h post-
treatment in the A549 cancerous cells, while normal cells continued to proliferate, until a 
decline in cell viability attributed to possibly nutrient deprivation, was observed. 
The Annexin V-FITC/PI apoptosis assay confirmed the cytotoxic effects of LPV/r, as initially 
observed by the xCELLigence RTCA. While RTCA analysis showed loss of cell viability in 
LPV/r treated cells, the mode of cell death was confirmed here by the apoptosis assay in both 
normal lung and cancerous cells. In association with this, the nuclei of ARV treated cells 
showed changes in morphology. Following on this confirmation of apoptosis and associated 
nuclear changes, gene expression changes associated with the cell-cycle were evaluated.  
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4.3 PROFILING OF THE HUMAN CELL-CYCLE GENE 
RESPONSE AFTER ART TREATMENT IN HUMAN NON-
SMALL CELL LUNG CARCINOMA (NSCLC) CELLS 
 
4.3.1 Human cell-cycle PCR Arrays 
 
Following on the aforementioned observations relating to cell proliferation, the involvement 
of the cell-cycle and potential pathways of apoptosis, a specific gene panel was employed here 
to more specifically interrogate changes in the expression of cell-cycle related genes in 
response to ARV treatments. These findings are presented below. 
(i) Assessment of Quality Control (QDC) 
PCR arrays, incorporating 84 genes related to the cell-cycle were profiled on 6 samples, 
inclusive of vehicle (methanol) controls on both MRC-5 cells and A549 cells, EFV (13 μM) 
treated MRC-5 cells and A549 cells; and LPV/r treated (32 μM) MRC-5 cells and A549 cells.  
The results of the gene expression arrays were analysed by GeneGlobe program (Qiagen), by 
comparing the normalised fold changes of the test group against the control group. Potential 
changes in gene expression were also analysed by the GeneGlobe program (Qiagen), by 
comparing the normalised fold changes of the test against the control groups.  
 All six (6) PCR Arrays were subjected to data quality control checks (using the GeneGlobe 
Program, for monitoring genomic DNA contamination (GDC), the first strand synthesis 
(RTC) as well as real-time PCR efficiency (PPC). All six arrays passed these checks (see 
Table 4.1).  
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Table 4.1: RT Profiler PCR Arrays data quality control checks 
Test performed Test Result 
1. PCR Array Reproducibility All Samples Passed 
2. RT Efficiency All Samples Passed 
3. Genomic DNA Contamination None-All Samples Passed 
 
(ii) Representation of Results 
The data representing changes in gene expression are represented here as fold changes in gene 
expression, in tables, heat maps and scatter plots. The heat map setting reflects the PCR array 
layout, where green represents down-regulated genes and red indicates up-regulated genes; 
and the intensity of the colours correlates with the degree of up- or down-regulation. Thus, the 
heat map provides a relative visualization of the fold changes in gene expression between the 
test cells as compared to (vehicle) control samples. Alterations in gene expression were 
analysed by the GeneGlobe software (Qiagen), by comparing the normalised fold changes of 
the drug treated cells against the control cells. Group 1 in the Y-axis of scatter plots denotes 
the test groups. GE represents gene expression. Figure 4.23  illustrates the associated heat map 
and scatter plot for test (A549) versus MRC-5 vehicle control cells. All of the remaining heat 
maps and scatter plots are included in Appendix C5, for EFV and LPV/r gene array 
supplementary data. The ±2 fold significantly up-or-down regulated genes for all groups are 
represented in Tables 4.2 to 4.11.  
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(iii) Gene expression analysis in fold change 
(a) A549 (test) vs MRC-5 (control)-untreated cells 
 
 
Figure 4. 23: The heat map (left panel) representing gene expression (GE) in untreated A549 
(test) vs MRC-5 cells (control). Down-regulated genes are represented in green, while 
overexpressed genes are represented in red and unchanged expression in black. The colour 
intensity correlates with the degree of up/down regulation. The fold change of ±11.79 
represents the lowest and the highest value for down and up-regulation.  
The scatter plot shown in the right panel above compares the normalized expression of every 
gene on the array between the A549 cells and the MRC-5 cells (control), by plotting them 
relative to one another, to visualize gene expression changes. Each data point on the scatter 
plot represents a single gene, with normalised expression. The central (unbroken) line 
indicates unchanged gene expression, while the dotted lines indicate the selected (±2) fold 
regulation threshold. Up-regulation is indicated by the yellow points/red arrow, while down-
regulation is shown by the black points/green arrow.  
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Table 4.2: The up-regulated genes in untreated (A549 vs MRC-5) cells 
Gene Symbol GenBank Accession no. Fold change/upregulation 
CCNB2 NM_004701 14.62 
AURKB NM_004217 14.12 
CCNB1 NM_031966 7.62 
CDKN3 NM_005192 7.46 
CDC6 NM_001254 5.03 
KNTC1 NM_014708 4.96 
RAD9A NM_004584 4.89 
AURKA NM_003600 4.44 
TP53 NM_000546 4.32 
MCM4 NM_005914 4.29 
CHEK2 NM_007194 4.23 
CCNF NM_001761 4.08 
BRCA2 NM_000059 4 
CDC25C NM_001790 3.97 
BRCA1 NM_007294 3.84 
CDK1 NM_001786 3.76 
CCNE1 NM_001238 3.68 
BIRC5 NM_001168 3.61 
GTSE1 NM_016426 3.58 
MCM5 NM_006739 3.51 
RBL1 NM_002895 3.46 
MKI67 NM_002417 3.39 
MCM3 NM_002388 3.07 
CCNA2 NM_001237 3.01 
CDC20 NM_001255 2.95 
MAD2L2 NM_006341 2.83 
E2F1 NM_005225 2.81 
CCND3 NM_001760 2.38 
BCCIP NM_016567 2.06 
 
Table 4.3: The down-regulated genes in untreated (A549 vs MRC-5) cells 
Gene Symbol GenBank Accession no. Fold 
change/downregulation 
CCND2 NM_001759 -3541.14 
CDKN2A NM_000077 -891.44 
CDKN2B NM_004936 -64.45 
CDKN1A NM_000389 -16.11 
CCNG1 NM_004060 -11.63 
GADD45A NM_001924 -10.7 
CCND1 NM_053056 -10.7 
HUS1 NM_004507 -8.11 
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Gene Symbol GenBank Accession no. Fold 
change/downregulation 
   
RAD1 NM_002853 -4.79 
SERTAD1 NM_013376 -4.5 
CDC16 NM_003903 -4.41 
CASP3 NM_004346 -3.73 
SKP2 NM_005983 -3.48 
CUL2 NM_003591 -3.23 
CCNG2 NM_004354 -3.23 
ABL1 NM_005157 -2.87 
RAD17 NM_002873 -2.71 
ANAPC2 NM_013366 -2.64 
CDK6 NM_001259 -2.16 
RB1 NM_000321 -2.1 
 
(b) EFV treated test vs control gene expression analysis 
(i) MRC-5 cells 
Table 4.4: The up-regulated genes in EFV-treated vs untreated MRC-5 cells 
Gene Symbol GenBank Accession no. Fold change/upregulation 
CCNG2 NM_004354 8.76 
CCNH NM_001239 7.95 
CDKN2B NM_004936 4.2 
CCND2 NM_001759 3.97 
MDM2 NM_002392 3.92 
CDK7 NM_001799 3.16 
RBL1 NM_002895 2.85 
CCNB1 NM_031966 2.73 
ATM NM_000051 2.68 
ATR NM_001184 2.57 
MCM3 NM_002388 2.51 
BRCA1 NM_007294 2.4 
BCCIP NM_016567 2.36 
CHEK1 NM_001274 2.28 
HUS1 NM_004507 2.13 
CDK6 NM_001259 2.13 
RAD51 NM_002875 2.11 
 
Table 4.5: The down-regulated genes in EFV-treated vs untreated MRC-5 cells 
Significantly down-regulated (-2) genes None 
RM. Marima: PhD Thesis 
85 
 
(ii) A549 cells 
Table 4.6: The up-regulated genes in EFV-treated vs untreated A549 cells 
Gene Symbol GenBank Accession no. Fold change/upregulation 
NBN NM_002485 3.42 
CCNG2 NM_004354 3.32 
RAD17 NM_002873 3.3 
CDK5RAP1 NM_003885 3.14 
SERTAD1 NM_013376 2.76 
CASP3 NM_004346 2.74 
CCNG1 NM_004060 2.57 
CDKN1B NM_004064 2.57 
CDK4 NM_000075 2.43 
BRCA1 NM_007294 2.33 
CUL2 NM_003591 2.32 
RAD1 NM_002853 2.29 
HUS1 NM_004507 2.21 
SKP2 NM_005983 2.21 
CDC20 NM_001255 2.13 
 
Table 4.7: The down-regulated genes in EFV-treated vs untreated A549 cells 
Gene Symbol GenBank Accession no. Fold 
change/downregulation 
MAD2L2 NM_006341 -5.85 
AURKB NM_004217 -4.28 
MCM4 NM_005914 -3.65 
RBL1 NM_002895 -3.52 
ATR NM_001184 -3.07 
CCNB2 NM_004701 -2.71 
 
(c) LPV/r treated test vs control gene expression analysis 
Table 4.8: The up-regulated genes in LPV/r-treated vs untreated MRC-5 cells 
(i) MRC-5 cells 
Gene Symbol GenBank Accession no. Fold change/upregulation 
CDKN2B NM_004936 5.17 
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Table 4.9: The down-regulated genes in LPV/r-treated vs untreated MRC-5 cells 
Gene Symbol GenBank Accession no. Fold change/down 
regulation 
CDC20 NM_001255 -95.67 
MCM2 NM_004526 -40.79 
GTSE1 NM_016426 -34.3 
MKI67 NM_002417 -27.28 
CDK1 NM_001786 -27.1 
CDK2 NM_001798 -24.25 
CCNB1 NM_031966 -21.41 
BIRC5 NM_001168 -20.68 
STMN1 NM_005563 -18 
CCNB2 NM_004701 -17.75 
CCNA2 NM_001237 -17.15 
CCNF NM_001761 -14.52 
MCM3 NM_002388 -14.32 
CDC25C NM_001790 -14.32 
AURKA NM_003600 -12.82 
KPNA2 NM_002266 -12.73 
MCM5 NM_006739 -12.3 
AURKB NM_004217 -11.96 
RAD51 NM_002875 -11.08 
SERTAD1 NM_013376 -10.78 
ANAPC2 NM_013366 -10.78 
CDKN3 NM_005192 -10.13 
MAD2L2 NM_006341 -9.71 
MAD2L1 NM_002358 -9.71 
SKP2 NM_005983 -9.38 
MCM4 NM_005914 -9.06 
CCND1 NM_053056 -8.82 
CCND3 NM_001760 -8.22 
TFDP1 NM_007111 -5.94 
CKS1B NM_001826 -5.66 
CKS2 NM_001827 -5.58 
CDK5RAP1 NM_016408 -4.41 
CASP3 NM_004346 -4.29 
E2F1 NM_005225 -4.17 
MRE11A NM_005590 -3.84 
KNTC1 NM_014708 -3.73 
CDC25A NM_001789 -3.73 
CHEK1 NM_001274 -3.68 
CCNG1 NM_004060 -3.61 
RBL1 NM_002895 -3.48 
CHEK2 NM_007194 -3.46 
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Gene Symbol GenBank Accession no. Fold change/down 
regulation 
   
WEE1 NM_003390 -3.36 
CDK6 NM_001259 -3.23 
E2F4 NM_001950 -3.18 
BRCA1 NM_007294 -3.03 
CCNE1 NM_001238 -2.83 
CCND2 NM_001759 -2.77 
TFDP2 NM_006286 -2.75 
CDKN1B NM_004064 -2.71 
CDKN2A NM_000077 -2.66 
ABL1 NM_005157 -2.53 
RAD1 NM_002853 -2.33 
MNAT1 NM_002431 -2.28 
HUS1 NM_004507 -2.23 
RAD9A NM_004584 -2.22 
CDC34 NM_004359 -2.22 
CDC16 NM_003903 -2.19 
CDK8 NM_001260 -2.08 
CCNG2 NM_004354 -2.04 
 
(ii) A549 cells 
Table 4.10: The up-regulated genes in LPV/r-treated vs untreated A549 cells 
Gene Symbol GenBank Accession no.  Fold change/upregulation 
GADD45A NM_001924 40.12 
HUS1 NM_004507 23.36 
BCL2 NM_000633 10.38 
RAD17 NM_002873 5.45 
CCNH NM_001239 4.71 
CDK5RAP1 NM_016408 4.52 
ATM NM_000051 4.1 
CUL2 NM_003591 4.1 
CCNG2 NM_004354 3.55 
SERTAD1 NM_013376 3.4 
TP53 NM_000546 3.4 
RAD1 NM_002853 3.26 
CDKN2A NM_000077 3.24 
CDK4 NM_000075 3.17 
CDKN1A NM_000389 3.15 
CUL3 NM_003590 3.13 
CDKN1B NM_004064 3.13 
RBL2 NM_005611 2.88 
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Gene Symbol GenBank Accession no. Fold change/down 
regulation 
   
BCCIP NM_016567 2.63 
CCNT1 NM_001240 2.52 
CCNG1 NM_004060 2.42 
CASP3 NM_004346 2.34 
CCND2 NM_001759 2.18 
 
Table 4.11: The down-regulated genes in LPV/r-treated vs untreated A549 cells  
Gene GenBank Accession no. Fold 
change/downregulation 
GTSE1 NM_016426 -47.3 
CCNB1 NM_031966 -45.69 
CCNB2 NM_004701 -44.13 
CDC25C NM_001790 -36.6 
CCNA2 NM_001237 -23 
CDK1 NM_001786 -20.31 
MCM4 NM_005914 -15.93 
STMN1 NM_005563 -15.71 
E2F1 NM_005225 -14.97 
MCM5 NM_006739 -14.66 
AURKB NM_004217 -13.3 
MKI67 NM_002417 -13.12 
CDC20 NM_001255 -13.03 
MAD2L1 NM_002358 -9.34 
CDKN3 NM_005192 -9.34 
CCND3 NM_001760 -8.02 
CCNF NM_001761 -6.61 
RAD51 NM_002875 -6.61 
BIRC5 NM_001168 -6.34 
MCM2 NM_004526 -5.22 
CDC6 NM_001254 -4.94 
MAD2L2 NM_006341 -4.84 
CHEK2 NM_007194 -4.61 
MCM3 NM_002388 -4.61 
KNTC1 NM_014708 -4.24 
BRCA2 NM_000059 -4.18 
CDK2 NM_001798 -3.96 
CKS2 NM_001827 -3.85 
AURKA NM_003600 -3.74 
CDC25A NM_001789 -3.47 
CCNE1 NM_001238 -3 
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Gene Symbol GenBank Accession no. Fold change/down 
regulation 
   
RBL1 NM_002895 -2.8 
CHEK1 NM_001274 -2.61 
 
 
4.3.1.1 EFV and LPV/r treatments modulate the expression of genes related to the cell-cycle 
in lung cancer cells (A549) and in normal lung cells (MRC-5) groups  
Prior to treatment a significant number of genes are shown to be dysregulated, either up-or 
down, and were represented as shifting from the median-solid line, in the scatter plots as 
shown in Figure 4.29. The upregulated genes (Table 4.2) included cyclin/CDK complexes, 
while the down-regulated genes (Table 4.3) included growth-arrest genes, such as p21 and 
GADD45A. On the other hand, RT-PCR arrays indicated a general up-regulation in the 
transcription of cell-cycle genes in MRC-5 cells treated with EFV (Table 4.4), while most 
genes remained in a normal (unchanged) state (Table 4.5). EFV treatment of A549 cells led to 
the increase (Table 4.6) in the transcription of other cell-cycle genes and a decrease (Table 
4.7) in the transcription of others. However, most genes were observed to be normalised 
across the solid line, as compared to the untreated (vehicle control) cancerous cells.  
LPV/r treatment of MRC-5 cells resulted in the upregulation of the CDKN2B gene (Table 4.8) 
a decreased transcription of cell-cycle genes assayed (Table 4.9). In contrast, LPV/r treatment 
of A549 cells led to a significant dysregulation of the cell-cycle genes arrayed, moving away 
from the normal level of expression. Most of the upregulated genes here (Table 4.10) include 
the DNA damage response genes such as ATM, p53 and GADD45A, while the downregulated 
genes are shown in Table 4.11 (please refer to  appendix C5 for all heat maps and scatter 
plots).    
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4.3.2 Validation of selected cell-cycle associated gene targets using 
Real-Time quantitative Polymerase Chain Reaction (RT-qPCR)  
 
4.3.2.1 Introduction 
 
The Real-Time quantitative Polymerase Chain Reaction (RT-qPCR), a highly sensitive 
method for gene expression studies was used here to assess and confirm the relative gene 
expression levels of selected target genes from the cell-cycle expression study.  
Three differentially expressed genes were selected, shown to be either up-or-down-regulated, 
from the gene array studies. The rationale for the selection of the target genes was based on 
the following: the differential expression (significantly up-or-down-regulation) across most/all 
template samples and their role in the cell-cycle in relation to the observed phenotypic 
changes in the upstream experiments such as the xCELLigence-RTCA, the cell-cycle and the 
apoptosis assays. The three genes selected were Mitotic Arrest Deficient-Like 2 (MAD2L2) 
which functions at the cell-cycle checkpoint, Caspase 3 (CASP3) which is apoptosis related 
and Aurora Kinase B (AURKB), a mitotic gene.  
 Primers’ description details for these gene targets, including GAPDH as a housekeeping 
(HKG) gene are shown in section 3.8.1 and Appendix C6, Table C6.1. These were designed 
using the online program, Primer 3 (http://primer3.wi.mit.edu/), then optimized by 
conventional PCR by running a gradient PCR (53°C to 65°C). The specificity of primer sets at 
60°C was demonstrated by single bands on 1% agarose gel electrophoresis, and single peaks 
on the melt-curves, as shown in Appendix C6, Figure C6.1 to Figure C6.5.  
Following fold change calculations, (see section 3.8.2), the calculated fold changes were then 
exported to GraphPad Prism 5, for further statistical analysis, plotting test against control, for 
all three selected target genes.  Results are represented as fold changes in tables and bar 
graphs.  
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4.3.2.2 Analysis of MAD2L2, CASP3 and AURKB gene expression levels 
before and after ARV treatment 
 
(i) Expression of target genes in untreated A549 vs MRC-5 cells  
Prior to assessing the effects of ARVs on target gene expression, the expression levels of 
MAD2L2, CASP3 and AURKB were first assessed in untreated (vehicle control) A549 vs 
MRC-5 cells, respectively. The relative gene expression levels are represented in Table 4.12 
and Figure 4.24 below. Both MAD2L2 (~3 fold) and AURKB (3-4 fold) at 24h and 48h were 
significantly upregulated in A549 cells relative to the normal MRC-5 fibroblasts. Caspase 3 in 
contrast was significantly down-regulated (~ -5 fold) at both 24h and 48h in A549 lung cancer 
cells.  
 
Table 4.12: Target gene expression levels in untreated A549 vs MRC-5 cells 
Gene  Fold change 24h Fold change 48h 
MAD2L2 3.06 3.0 
CASP3 -4.48 -5.30 
AURKB 3.33 4.02 
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Figure 4.24: Bar graph representing MAD2L2, CASP3 and AURKB relative gene expression 
levels in the untreated cancerous A549 cells compared to the normal MRC-5 lung fibroblasts. 
The relative gene expression levels are represented as a fold change as compared to MRC-5 
cells. An upregulation of MAD2L2 and AURKB is observed, as opposed to the 
downregulated CASP3 in A549 cells relative to the non-cancerous counterpart, observed at 
24h and 48h. * p< 0.05, **p<0.01, ***p<0.001.  
 
(ii) Expression of target genes in cells treated with EFV  
After assessing target gene expression in untreated cells, gene expression was assessed 
following treatment with 13µM EFV (physiologically relevant dose) at 24h and 48h, 
respectively.  
(a) Target gene expression analysis in EFV-treated MRC-5 cells 
In MRC-5 cells, MAD2L2 was significantly upregulated (~2 fold) at 24h, followed by a -1.34 
down-regulation at 48h (see Table 4.13 and Figure 4.31). In contrast, CASP3 (~ -1.8 fold) and 
AURKB (~ -1.5 fold) were significantly down-regulated at 24h and 48h, as shown in Table 
4.13 and Figure 4.25.  
 
Table 4.13: Target gene expression levels in 13µM EFV treated MRC-5 vs untreated cells 
Gene  Fold change 24h Fold change 48h 
MAD2L2 1.97 -1.34 
CASP3 -1.77 -1.88 
AURKB -1.76 -1.32 
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Figure 4.25: Representation of the expression levels of MAD2L2, CASP3 and AURKB in 
MRC-5 cells treated with 13µM EFV at 24h and 48h, relative to untreated cells. The relative 
gene expression levels are represented as a fold change as compared to untreated MRC-5 
cells. MAD2L2 was upregulated at 24h post 13µM EFV treatment, followed by a significant 
downregulation at 48h. Both CASP3 and AURKB were significantly down-regulated at 24h 
and 48h. * p< 0.05, **p<0.01, ***p<0.001 levels of significance.  
   
(b) Target gene expression analysis in EFV-treated A549 cells 
In EFV treated A549 lung cancer cells, EFV significantly decreased expression levels of both 
MAD2L2 (fold changes, p< 0.001 and p< 0.01) and AURKB (fold changes, p < 0.001) genes 
at 24h and 48h.  The expression of CASP3, though upregulated (~ 2 fold) at 24h and 48h post 
treatment, was not statistically significant (see Table 4.14 and Figure 4.26).   
Table 4.14: Target gene expression levels in 13µM EFV treated A549 vs untreated cells 
Gene  Fold change 24h Fold change 48h 
MAD2L2 -4.43 -2.94 
CASP3 2.01 1.88 
AURKB -38.91 -8.0 
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Figure 4.26: Expression levels of MAD2L2, CASP3 and AURKB genes in A549 cells treated 
with 13µM EFV at 24h and 48h, respectively. The relative gene expression levels are 
represented as a fold change as compared to untreated cells. * p< 0.05, **p<0.01, ***p<0.001 
levels of significance.  
 
(iii) Expression of target genes in cells treated with LPV/r 
Gene expression of MAD2L2, CASP3 and AURKB were evaluated in both MRC-5 and A549 
cells after treatment with 32µM LPV/r (physiologically relevant dose) at 24h and 48h, 
respectively. 
 
(c) Target gene expression analysis in LPV/r-treated MRC-5 cells 
All three target genes were down-regulated following 32µM LPV/r drug treatment at 24h and 
48h in MRC-5 cells (p <0.001), as shown in Table 4.15. CASP3 gene expression although 
marginally up-regulated at 24h, was not statistically significant, as represented in Table 4.15 
and Figure 4.27.    
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Table 4.15: Target gene expression levels in 32µM LPV/r treated MRC-5 vs untreated cells 
Gene  Fold change 24h Fold change 48h 
MAD2L2 -1.64 -1.57 
CASP3 1.47 -2.02 
AURKB -6.69 -15.28 
 
 
Figure 4.27: Representation of MAD2L2, CASP3 and AURKB gene expression in MRC-5 
cells treated with LPV/r. The relative gene expression levels are represented as a fold change 
as compared to control MRC-5 cells. * p< 0.05, **p< 0.01, ***p< 0.001 levels of 
significance.  
 
(d) Target gene expression analysis in LPV/r-treated A549 cells 
In A549 cells, both MAD2L2 (-5.57 and -2.57 fold) and AURKB (-11.42 and -19.33) genes 
were significantly down-regulated at 24h and 48h post 32µM LPV/r treatment. In comparison, 
however, CASP3 gene expression (2.2 fold) though up-regulated, was not statistically 
significant (see Table 4.16 and Figure 4.28).   
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Table 4.16: Target gene expression levels in 32µM LPV/r treated A549 vs untreated cells 
Gene  Fold change 24h Fold change 48h 
MAD2L2 -5.57 -2.57 
CASP3 1.79 2.72 
AURKB -11.42 -19.33 
 
Figure 4.28: Representation of the gene expression levels MAD2L2, CASP3 and AURKB in 
A549 cells treated with LPV/r. The relative gene expression levels are represented as a fold 
change as compared to untreated cells. * p< 0.05, **p< 0.01, ***p< 0.001 levels of 
significance.  
 
(iv) MAD2L2, AURKB and CASP3 expression are altered by EFV and LPV/r drug treatments 
at 24h and 48h 
The drug naïve lung cancer cells had raised expression levels of both MAD2L2 and AURKB 
and decreased CASP3 levels, relative to the normal MRC-5 cells. Following ARV treatment, 
the overall effects of both drugs were essentially to down-regulate target gene expression in 
the normal lung fibroblasts and the lung cancer cells. Whilst there was a minor up-regulation 
of CASP3 in lung cancer cells, this was not statistically relevant.    
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Abnormal cell proliferation associated with the deregulation of CASP3 and overexpression of 
AURKB and MAD2L2 has been previously reported ((Hochegger et al., 2013); (Boersma et 
al., 2015)). While both AURKB and MAD2L2 function at the mitotic spindle assembly 
checkpoint, the down-regulation of these genes after ARV treatment here, particularly in the 
A549 cells portrays an anti-cancer characteristic. This is also associated with the CASP3 (an 
apoptosis related gene) up-regulation, post ARV treatment. Notably, the GAPDH levels were 
not affected by any of the treatments.  
The relationship between these selected target genes and their potential interactions with 
relevant signalling pathways are further evaluated using a number of in silico analyses. These 
are elaborated on below. 
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4.4 IN SILICO BIO-INFORMATICS ANALYSIS OF CELL-
CYCLE RELATED GENES TREATED WITH EFAVIRENZ 
(EFV) AND LOPINAVIR/RITONAVIR (LPV/r) IN HUMAN 
LUNG CANCER CELLS 
 
The next approach in this study was to engage a series of bioinformatics tools to determine 
potential interactions between differentially expressed gene products elucidated in the cell-
cycle array analysis and to then map the molecular pathways that are regulated by these 
targets. The programmes used here included, STRING to determine protein-protein 
interactions; Database for Annotation, Visualisation and Integrated Discovery (DAVID) that 
provides a functional interpretations of genes; the Reactome Pathway Database, a database of 
biological pathways; and Ingenuity Pathway Analysis (IPA), which analyses pathway 
relationships. The findings ensuing from these analyses are presented below. 
 
4.4.1 A STRING analysis of gene products whose transcription levels 
change following EFV or LPV/r treatment indicate a change in the 
expression of proteins involved in genotoxic damage response pathways.   
 
The STRING database (v10.0) was used to establish the protein-protein interactions of the 84 
cell-cycle genes profiled in response to ARV treatments (see section 3.9 above). The resulting 
interaction is depicted in Figure 4.29. STRING was then used to construct protein-protein 
interaction pathways for genes which expression was significantly up-or down-regulated in 
untreated A549 cells as compared to MRC-5 cells.  
In the network generated by STRING V10, each node represents a protein and each edge 
represents an interaction. Furthermore, network nodes represent proteins, where either splice 
isoforms or post-translational modifications are collapsed, that is, each node represents all the 
proteins produced by a single, protein-coding gene locus. The STRING interaction threshold 
was set at 0.40 (medium). Protein nodes lacking or with weak interaction (< 0.40) are not 
shown. The PPIs were determined for untreated A549 cells vs MRC-5 cells, EFV and LPV/r 
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treated MRC-5 and A549 cells. The significance of node sizes and their colour in relation to 
their protein association is summarized below.  
 
Node Size: 
Small nodes represent:  
 
protein of unknown 3D structure 
Large nodes depict:  
 
some 3D structure is known or predicted 
 
Node Color: 
Colored nodes: 
 
 
query proteins and first shell of interactors 
White nodes: 
 
 
second shell of interactors 
 
The resulting protein-protein interaction network of up-regulated gene transcription in 
untreated cells is depicted in Figure 4.30, while the network of down-regulated genes in 
untreated cells is depicted in Figure 4.31. The transcriptionally up-regulated gene targets in 
the cancer cells included the AURKB and TP53 interaction, known to be dysregulated in 
cancer cells, while RAD1 and HUS 1, which form part of the RAD9-RAD1-HUS1 (9-1-1) 
DNA damage response, were displaced from the interaction network.  
Treatment of MRC-5 cells and A549 cells with 13µM EFV led to an increase or decrease in 
the transcription levels of various gene targets. STRING was then used to construct protein- 
protein interaction networks for both those gene targets whose transcription level increased or 
decreased. Pathways whose members show an increase in transcription include the ATR-
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BRCA1 DNA damage response pathways, Figure 4.32 for MRC-5 cells. In the A549 cells, the 
protein-protein interaction network of those gene targets whose expression is upregulated is 
depicted in Figure 4.33. As shown here, there is an increase in the transcription of members of 
the genotoxic cell-cycle checkpoint pathway (RAD1 and HUS1). Pathways whose members 
demonstrate a decrease in transcription include members of the DNA replication pathway 
(MCM4), stress response pathway (ATR); and also noting the presence of AURKB in this 
network, (see Figure 4.34).  
Treatment of MRC-5 and A549 cells with 32µM LPV/r led to an upregulation or down-
regulation in the transcription level of multiple genes. STRING was then used to construct 
protein-protein interaction networks based on these gene targets.  A representation of the 
resulting protein-protein interaction pathway for down-regulated gene expression in MRC-5 
cells is depicted in Figure 4.35 and Figure 4.37 for the A549 cells. What is evident here is a 
decreased expression of the E2F (TFs), survivin (BIRC5), the MCM DNA synthesising genes 
and AURKB, in both groups of cells. An illustration of the resulting protein-protein 
interaction pathway for up-regulated gene expression in A549 cells is shown in Figure 4.36, 
where an increase in the expression of members of the genotoxic cell-cycle checkpoint (RAD1 
and HUS1), as well as GADD45 was observed.   
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Figure 4.29: STRING protein-protein interaction (PPI) analysis of cell-cycle related proteins 
in untreated A549 compared to MRC-5 cells. The medium threshold (0.4) was set, and 
therefore weaker interactions (<0.4) are not shown. The intensity of the blue colour in this 
network denotes a strong interaction and relation between these proteins.     
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Figure 4.30: STRING protein-protein interaction (PPI) analysis of proteins significantly 
increased in vehicle control A549 cells. The interaction threshold was set at 0.40. Protein 
nodes with no or weak (< 0.40) interactions are not shown. Thick lines depict stronger 
interactions. The stronger interaction observed between TP53 and AURKB is indicated by the 
red circle.    
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Figure 4.31: STRING protein-protein interaction (PPI) analysis of proteins significantly 
decreased in untreated A549 cells. The threshold of the interaction was set at 0.40. Weak or no 
interactions (<0.4) are not shown here. CASP3 is isolated as it does not directly interact with 
any of the other down-regulated targets in the network. Similarly, RAD1 and HUS1 (which 
are shown to directly interact, highlighted in red) are observed to be dissociated from the 
network.     
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Figure 4.32: STRING protein interaction analysis of proteins significantly upregulated in 
MRC-5 cells treated with 13µM EFV. The interaction threshold was set at 0.40, only 
depicting stronger interactions. Therefore weak or no interactions (<0.4) are not shown in this 
network. The thickness of the lines illustrates a stronger interaction. The DNA damage 
response ATR/ATM, CHEK, HUS1 and BRCA1 proteins are shown to strongly interact.  
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Figure 4.33: STRING protein-protein interaction (PPI) analysis of proteins significantly 
increased in A549 cells treated with 13µM EFV. The threshold of the interaction was set at 
0.40. Weak or no interactions (<0.4) are not shown in this network. Stronger interactions are 
shown by dark blue lines. CDK5RAP1 is distanced from the network, as its direct interactor 
(CDK5R) that associates it to the main network was not co-upregulated.  DNA damage 
response genes such as RAD 1 and RAD 17, NBN and HUS1 form a close association, 
depicted in a red circle.    
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Figure 4.34: STRING protein-protein interaction (PPI) analysis of proteins significantly 
down-regulated in A549 cells treated with 13µM EFV. The interaction threshold was set at 
0.40, with weak or no interactions (<0.4) not depicted. No direct interaction is observed 
between MAD2L2 and the other five down-regulated targets in this network. A strong 
interaction is observed between AURKB and cyclin B2 (CCNB2), which directly interacts 
with ATR.    
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Figure 4.35: STRING protein interaction analysis of proteins significantly decreased in MRC-
5 cells treated with 32µM LPV/r. The interaction threshold was set at 0.40, thus only 
permitting stronger interactions. In this network, there is no stand-alone target, and the 
intensity of the blue colour indicates a strong and direct interaction between the down-
regulated targets.   
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Figure 4.36: STRING protein-protein interaction (PPI) analysis of proteins significantly 
increased in A549 cells treated with 32µM LPV/r. The interaction threshold was set at 0.40 
and therefore weak or no interactions (<0.4) are not shown in this network. The line intensities 
are indicative of the strength of the interactions. The stand-alone CDK5RAP1 is not directly 
linked to this network, due to the absence of its direct interactor CDK5R1 in this network.   
RM. Marima: PhD Thesis 
109 
 
 
Figure 4.37: STRING protein-protein interaction (PPI) analysis of proteins significantly 
decreased in A549 cells treated with 32µM LPV/r. The interaction threshold was set at 0.40, 
with interactions below this threshold (<0.4) not being shown in this network. The thickness 
of the lines indicates stronger direct interactions between targets, while a co-down-regulation 
of the MCM DNA synthesising family of genes is observed here, in a red circle.    
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4.4.2 DAVID was used to perform a functional enrichment analysis of the 
target genes in order to identify those genes of interest involved in cell-cycle 
regulation and progression pre- and post-EFV and LPV/r drug treatment.  
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) v6.7 was used 
for functional enrichment analysis in a set of genes, to visualise differentially expressed genes 
within a particular KEGG pathway. Within the KEGG representations, the red stars represent 
the input target genes/products; the green boxes represent (all) genes related to the cell-cycle 
pathway (Figure 4.38), while white boxes denote other pathways associated with the cell-
cycle (see section 3.9, Figure 3.2 for annotation).  
A functional enrichment analysis of differences in the gene expression between vehicle 
control A549 vs MRC-5 cells indicated that most of the up-regulated gene targets are also 
related to cell-cycle progression in the form of cyclin/ CDK complexes (Figure 4.39). Those 
cell-cycle related genes whose expression was down-regulated include Anaphase-Promoting 
Complex or Cyclosome (APC/C) and Rb (Figure 4.40), which lead to uncontrolled cell 
division. Treatment of MRC-5 and A549 cells with 13µM EFV resulted in the up-regulation 
of cell-cycle regulators in MRC-5 cells. The ATM/ATR DNA repair pathway was also 
activated in MRC-5 cells. This pathway is known to negatively regulate the cell-cycle (Figure 
4.41). In A549 cells the APC complex which regulates cell-cycle protein expression (CDC 20) 
was up-regulated (Figure 4.42), while EFV treatment of A549 cells resulted in the down-
regulation of MAD2L2, an important cell-cycle checkpoint and arrest protein (see Figure 
4.43).  
Treatment of MRC-5 cells with 32µM LPV/r resulted in the up-regulation of a single target 
CDKN2B (p15/INK4b) (Figure 4.44), and the down regulation of cyclin/CDK complexes, 
known to inhibit cell-cycle progression (Figure 4.46). Treatment of A549 cells with 32µM 
LPV/r activated DNA damage response gene targets such as ATM/ATR, p53 and GADD45 
and suppressed cell-cycle progression (Figure 4.45) by down-regulating cyclin/CDK 
complexes (Figure 4.47).   
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KEGG visualisation pathway for untreated cells 
 
Figure 4. 38: The KEGG pathway visualisation of cell-cycle related genes of the RT
2
 Profiler 
human cell-cycle gene array. The input genes of interest are shown by the red stars across the 
pathway. 
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Figure 4.39: The KEGG pathway depiction of the up-regulated target genes in untreated 
A549 vs MRC-5 cells. A representation of the upregulated gene targets in untreated cells is 
shown by the red stars. Most of these up-regulated targets are cyclin/CDK complexes, as 
shown in the diagram.  
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Figure 4.40: The KEGG pathway demonstration of the down-regulated gene targets in 
untreated A549 vs MRC-5 cells. A representation of the down-regulated gene targets in 
untreated cells is shown by the red stars. The deregulation of important cell-cycle regulatory 
elements such as the APC/C, the tumour suppressor Rb is observed here.   
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KEGG visualization pathway for EFV treated (MRC-5 and A549) lung cells 
 
Figure 4.41: The KEGG pathway illustration of the up-regulated target genes in response to 
13µM EFV treatment in MRC-5. The up-regulation of cell-cycle regulators such as cyclin D, 
B and H is seen. Interestingly, an activation of the ATM/ATR, which negatively regulates the 
cell-cycle is observed upstream of the cyclins.  
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Figure 4.42: The KEGG pathway representation of up-regulated gene products in A549 cells 
treated with 13µM EFV. Few targets which include the APC complex are shown to be 
upregulated in response to EFV drug treatment.   
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Figure 4.43: The KEGG pathway visualization of down-regulated gene targets in A549 cells 
treated with 13µM EFV. The deregulation of MAD2L2, an important cell-cycle checkpoint 
and arrest protein is observed here.  
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KEGG visualisation pathway for the LPV/r treated (MRC-5 and A549) lung cells 
 
Figure 4.44: The KEGG pathway illustration of the up-regulated target(s) in MRC-5 cells in 
response to 32µM LPV/r treatment. Only one target (CDKN2B (p15/INK4b)) is shown to be 
activated by the LPV/r treatment in the normal cells. This target forms part of the cell-cycle 
checkpoint and arrest.  
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Figure 4.45: The KEGG pathway demonstration of up-regulated target genes in A549 cells 
treated with 32µM LPV/r. Here, an activation of DNA damage response gene targets such as 
ATM/ATR, p53 and GADD45 is observed.  
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Figure 4.46: The KEGG pathway representation of down-regulated gene targets in MRC-5 
cells treated with 32µM LPV/r. Most of the cyclin/CDK complexes are shown to be repressed 
here, restricting cell-cycle progression and cell proliferation in normal cells.  
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Figure 4.47: The KEGG pathway illustration of down-regulated genes in A549 cells in 
response to 32µM LPV/r drug treatment. The deregulation of cyclin/CDK complexes is 
observed here, as these positively regulate the cell-cycle. This inactivation of the cyclin/CDK 
complexes suppresses the progression of the cell-cycle.    
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4.4.3 Reactome analysis indicates that EFV alters cellular response to stress, 
DNA repair and programmed cell death (PCD)/apoptosis, while LPV/r 
treatment leads to an increase in PCD genes in A459 cells 
 
Reactome is an open-source, open access, manually curated and peer-reviewed pathway 
database. This database is an all-inclusive resource of human pathways for basic research, 
genome analysis, pathway modelling, systems biology and education. In this study Reactome 
version V58 was used to map and analyse biological and molecular pathways other than the 
focused cell-cycle pathway, which may be influenced by the identified targets. Within the 
generated maps, gene expression level corresponds to the yellow colour, and the degree of 
expression correlates with the colour intensity.      
A comparison between untreated cancer and untreated normal cells showed an increase in the 
expression of genes involved in DNA replication and cell-cycle regulation in the cancer cells 
(Figures 4.48 and 4.49). The exposure of A549 and MRC-5 cells with 13µM EFV, led to 
changes in the expression of genes involved in the cellular response to stress, DNA repair and 
programmed cell death (PCD)/apoptosis (Figure 4.48).  
There was an up-regulation of the cellular response to stress genes, in both normal and 
cancerous cells at 32µM LPV/r. Genes associated with DNA repair were not up-regulated in 
MRC-5 cells, while the up-regulation of PCD genes is evident in A549 LPV/r treated cells 
(Figure 4.49).  
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Figure 4.48 The Reactome map illustration of biological/molecular pathways influenced by 
the identified targets in response to 13µM EFV drug treatment. Change in gene expression 
(GE) patterns of the targets was compared between untreated cells and EFV treated A549 and 
MRC-5 cells. Change in GE patterns is represented between three pathways: Cellular response 
to stress, DNA repair and programmed cell death (PCD)/apoptosis. In response to EFV drug 
treatment, the DNA repair genes are up-regulated in both normal and cancerous cells, 
extending to the activation of apoptosis genes in the A549 cells.    
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Figure 4.49: The Reactome map representation of biological/molecular pathways influenced 
by the selected targets in response to 32µM LPV/r drug treatment. Compared to the untreated 
cells, cellular response to stress genes are activated in response to LPV/r drug treatment, 
observed in both MRC-5 and A549 cells. Interestingly, DNA repair genes are not up-regulated 
in MRC-5 cells, while the up-regulation of PCD genes is evident in A549 LPV/r treated cells.   
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4.4.4 IPA analysis demonstrates ATM-pathway activation in EFV treated 
MRC-5 cells, while LPV/r treatment particularly triggers the p53-pathway 
in A549 cells. 
 
Qiagens’s Ingenuity Pathway Analysis (IPA) has been widely used to model, analyse and 
understand complex biological systems. In this study, the core analysis function of IPA was 
used to help build a more complete regulatory picture to better elucidate the biology 
underlying the studied gene expression profiles. The analyses are represented as bar graphs, 
with the z-score referring to the activation state, either up- (orange bars) or down (blue bars) 
regulation of the pathway.  
IPA allows for the identification of well-characterized metabolic and cell signalling pathways 
(canonical pathways) that the genes whose expression is altered by drug treatment are 
involved in. The untreated cancer cells showed higher transcription levels of genes involved in 
DNA damage response and cell checkpoint pathways (Figures 4.50 and 4.51). EFV treatment 
of MRC-5 and A549 cells led to the activation of the cell-cycle regulation pathway in MRC-5 
cells. Based on the observed change in expression of genes involved in cellular response to 
stress, DNA repair and PCD pathways, the p53 pathway was selected as the pathway of 
interest as it plays a significant role in the identified pathways by Reactome. In EFV treated 
cells the ATM signalling pathway activates its down-stream effector pathway, p53, Figure 
4.50. Both the ATM and the p53 pathways are activated in response to DNA damage.   
LPV/r treatment does not activate the ATM and the p53 signalling pathways in MRC-5 cells, 
while treatment of the A549 cells resulted in the activation of the p53 pathway despite the 
repressed upstream ATM pathway, which is vice versa to the untreated cells (Figure 4.51).  
These results led to the selection of the ATM and the p53 signalling pathways as the pathways 
of interest (POI) for the core analysis. The pink/red and green colours represent upregulation 
and down-regulation, respectively with the colour intensity corresponding to the degree of 
expression level (please refer to section 3.9 above, Figure 3.3 for further annotation details).  
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Figure 4.50: IPA Canonical Pathway analysis of differentially expressed genes in EFV treated 
vs untreated cells. The orange bars indicate activated pathways, while blue bars indicate 
repressed pathways. The colour intensity is proportional to the degree of in/activation. The 
green boxes highlight pathways of interest, the ATM signalling pathway and the p53 
signalling pathway. Being upstream of the p53 pathway, the ATM signalling pathway does 
not activate its down-stream effector p53 pathway in untreated cells, compared to EFV-treated 
cells.  
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Figure 4.51: IPA Canonical pathway analysis of gene targets in cells treated with 32µM 
LPV/r vs untreated cells. The ATM and the p53 signalling pathways (highlighted in green 
boxes) are shown not to be activated by the LPV/r drug treatment in normal MRC-5 cells. 
Contrarily, the p53 pathway is activated in the A549 cells irrespective of the repressed 
upstream ATM pathway, which is opposite to what is observed in the untreated cells.    
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4.4.4.1 The downstream effectors of the ATM signalling pathway are activated in both cancer 
and normal cells following EFV treatment 
The transcription of the ATM gene was increased in MRC-5 cells following EFV treatment. 
This leads to the downstream activation of the targets of ATM such as p53, BRCA-1 and 
CHK1 leading to DNA repair, cell-cycle arrest, DNA damage checkpoint regulation or 
apoptosis (Figure 4.52).  EFV treatment of the A459 cells does not lead to an increase in the 
transcription of ATM. However, the downstream effectors of ATM are still activated due to 
DNA damage induced by the drug treatment. These include the p53 targets such as p21 and 
GADD45 and the DNA damage response molecules BRCA1 and NBS (Figure 4.53). 
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Figure 4.52: IPA ATM-signalling pathway in EFV treated MRC-5 cells. The green and the 
red colours indicate down and up-regulation. The activated ATM activates its downstream 
targets such as p53, BRCA-1 and CHK1, which in turn further activate their downstream 
targets to initiate DNA repair and growth arrest mechanisms.    
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Figure 4.53: IPA ATM-signalling pathway in EFV-treated A549 cells. The green and red 
colours denote down and up-regulation. Here the downstream effectors of ATM in response to 
DNA damage are activated regardless of the ATM being inactive. The overexpression of the 
up-regulated p53 targets such as p21 and GADD45 (inhibiting the cyclin/CDK activation and 
thus the cell-cycle progression) is denoted by the intensified red colour. The increased 
expression of BRCA1 and NBS are also observed in response to damaged DNA.  
RM. Marima: PhD Thesis 
130 
 
4.4.4.2 LPV/r drug treatment activates the p53 signaling pathway in cancer cells 
The downstream  effectors of the p53 pathway are repressed in untreated cancer cells 
compared to normal cells. This would allow for the cancer cells to continue to proliferate and 
survive (Figure 4.54 and Figure 4.55). Following treatment of A549 cells with 32µM LPV/r, 
the p53 pathway and its downstream effectors were activated, leading to growth arrest and a 
decrease in cell survival (Figure 4.56 and Figure 4.57). A further demonstration of MAD2L2, 
CASP3 and AURKB interacting with p53 and p53 signalling proteins is shown in Figures 
4.58 and 4.59.  
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Figure 4.54: IPA p53 signalling pathway in untreated A549 vs MRC-5 cells. The green and 
red colours represent down and up-regulation. The orange boxes encompass most of the 
activity in this pathway. Although p53 is active here, its downstream effectors (p21, Cyclin G 
and GADD45) are repressed. The down-regulation of Rb is also observed, leading to cell-
cycle progression. The overexpression of pro-survival targets such as Bcl-2 and survivin 
(BIRC5) leading to cell survival is also seen.   
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Figure 4.55: The KEGG pathway illustration of p53-signalling pathway in untreated A549 vs 
MRC-5 cells. Although p53 is active here, its downstream targets such as p21 and GADD45 
are not activated in response to p53 up-regulation. This leads to a bypass of cell-cycle 
checkpoints and arrest, thus promoting cell survival.    
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Figure 4.56: IPA p53-signalling pathway in A549 cells treated with 32µM LPV/r. The green 
and the red colours signify down and up-regulation. The over expression of growth arrest 
molecules such as p21, Cyclin G and GADD45 in response to the activated p53 is represented 
here. The active (unphosphorylated) Rb is bound to and represses E2F1, with the deregulated 
CDK2, and thus arresting the progression of the cell-cycle. The activation of Bcl-2 is obscure 
here, while the expected down-regulation of survivin is observed.      
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Figure 4.57: The KEGG pathway demonstration of the p53-signalling pathway in A549 cell 
treated with 32µM LPV/r. ATM signaling is up-regulated in response to genotoxic stress, 
which in turn activates the p53 signaling pathway. P21, Cyclin G and GADD45 are activated 
downstream of p53, effecting cell-cycle checkpoint and arrest.  
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4.4.5 The integration of MAD2L2, CASP3 and AURKB to the p53 signaling 
pathway. 
 
 
Figure 4.58: STRING protein-protein interaction (PPI) analysis between ATM, p53 and 
selected targets. The interaction threshold was set at 0.4. In this interaction, MAD2L2 is a 
stand-alone due to lack of evidence of either direct or indirect interaction with all four of the 
proteins. Both CASP3 and AURKB show a strong and direct interaction to p53, while 
AURKB strongly interacts with both ATM and p53, as illustrated by bold lines.   
RM. Marima: PhD Thesis 
136 
 
 
Figure 4.59: STRING protein-protein interaction (PPI) analysis between p53 signalling 
pathway and selected targets MAD2L2, CASP3 and AURKB. The interaction threshold was 
set at 0.4. CASP3 and AURKB show a strong and direct interaction to p53 and other proteins 
within the pathway such as BIRC5 (Survivin), while MAD2L2 is secluded from the 
interaction network.   
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CHAPTER 5: DISCUSSION 
 
5.1 Cell Biological Response to ARV Treatment 
5.1.1 ARVs affect cell proliferation by modulating cell-cycle progression 
 
The cell responses to antiretroviral treatment were assessed in real time to quantitate cell 
proliferation and to effectively determine cellular response to the pharmacological treatments. 
The ARTs acted to decrease cell viability in a dose-dependent manner in both cell lines. 
Notably, however, the two plasma level EFV concentrations increased cell proliferation, while 
only the lowest LPV/r treatment caused a proliferative increase. Moreover, the most 
physiologically relevant LPV/r dose resulted in growth arrest, in lung cancer cells. Thus 
dependent on concentration and at specific window periods of treatment, both EFV and   
LPV/r can exert either pro- or anti-tumorigenic effects on cells.  
 
As previously described, the cell-cycle is normally a tightly regulated process with multiple 
control points at different phases of cell growth, with the failure or improper functioning of 
these check  points potentially  leading to abnormal cell proliferation or apoptosis. In 
association with increased cell proliferation, subsequent cell-cycle analyses showed a 
significant increase in S-phase in response to ARV treatments; with an apoptotic induction for 
one of the ARVs (LPV/r).  However, it was noted that besides apoptosis, LPV/r treatment 
additionally triggered necrotic cell death in a time-dependent manner. A model summarizing 
the pro- and anti-proliferative effects of EFV and LPV/r is represented below (Figure 5.1). 
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Figure 5.1: Diagrammatic representation of the effects of EFV and LPV/r at low and high 
doses. Both EFV and LPV/r exhibit pro-survival effects at low doses, while anti-proliferative 
and cytotoxic effects are observed at high doses. The solid arrows represent the effects of the 
drugs on cellular health, while the dashed line shows partial/dual effect. At a high dose, EFV 
is anti-proliferative, arresting cellular growth, while low doses favour survival modes, as also 
observed with low LPV/r dose. In contrast, moderate (plasma-level) and high LPV/r doses 
have anti-proliferative and cytotoxic properties on the cells.  
 
Based on these observations, it is proposed here that both EFV and LPV/r alter the cell-cycle 
progression of both normal and cancerous cells, especially arresting cells at S-phase to inhibit 
further progression through the cycle, with extended LPV/r apoptosis inducing properties.   
The apoptotic inducing properties of LPV/r merit further investigations not only as an ARV 
drug, but also as an anti-cancer treatment. However, a current limitation of LPV/r is its ability 
to not only kill tumour cells, but also to eliminate normal healthy cells, On the other hand, 
while an S-phase arrest is evident from both EFV and LPV/r treated cells,  DNA damage 
usually precedes S-phase arrest. It follows then that both EFV and LPV/r could potentially be 
causing damage to the genomic DNA, with an arrest at S-phase, during which time there may 
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be an attempt to either repair the damaged DNA or an induction of premature senescence or 
cell death. While the S-phase arrest is induced in the A549 lung cancer cells, it is also evident 
in the normal MRC-5 cells. This observation particularly implicates EFV and LPV/r as 
inducing stress on the DNA, with cells attempting to establish defense mechanisms by 
blocking the transmission to G2/M phase. 
 
5.2 In silico analyses of cell-cycle associated pathways 
5.2.1 The DNA damage response pathway 
DNA damage can be caused by genotoxic agents and if not repaired, could result in 
chromosomal changes, gene mutations, excessive cell death or ultimately cancer. When 
encountering genotoxic stress, cells respond by activating DNA repair mechanisms. 
Depending on the degree of DNA damage, the induced repair mechanisms either eliminate the 
DNA lesions or bypass them. Most of the DNA repair mechanisms involve nucleases, which 
in themselves pose a threat to the genome if not carefully regulated  (Christmann and Kaina, 
2013).  
In response to DNA damage imposed by genotoxic stress, DNA damage sensors must first 
detect the DNA lesions, in order to initiate the DNA damage response (DDR). DNA damage 
is detected by the Mre11–Rad50–Nbs1 (MRN) complex which acts as the sensor of damaged 
DNA and maintains genomic stability by processing DNA ends and recruiting other members 
of the DNA damage response pathway ((Li et al., 1999), (Christmann et al., 2005), (Islaih et 
al., 2004)). In particular, Rad50 recognizes the damaged DNA, Nbs1 recruits other DNA 
repair proteins to DSB lesions, and Mre11 processes the DNA ends with its DNA nuclease 
activity (Christmann et al., 2005). This then leads to activation of Ataxia Telangiectasia 
Mutated (ATM) or Ataxia Telangiectasia and Rad3 Related (ATR), depending on where the 
damage is. ATM is activated in response to DSDs on DNA and chromatin remodeling while 
ATR is activated in response to stalled replication forks ((Myung et al., 1998), (Montecucco et 
al., 1995)). This is followed by a signalling cascade that activates repair checkpoints and 
recruits the remaining members of the DNA repair complex. 
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In mammalian cells the DNA damage response includes ATM, ATR and PARP1 as well as 
key transcription factors, which in turn target their downstream effectors such as BRCA1, NF-
Кβ, AP-1 and p53. Following the induction of DNA damage response (DDR), transcription 
factors are activated. In addition, the induction of DNA repair genes in mammalian cells is 
lower, for example, for Methylguanine-DNA Methyltransferase (MGMT) up to 15-fold in rat 
liver, which is a comparatively high level;and in rat hepatoma cells in vitro, 2–4-fold  ((Chan 
et al., 1992), (Christmann and Kaina, 2013)), compared with bacteria, in which the induction 
of DNA repair genes such as ADA is 1000-fold, following Methylnitronitrosoguanidine 
(MNNG) exposure. However, this does not essentially mean that the induction of DNA repair 
genes is biologically insignificant noting the fact that mammalian cells express DNA repair 
genes at a detectable basal level and that even a slight upregulation may significantly improve 
repair ability.  
The activation of ATM requires the activation of the MRN complex comprising of MRE11, 
NBS1 and RAD50 that triggers ATM auto-phosphorylation. This leads to dissociation of 
inactive ATM dimers to active monomers. The ATM monomers then interact with the MRN 
complex and single-stranded DNA (ssDNA) (Lee and Paull, 2005). The MRN complex itself 
recognizes and moves to DSBs induced by ionizing radiation (Mirzoeva and Petrini, 2001) 
and to ssDNA on replication blockages (Mirzoeva and Petrini, 2003) and remains at the site of 
DNA damage. In the deregulation of the MRN complex, the autophosphorylation of ATM is 
inhibited, and thus cannot be recruited to the DSB site (Lee and Paull, 2005). On the other 
hand, ATR is activated following blockage of DNA polymerases and the formation of lengthy 
ssDNA, which are formed by uncoupling of the mini-chromosome maintenance (MCM) 
helicase from the replication fork and then binding of replication protein A (RPA) to ssDNA 
((Byun et al., 2005). RPA labelled ssDNA activates the recruitment of ATR complexed with 
ATR-interacting protein (ATRIP) and the Rad9, Hus1 and Rad1 (9–1–1) complex to the site 
of damage (Parrilla-Castellar et al., 2004).  
p53 is a sequence-specific transcription factor  that plays a major role in DNA repair, 
apoptosis and cell-cycle regulation  ((Haupt et al., 2003), (Wu et al., 2013)). P53 is activated 
by DNA replication arrest following the formation of DSBs caused by genotoxins and 
irradiation via the ATM/ATR pathway. In turn, ATM phosphorylates the checkpoint kinase-2 
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(CHK2), following replication blockage while, ATR phosphorylates CHK1. Then, CHK2 and 
CHK1 activate p53 by phosphorylation. ATM and ATR can also directly phosphorylate p53. 
Furthermore, ATM/ATR also phosphorylates MDM2, resulting in MDM2 degradation by 
ubiquitination and thus stabilizing p53 (Khosravi et al., 1999).  
During cell division, proper genomic DNA replication is critical towards maintaining genomic 
instability. This replication process is facilitated by high-fidelity error-free DNA polymerases 
that cannot synthesize across damaged DNA. Error-prone specialized DNA polymerases, 
known as DNA translesion synthesis polymerases (TLS polymerases), can replicate damaged 
DNA thereby avoiding replication fork breakdown and thus chromosomal instability. Among 
DNA polymerases, the family B DNA polymerases include the highly accurate DNA 
polymerases δ (delta), ε (epsilon), α (alpha), and the error-prone TLS Pol (zeta) ζ ((Uziel et 
al., 2003), (Byun et al., 2005), (Zietlow et al., 2009), (Braithwaite and Ito, 1993)).  TLS Pol ζ 
lacks the 3’ to 5’ exonuclease proofreading activity, unlike the replicative DNA polymerases δ 
and ε. The human TLS Pol ζ and its yeast homologue are heterodimeric proteins consisting of 
the catalytic subunit REV3 and the structural subunit REV7 ((Lavon et al., 2007), (Nelson et 
al., 1996), (Murakumo et al., 2000)).   
The DDR pathways includes non-homologous end joining (NHEJ) and homologous 
recombination (HR) pathways to repair double strand breaks (DSBs), base excision repair 
(BER) to counteract modification of the nitrogenous bases, nucleotide excision repair (NER) 
to excise bulky nucleotide alterations, mismatch repair (MMR) to exchange mispaired 
nucleotides and direct damage repair and the translesion DNA synthesis (TLS), which tolerate 
and bypass DNA lesions.   
DNA damage response (DDR) genes have been shown to play a role not only in tumour 
initiation, at least in part when they fail to properly repair the damaged DNA, but in tumour 
progression and metastasis ((Knobel and Marti, 2011), (Broustas and Lieberman, 2014)).  
Due to  the use of the homologous sister chromatid as template, it has been reported that HR is 
an error free repair pathway and the major mechanism used by cells for repairing DSBs and 
restarting stalled replication forks ((Nowsheen and Yang, 2012), (Falck et al., 2012)). If DNA 
repair is unsuccessful, then p53 initiates apoptosis by activating pro-apoptotic proteins such as 
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BAX, BID, PUMA and NOXA which permeabilizes the mitochondrial membrane leading to 
the release of pro-apoptotic factors ((Pauklin et al., 2005), (Levine, 1997)).   
 
5.2.2 In Silico Bio-Informatics analysis of cell-cycle related genes treated 
with Efavirenz (EFV) and Lopinavir/ritonavir (LPV/r) in lung cells 
 
(a) STRING Analysis 
STRING PPI analysis of the cell-cycle genes evaluated here in response to ART treatment 
elucidated a series of tight interactions.  Pivotal factors were identified in relation to the DNA 
damage response including GADD45, HUS and RAD gene products and are discussed further 
below. 
The emerging evidence of the regulatory role of AURKB on p53 activity is observed by the 
strong and direct interaction between these two molecules, while MAD2L2 is indicated to 
strongly interact with CDC20, which forms part of the APC complex (see Figure 4.30). The 
deregulation of CASP3 and RAD9-HUS1 suggests the malfunctioning of the DNA damage 
sensors, and the non-functioning of the effector CASP3 in the lung adenocarcinoma cells, 
thereby preventing them from undergoing CASP3 mediated apoptosis (Figure 4.31). The 
13µM EFV drug treatment up-regulates the DNA damage response genes in both normal and 
cancerous cells, Figure 4.32 and Figure 4.33, while repressing the expression of AURKB and 
MAD2L2 in the A549 cells, Figure 4.34. In a similar manner, 32µM LPV/r drug exposure 
stimulates the expression of p53 and its downstream targets such as GADD45A (DNA 
damage response gene) in the A549 cells, Figure 4.36, while suppressing DNA replication 
genes (MCM), the cell division cycle genes CDC20 and CDC25, Figure 4.37. In normal cells, 
most of the genes maintain a suppressed state, even post LPV/r exposure (Figure 4.35). ARV 
drugs stimulated DNA damage response pathways and repressed cell proliferation in both 
normal and cancer cells. Figure 5.2 below summarises the findings of the STRING analyses.  
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Figure 5.2: Summarized schematic representation of the activated DDR pathway as analysed 
by STRING database in lung cancer cells. Activated DNA damage sensors and signalers 
interact subsequent to ARV treatment, while these mechanisms remain inactivated in 
untreated conditions. This is followed by reduced cell proliferation and or cell death in ARV 
treated cells, and uncontrolled cell proliferation in vehicle treated lung cancer cells. The 
observations are based on plasma level doses.   
 
(b) DAVID Analysis 
DAVID analysis identified the change in expression of cell-cycle regulatory factors such as 
the cyclin/CDK activity, and the p53 downstream targets. Even though the p53 tumour 
suppressor is activated in the cancer cells, its down-stream effector targets such as p21, 
GADD45A (to arrest growth and possibly repair the damaged DNA) are suppressed (Figure 
4.39 and Figure 4.40). In response to 13µM EFV exposure, ATM/ATR DNA damage 
checkpoints are activated, which in turn activates CHK1 and 2 in the normal cells; and also 
noteworthy is the up-regulation of the CDK-inhibitor p15 (Figure 4.41). On the other hand, 
p27/57 is up-regulated by the EFV treatment in the A549 cells (Figure 4.42) and MAD2L2 is 
repressed in cancer cells following EFV treatment (Figure 4.43) where it is normally up-
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regulated in untreated cancer cells (Figure 4.39). Unlike in the untreated cells with repressed 
CDK-inhibitors’ activity (Figure 4.39), the EFV treatment up-regulates the CDK-inhibitors in 
both cancerous and normal cells, even though the cyclin (D and H)/CDK are active in normal 
cells. The activation of the CDKIs could be attributed to the drugs repressing progression of 
the cell-cycle driven by the cyclin/CDK interactions. Similar to EFV, LPV/r treatment up-
regulates the CDKI-p15 which inhibits the activity of cyclin/CDK complexes, thereby 
inhibiting the progression of the cell-cycle in normal cells (Figure 4.44). Similarly, the 
activation of p16, p21 and p27/57 (dependent on p53 up-stream activation) is observed in 
A549 EFV treated cells, leading to the reduced activity of the cyclin/CDK complexes in both 
normal and cancerous cells (Figure 4.46 and Figure 4.47). Both EFV and LPV/r target the 
activation of growth-arrest genes, leading to the reduction in cell-cycle progression.  
 
(c) Reactome Analysis  
This revealed that EFV and LPV/r drug treatment altered the expression of the profiled cell-
cycle related genes, affecting other pathways besides the cell-cycle. In particular, EFV was 
shown to activate the cellular response to stress genes in MRC-5 cells, DNA repair genes in 
both normal and cancerous cells, while up-regulated programmed cell-death genes and an 
obvious decline in expression of genes involved in DNA replication in A549 cells was 
observed compared to the untreated cells (Figure 4.48).  LPV/r treatment results in the 
reduced expression of DNA replication in normal cells, while an increase in genes involved in 
programmed cell death in the cancerous cells was observed (Figure 4.49).  
 
(d) IPA analysis 
To understand the mechanisms underlying the observed change in gene expression in the 
pathways identified using Reactome, IPA core analysis particularly showed that the ATM and 
p53-signalling pathways were affected. These are DNA damage response pathways, and the 
deregulation of these pathways plays an essential role in genomic instability, leading to 
cancer.  
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EFV treatment triggered the ATM pathway in A549 cells, and particularly in the MRC-5 cells, 
with an insignificant increase in the activation of the down-stream p53 pathway, which is not 
in a repressed state in the untreated cells. Both ATM and p53-signalling pathways remained 
inactivated in MRC-5 LPV/r treated cells. In contrast, an opposite effect was observed in 
LPV/r treated compared to the untreated A549 cells. This was indicated by the activation of 
the p53-pathway in A549 LPV/r treated cells, despite the repressed up-stream ATM-signalling 
pathway. This suggests that there could be other as yet un-elucidated upstream molecules 
triggering the p53-signalling pathway in response to DNA damage in A549 LPV/r treated 
cells.  
 
5.2.3 Details of the ATM and p53 pathways 
 
In EFV-treated MRC-5 cells (Figure 4.52), DNA damage causes the activation of MRN 
complex (MRE11, NBS1 and RAD50). This leads to ATM-autophosphorylation and then to 
the dissociation of inactive dimers to active monomers. The ATM monomers then interact 
with the MRN complex and single-stranded DNA (ssDNA). The MRN complex itself 
recognizes and moves to DSBs induced by ionizing radiation and to ssDNA on replication 
blockage and remains at the site of DNA damage. In the deregulation of the MRN complex, 
the autophosphorylation of ATM is inhibited, and thus cannot be recruited to the DSB site 
(Christmann and Kaina, 2013). 
The active ATM then phosphorylates CHK2 which in turn phosphorylates p53. Active ATM 
can also directly phosphorylate p53. Furthermore, the MDM2 phosphorylation by ATM 
results in MDM2 degradation by ubiquitination and thus stabilizes p53. The activated p53 
then acts to up-regulate the transcription of down-stream targets, such as p21 and GADD45A, 
which in turn suppress the expression of cyclin/CDK complexes and thus the progression of 
the cell-cycle (Nowsheen and Yang, 2012).  
In EFV-treated A549 cells (Figure 4.53), the MRN complex is activated upon DNA damage. 
However, for reasons unknown here, ATM remains inactivated. Even though CHEK2 is 
inactivated, other ATM down-stream effectors such as CHEK1, BRCA1 and p53 are 
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activated. P53 then in turn activates p21 and GADD45A, while repressing cyclinB/CDK1 
activity.  
Previous reports (Zhang et al., 2009) show that the A549 cells have a wild-type p53. Similarly 
in this study, in untreated cancerous cells, p53 is activated, however, its downstream effectors 
such as p21, GADD45A and cyclin G are down-regulated, while pro-survival molecules such 
as survivin and Bcl2 are up-regulated (Figure 4.54 and Figure 4.55). Following exposure to 
32µM LPV/r, p53 and its downstream targets are activated (p21, GADD45A and cyclin G) 
and pro-survival molecules are repressed (survivin) (Figure 4.56 and Figure 4.57). Lack of 
activity from p53 anti-proliferative downstream effectors in untreated A549 cells allows cells 
to grow uncontrollably, proliferate and survive. On the other hand, 32µM LPV/r treatment not 
only activated p53, but ensured the up- and -down-regulation of p53 targets to control and 
inhibit excessive proliferation. Furthermore, Figure 4.58 and 4.59 illustrate STRING analysis 
of the selected targets with p53 and p53 signalling pathway members.      
Malfunctioning within cell-cycle DNA damage response pathways results in genome 
instability and often leads to carcinogenesis. The cyclins/CDKs are important regulators of 
cell-cycle progression, controlling the transition between different cell-cycle interphases.   
Their activity is regulated by CDKIs, and inversely activated by phosphatases, such as CDC25 
that dephosphorylate the inhibitory effects of the CDKIs. p53 also plays a role  in DNA repair 
and it is the main factor determining the choice between DNA damage repair or the induction 
of senescence or apoptosis (Nowsheen and Yang, 2012). Figure 5.3 below summarises this 
study’s p53 pathway in relation to ARV treated as compared to untreated cells.  
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Figure 5.3: Summarised diagrammatic illustration of the p53 pathway as analysed by 
DAVID, Reactome and IPA. A represents ARV treatment, and B denotes untreated cells. 
ARV drug treatment activates the p53 anti-proliferative mechanisms by the repression of 
cyclin/CDK activity and induction of CDKIs such as p21. In the absence of ARV treatment, 
the p53 downstream targets are not activated.   
  
5.2.4 EFV and LPV/r alter cycle associated gene expression 
The emergence of regulatory roles of cell-cycle related genes in ARV associated 
carcinogenesis is likely to contribute to the development of novel diagnostic, prognostic and 
therapeutic markers, for NADCs in the HAART era. The present study provides the first 
evidence regarding the double-edged anti- or- pro oncogenic properties of two anti-retroviral 
drugs (EFV and LPV/r) in lung cancer.  
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5.2.5 Effects of EFV and LPV/r on cell-cycle related gene expression  
 
Progression through the cell-cycle is a finely regulated process, wherein cyclins and CDKs 
promote the cell-cycle whilst the CDKIs inhibit progression. The balance between 
cyclins/CDKs and CDKIs is essential in maintaining cellular homeostasis, and determines cell 
fate, that is, proliferation, senescence or cell death (apoptosis). To ensure integrity of DNA 
replication and cell division, cell-cycle checkpoints exist at the key transition points of G1/S 
and G2/M, respectively. As the CDKIs act at multiple phases of the cycle, they are 
particularly important at these checkpoints. Prior to the synthesis of DNA (during the S-
phase), the G1/S checkpoint allows for the monitoring of DNA integrity before the cell’s 
DNA is replicated. The G2/M checkpoint allows the cell-cycle to pause prior to mitotic cell 
division. P53 is an important regulator of these checkpoints (Lim and Kaldis, 2013).  
In the present study, gene expression in the untreated tumour versus the normal lung cells’ 
array, p53 was 4.32 fold up-regulated. However, most of the CDKIs (which also act as p53 
down-stream effectors), were significantly down-regulated and these included CDKN3, p21, 
p15 and most significantly p16 at -891 fold. CASP3, an effector caspase in apoptosis was also 
significantly down-regulated. In addition, GADD45A, which is also triggered by p53 in 
response to DNA damage and growth-arrest was significantly down-regulated (-10.7 fold). 
Cyclin G1 and G2, which are both induced following DNA damage and maintain the p53-
dependent cell-cycle arrest and RAD DNA repair genes were also down-regulated. On the 
other hand, the cyclins such as cyclin A, B, D3, E and F and CDK1 were found to be 
significantly upregulated. Also, survivin (BIRC5), a pro- survival gene was up-regulated here. 
Further, the E2F1 transcription factor, important for the transcription of S-phase genes was 
up-regulated.  Additionally, genes required for S-phase and DNA replication, the MCM gene 
family was significantly up-regulated. Furthermore, the AURK family (A and B), as well as 
MAD2L2 (involved in the mitotic spindle-checkpoint), were significantly up-regulated.  
The treatment of MRC-5 and A549 cells with EFV alters the gene expression of important 
factors that are essential in the maintenance of genomic stability in relation to the cell-cycle. 
This is particularly observed in the cancerous cells, with the significant down-regulation of 
AURKB and MAD2L2. Even though the normal p53 (1.02 fold) expression was shown here, 
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p27, CASP3, Cyclin G1 and G2, NBN, RAD1 and RAD17 were significantly up-regulated. 
The E2F4 transcription factor, important for the transcription of S-phase genes, was also 1.93 
(~2) fold up-regulated. Interestingly, the S-phase and DNA replication genes were down-
regulated; MCM4 in particular was -3.65 significantly down-regulated. These EFV-treated 
genotypic alterations observed here are characteristic of anti-tumour properties.  
The LPV/r treatment resulted in very similar effects to those observed following EFV 
treatment. Post LPV/r exposure p53 expression was triggered, by inhibiting AURKB in A549 
cells, and this in-turn repressed MAD2L2 expression. This was then followed by the 
activation of p53 downstream targets including p21, p27 and p16. A significant down-
regulation of cyclins A, B, D3, E and F was observed. CDK1 and 2 (except for CDK4) were 
also down-regulated. E2F1 transcription factor, important for the transcription of S-phase 
genes was additionally down-regulated. Further, the MCM family of DNA synthesis genes 
was significantly down-regulated. Survivin (BIRC5) was down-regulated, while CASP3 was 
up-regulated. Moreover, GADD45A was 40 fold significantly up-regulated. Similarly in 
MRC-5 cells, insignificant (1.26 fold) p53 activation led to p15 activation, resulting in 
inactivation of cyclins/CDKs, deregulation of AURKB and subsequent MAD2L2 down-
regulation, and a repression in the expression of the MCM gene family. LPV/r exhibited 
characteristics of anti-tumour agents. From this dataset, it is evident that both EFV and LPV/r 
induce DNA damage response pathways. With respect to the DDR pathway, members such as 
Aurora kinases (AURKB) and MAD2L2, have previously been shown to be frequently 
overexpressed in human tumours, causing aberrations in the spindle assembly checkpoint, 
resulting in chromosomal mis-segregation and centrosome amplification, leading to 
chromosomal instability and tumorigenesis (Hochegger et al., 2013). Failure to arrest the cell-
cycle and repair the DNA damage, may lead to apoptosis. CASP3, an effector caspase 
important in apoptotic-mediated cell death, was also shown here to be differentially expressed 
in response to EFV and LPV/r drug treatment. All three gene targets (MAD2L2, AURKB and 
CASP3) were selected on the basis of their regulatory involvement in DNA damage response 
(DDR) pathways for further analysis.  
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5.2.6 MAD2L2, AURKB and CASP3 as mediators in EFV and LPV/r in 
lung carcinogenesis via DDR. 
 
The protein encoded by the MAD2L2 gene, also known as REV7, is a protein of 211 amino 
acids and is a component of the mitotic spindle assembly checkpoint (SAC) that prevents the 
onset of anaphase to permit the correct alignment of all chromosomes at the metaphase plate 
(Sale, 2015). MAD2L2 also plays important roles in translesion DNA synthesis, mitotic 
control, and in repair pathway choice during DNA double-strand breaks. REV7 is a subunit of 
the enzyme DNA polymerase ϛ, which is a key enzyme involved in replicating damaged DNA 
by translesion synthesis. REV7 acts as a connector protein between REV1 and REV3. REV7 
is the catalytic subunit of Pol ϛ, and helps direct the sequential insertion and extension steps of 
lesion replication (Sale, 2015). Upon DNA damage, MAD2L2 is recruited to DSB sites but is 
not needed to initiate damage signalling. While 53BP1 (p53 binding protein) is recruited to 
DSB and plays an important role in promoting non-homologous end joining (NHEJ). 53BP1 
recruits RIF1, (telomere associated protein) and thus inhibits the resection of the DNA ends 
(Zimmermann and de Lange, 2014). MAD2L2 is proposed to act downstream of RIF1 and is 
needed for the inhibition of DNA 5’ end resection. Furthermore, proper DNA lesion repair 
and the inhibition of DNA repair activities at telomeres are essential in preventing genomic 
instability. To date, mechanisms underlying telomere-driven genomic instabilities are poorly 
understood. However, the findings by Boersma et al., (2015) have placed MAD2L2 as a 
potential contributor to genomic instability, if aberrantly expressed during DNA repair at 
uncapped telomeres and DSBs.   
Furthermore, it has been shown that MAD2L2 is essential for telomere fusion when there are 
defects in capping. In addition, emerging evidence suggests DNA Pol ϛ is important for 
effective HR (Boersma et al., 2015). As a componential sub-unit of Pol ϛ, MAD2L2 may 
somehow also be involved not just in NHEJ as previously implicated, but also in the 
coordination of HR.  
Aurora kinases (AURKs) have been shown to play a central role in organizing bipolar spindle 
establishment, chromosome alignment and segregation. Three paralogues have been 
identified, AURKA, AURKB and AURKC. AURKs activity is required both at the spindle 
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pole and the kinetochore. Aurora B coordinates kinetochore attachment and cytokinesis 
(Hochegger et al., 2013).    
Aurora B forms part of the Chromosome Passenger Complex (CPC) and is partnered with 
Incenp, Survivin and Borealin. Chromosomal bio-orientation prior to segregation is ensured 
by AURKB and the CPC. AURKB destabilizes incorrectly attached microtubule (MT)–
kinetochore connections via mitotic centromere associated kinesin (MCAK) ((Lan et al., 
2004), (Andrews et al., 2004)). The phosphorylations (by AURKB) are removed by protein-
protein interactions (PPIs), once tension is established and the outer kinetochore is separated 
from the centromeric Aurora B ((Emanuele et al., 2008), (Liu et al., 2010), (Liu et al., 2009)). 
By generating unattached kinetochores during error correction, Aurora B then effects the 
spindle assembly checkpoint (SAC) by recruiting SAC components such as BubR1 and 
MAD2L2 to the kinetochore. Furthermore, CASP3 is an effector CASP3, playing a critical 
role in apoptotic cell death. De-regulation of CASP3 underlies human diseases including 
cancer.  
 
5.2.7 Target gene validation using qRT-PCR 
 
QRT-PCR was done to validate the target genes’ expression level, originally obtained from 
the PCR array data. Prior to EFV and LPV/r drug treatment (in untreated A549 vs MRC-5 
cells), CASP3 was down-regulated at both 24h and 48h. AURKB and MAD2L2 were also 
validated to be up-regulated at both time periods. Following treatment with EFV and LPV/r, 
all three gene targets relatively remained in the insignificantly repressed state in the normal 
cells. This however, was not the case in the adenocarcinoma cells. Both EFV and LPV/r drug 
treatment altered the expression of all targets, with a down-regulation of CASP3, and up-
regulation of AURKB and MAD2L2 at 24h and 48h, as indicated in the gene array data.  
Figure 5.4 below illustrates the summarised p53 pathway targeted by AURKB.   
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Figure 5.4: Summarised diagram of p53 pathway targeted by AURKB. As part of the 
chromosome passenger complex (CPC), AURKB overexpression affects the spindle assembly 
checkpoint (SAC) by recruiting its (SAC) components such MAD2L2, leading to aberrations 
in the mitotic spindle complex (MSC). The overexpression of AURKB also augments the 
expression of MAD2L2. In turn or perhaps simultaneously, p53 activity is inhibited by 
AURKB phosphorylation resulting in excessive cell proliferation, as demonstrated in panel A. 
However, ARV treatment down-regulates AURKB expression, thus also leading to reduced 
MAD2L2 activity, while p53 activity is induced, with subsequent p53 downstream targets 
activated, thus inhibiting cell proliferation in panel B.  
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5.3 Study limitations 
  
As this  study evaluated a single non-small lung adenocarcinoma cell-line, this analysis will be 
expanded to include a number of other NSCLC cell lines, for example, NCI –H228, Calu-3, 
NCI-HI563, NCI-H522, NCI-H2122, NCI-HI993 and SK-LU-1.    
Another consideration in the present analysis is that it focussed on an in vitro cell culture 
model and not on patients undergoing ARV treatment. While the cells were subjected to an 
intense exposure of ARVs, the time period of cell treatment for 24h, 48h and 72h may not 
reflect the extended years of ARV treatment in HIV-infected people. In this regard, it would 
be useful to validate selected findings of this study in samples from patients who have been 
treated with ART for many years, with and/or without lung cancer. The identification of cell-
cycle related genes treated with ARVs in lung cancer cells transfected with the HIV pro-virus 
could also be beneficial to this study’s findings.  
The possible contribution of HIV proteins and inflammation on the NADC’s tumourigenesis 
was not explored in the present study and the knowledge generated from these collaborative 
findings could aid in revealing the mechanisms underlying NADCs. The oncogenic potential 
of the HIV virus was not covered here.  
 
5.3.1 NADCs in the context of HIV infection 
 
A better understanding of HIV induced oncogenesis, viral mechanisms of immune 
suppression and HAART cytotoxicity will provide for the basis for better diagnosis and 
treatment of cancer in PLWHA. NADCs can be classified as either virus or non-virus related, 
depending on whether some of these cancers are directly linked to HIV infection, or not. Lung 
cancer in particular, is one of the NADCs that is non-virus related (Chiao, 2010).  A number 
of factors have been identified to contribute to the increased risk of NADCs, including CD4+ 
T-cell counts, chronic inflammation, tobacco usage, alcohol exposure, long-term ART 
exposure, advanced age and co-infection with oncogenic viruses (Loarca et al., 2017).  
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5.3.2 Multifactorial agents contributing to the NADCs 
 
HIV proteins, such as HIV-1 Tat has been shown to be involved in altering the DNA repair 
mechanism in host cells, possibly leading to genomic instability which may give rise to 
mutations and contribute to oncogenesis (Nunnari et al., 2008). In addition, Tat induces 
expression of the DNA polymerase beta gene, which codes for a central mediator in the DNA 
base-excision repair pathway (Srivastava et al., 2001). HIV-1 Tat has also been implicated in 
playing a direct role in double-strand break DNA repair (Chipitsyna et al., 2004). 
Additionally, HIV-1 Tat expression was reported to regulate gene expression levels of  
important cell-cycle regulators, and further  decreased the mRNA levels of cyclin-dependent 
kinase inhibitors p21 and p17 (Nyagol et al., 2006).  
  
On the other hand, the tumour micro-environment includes a number of immune cellular 
components, which include activated T cells, B cells and macrophages. HIV infection results 
in a major perturbation of cytokine/chemokine levels, which facilitates the development of 
antiviral immunity (reviewed in Reuter et al., 2012). For example, elevated levels of 
interleukin (IL) IL-6, IL-10, CXCL13 and tumour necrosis factorα (TNFα) are associated with 
increased risk for the development of NHL in HIV-infected individuals (Breen et al., 2011). 
The induction of pro-inflammatory mediators by HIV infection is likely to influence other 
immunomodulatory factors, affecting cellular proliferation, apoptosis sensitivity and other 
physiological functions associated with the microenvironment (De Paoli and Carbone, 2015).  
With regard to HAART cytotoxicity, HAART components such raltegravir, an integrase 
inhibitor, was found to induce host DNA rearrangements, which may lead to an increased risk 
of cancer (Varadarajan et al., 2013). To gain a better understanding of ARV impact on 
NADCs, continuous epidemiological surveillance is necessary to monitor the trends in 
NADCs.  
While this study aimed at the identification of cell-cycle related genes treated with ARVs in 
lung cancer, research groups and pharmaceutical companies are now trying to design and use 
modulators of the cell-cycle and cell-death programs as therapeutic tools. Understanding the 
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regulation of cell-cycle and cell-death may aid in knowledge application for the generation of 
improved treatment of human diseases such as HIV/AIDS and ARV mediated tumourigenesis. 
The cell-cycle and cell-death pathways are being targeted to better treat human diseases such 
as cancer in this era (Wiman and Zhivotovsky, 2017). Therefore, the cell-cycle related genes 
and their products can be targeted as promising therapeutic targets in the ART-mediated 
tumourigenesis.  
 
5.4 Future directions 
 
This study focused on identifying cell-cycle related genes targeted by EFV and LPV/r and 
demonstrated how these ARVs may cause damage to the genome. Future work may include in 
vitro functional studies, that is, it would be instructive to perform knockdown experiments 
using specific siRNA targeting the identified gene targets in lung cells. These findings 
demonstrate the double-edged oncogenic properties of both EFV and LPV/r, also implicating 
their role in genotoxicity. As a result, patients exposed to these ARVs seem to be vulnerable 
to continuous DNA damage, leading to NSCLC tumorigenesis.  
While the scope of this study sought to identify the cell-cycle related genes treated with EFV 
and LPV/r in lung cancer, expanded future directions of this study may include the exploration 
of other modes of cell-death  (such as autophagy) other than apoptosis, as LPV/r in particular 
was shown to induce cell-death. This could aid in better understanding of the ARVs effects on 
cell-proliferation and cell-death.  
The transfection of lung cells (both control and cancer) with the HIV provirus and testing of 
patient samples that have been on HAART for years, could better establish the findings and 
determine if HIV oncogenic potential , HIV proteins and inflammation, immunosuppression 
and HAART cytotoxicity act individually or in synergy to promote NADCs. It is also not clear 
whether HIV proteins and human disease pathway (such as cancer) proteins interact together 
to promote tumourigenesis. Therefore functional enrichment of genes and proteins to gain a 
deeper understanding of the association between HIV and human genes, proteins and 
pathways could be further explored.  
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CHAPTER 6: CONCLUSIONS 
 
A series of in silico analyses including STRING, DAVID, REACTOME and IPA were 
performed on the gene expression data obtained from the focused cell-cycle gene arrays. 
Protein-protein-interaction (PPI) network PI analysis of the cell-cycle genes in response to 
ART treatment elucidated a series of tight interactions, identifying pivotal factors associated 
with the DNA damage response, including amongst others GADD45, HUS and RAD. 
Changes in expression of cell-cycle regulatory factors, including cyclin/CDK activity, and the 
downstream targets of p53 were elucidated using DAVID analysis. In particular, the p53 
effector targets p21 and GADD45A, to arrest growth and possibly repair the damaged DNA, 
were suppressed. The analysis of biological pathways using Reactome showed that ARV 
treatments, dependent on the ARV and cell type, affected other pathways besides the cell-
cycle; EFV activated DNA repair genes in both normal and cancerous cells and the cellular 
response to stress genes was activated in normal cells.  In lung cancer cells, genes associated 
with programmed cell-death were up-regulated, with an allied decline in the expression of 
genes involved in DNA replication. A further understanding of the mechanisms underlying the 
observed changes in gene expression in the pathways identified by Reactome was gained by 
employing the Ingenuity Pathway Analysis (IPA) tool. This particularly showed that the DNA 
damage response pathway, the ATM pathway was activated in both lung cancer and in normal 
cells by EFV. Lopinavir/ritonavir, even though it reduced DNA synthesis in normal MRC-5 
cells, it however failed to activate ATM. Regardless of the up-stream ATM pathway 
repression, the p53-signalling pathway was activated in lung cancer cells. Notably, the de-
regulation of these two pathways play essential roles in genomic instability, leading to cancer.  
 
The anti-proliferative and cytotoxic properties of EFV and LPV/r are evident from this study. 
However, these properties should be tested on different types of cancer and the associated 
response profiles evaluated. Although there may be further steps to be considered, EFV and 
LPV/r demonstrate unique but also at the same time similar mechanisms, whereby they both 
dose dependently retard and inhibit cell proliferation. The recruitment of DNA damage 
response pathways following EFV and LPV/r treatment in both normal and cancer cells 
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indicates that these drugs possess anti-tumour activity, similar to those demonstrated by 
chemotherapeutic drugs. However, proper consideration is necessary as LPV/r in particular 
also poses the danger of excessive cell-death, as was particularly observed here in the normal 
lung cells. In the same manner, PLWHA previously not pre-disposed to cancer, particularly 
lung cancer, may be undergoing similar processes, where the administration of EFV and 
LPV/r impose damage to the genome, resulting in the activation of cellular response to stress 
and DNA damage response genes/pathways. Being actively induced by consistent and 
continuous HAART administration, these pathways may be dysregulated (possibly due to 
constant activation), ultimately leading to tumorigenesis. This however, does not exclude 
ARVs from being explored as anti-cancer drugs, due to their anti-cancer properties.      
Aberrant expression of AURKB seems to inhibit p53 activity, thereby suppressing CASP3, 
and impacting on the constitutive expression of SAC components such as MAD2L2, resulting 
in loss of maintenance of the SAC leading to chromosomal mis-segregation, genome 
instability and tumorigenesis.  
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Appendix B- Drugs and Alamar Blue 
B1) Drugs 
 
a) ARV drugs  
(i) Efavirenz (EFV) (Toronto Research Chemicals) 
 0.0158g EFV dissolved in 5ml methanol, to give 10mM. 
 
(ii) Lopinavir/ritonavir (Toronto Research Chemicals) 
4:1 ratio (32:8 µM) was used 
For (10:2.5) mM LPV/r stock solution, 
0.0314g (LPV) plus 0.009g (RTV) dissolved in 5ml methanol 
 
b) Camptothecin (Sigma) 
50µM Camptothecin (CPT) 
0.0348mg dissolved in 2ml methanol 
 
B2) Alamar Blue (Sigma)   
0.0005g in 5ml of sterile distilled water 
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Appendix C-Supplementary data 
C1) Alamar Blue (AB) assay 
 
Figure C1.1: Cell viability in response to EFV in MRC-5 cells. Cells were treated for 24h to 
72h (M24h to M72h) with 4, 13, 26 and 50µM EFV. Percentage (%) reduction of AB is 
directly proportional to the number of viable cells.    
 
 
Figure C1.2: Cell viability in response to EFV in A549 cells. Cells were treated for 24h to 
72h (A24h to A72h) with 4, 13, 26 and 50µM EFV. Percentage (%) reduction of AB is 
directly proportional to the number of viable cells.   
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Figure C1.3: Cell viability in response to LPV/r in MRC-5 cells. Cells were treated for 24h to 
72h (M24h to M72h) with 10, 32, 50 and 80µM EFV. Percentage (%) reduction of AB is 
directly proportional to the number of viable cells.   
 
 
Figure C1.4: Cell viability in response to LPV/r in A549 cells. Cells were treated for 24h to 
72h (A24h to A72h) with 10, 32, 50 and 80µM EFV. Percentage (%) reduction of AB is 
directly proportional to the number of viable cells. 
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C2) xCELLigence RTCA assay 
EFV treatment in MRC-5 
 
Figure C2.1: MRC-5 cells growth curves treated with EFV. The cells were exposed to 4, 13 
and 50µM EFV for 24h to 72h.  The curves were plotted in relative to the untreated (veh 
control).  
 
 
Figure C2.2: MRC-5 cells growth curves treated with EFV. The cells were exposed to 4, 13 
and 50µM EFV for 24h to 72h.  The curves were plotted in relative to the untreated (veh 
control).  
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EFV treatment in A549 
 
Figure C2.3: A549 cells growth curves treated with EFV. The cells were exposed to 4, 13 and 
50µM EFV for 24h to 72h.  The curves were plotted in relative to the untreated (veh control).  
 
 
Figure C2.4: A549 cells growth curves treated with EFV. The cells were exposed to 4, 13 and 
50µM EFV for 24h to 72h.  The curves were plotted in relative to the untreated (veh control).  
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LPV/r in MRC-5 cells 
 
Figure C2.5: MRC-5 cells growth curves treated with LPV/r. The cells were exposed to 10, 
32 and 80µM for 24h to 72h.  The curves were plotted in relative to the untreated (veh 
control).  
 
 
Figure C2.6: MRC-5 cells growth curves treated with LPV/r. The cells were exposed to 10, 
32 and 80µM for 24h to 72h.  The curves were plotted in relative to the untreated (veh 
control).  
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LPV/r in A549 cells 
 
Figure C2.7: A549 cells growth curves treated with LPV/r. The cells were exposed to 10, 32 
and 80µM for 24h to 72h.  The curves were plotted in relative to the untreated (veh control).  
 
 
Figure C2.8: A549 cells growth curves treated with LPV/r. The cells were exposed to 10, 32 
and 80µM for 24h to 72h.  The curves were plotted in relative to the untreated (veh control).  
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C3) Cell-cycle analysis by FACS 
EFV treated cells, first MRC-5 cells then A549 cells.  
MRC-5 EFV treated 
 
 
Figure C3.1: Analysis of the cell-cycle stages in MRC-5 cells treated with (4, 13 and 50)µM 
EFV at 24h and 48h. The histograms and the bar-graphs illustrate an increase in S-phase with 
increasing EFV concentration.  
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Figure C3.2: Analysis of the cell-cycle stages in MRC-5 cells treated with (4, 13 and 50)µM 
EFV at 24h and 48h. The histograms and the bar-graphs illustrate an increase in S-phase with 
increasing EFV concentration.  
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A549 cells EFV treated 
 
 
Figure C3.3: Analysis of the cell-cycle stages in A549 cells treated with (4, 13 and 50)µM 
EFV at 24h and 48h. The histograms and the bar-graphs illustrate an increase in S-phase with 
increasing EFV concentration.  
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Figure C3.4: Analysis of the cell-cycle stages in A549 cells treated with (4, 13 and 50)µM 
EFV at 24h and 48h. The histograms and the bar-graphs illustrate an increase in S-phase with 
increasing EFV concentration.  
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LPV/r treated cells, first MRC-5 cells, then A549 cells. 
MRC-5 LPV/r treated 
 
 
Figure C3.5: The analysis of the cell-cycle interphases in MRC-5 cells treated with (10, 32 
and 80) µM LPV/r. The histograms and the bar graphs show an arrest at S phase following 
32µM treatment. Cell death is illustrated by the sub-G0/G1 population towards the side-scatter 
in the histograms. 
RM. Marima: PhD Thesis 
182 
 
 
 
Figure C3.6: The analysis of the cell-cycle interphases in MRC-5 cells treated with (10, 32 
and 80) µM LPV/r. The histograms and the bar graphs show an arrest at S phase following 
32µM treatment. Cell death is illustrated by the sub-G0/G1 population towards the side-scatter 
in the histograms. 
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A549 LPV/r treated 
 
 
Figure C3.7: The analysis of the cell-cycle interphases in A549 cells treated with (10, 32 and 
80) µM LPV/r. The histograms and the bar graphs show an arrest at S phase following 32µM 
treatment.  Cell death is illustrated by the sub-G0/G1 population on the side-scatter in the 
histograms.   
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A549 cells LPV/r treated 
 
 
Figure C3.8: The analysis of the cell-cycle interphases in A549 cells treated with (10, 32 and 
80) µM LPV/r. The histograms and the bar graphs show an arrest at S phase following 32µM 
treatment.  Cell death is illustrated by the sub-G0/G1 population on the side-scatter in the 
histograms.  
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C4) Apoptosis assay by FACS 
MRC-5 cells 
 
Figure C4.1: MRC-5 cells apoptosis FACS analysis.  The cells were treated for 24h (A-D) 
and 48h (E-H) with; A and E (0.1% methanol-vehicle), B and F CPT as positive control, C 
and G, 32µM LPV/r and D and H 80µM LPV/r.   
 
Figure C4.2: MRC-5 cells apoptosis FACS analysis.  The cells were treated for 24h (A-D) 
and 48h (E-H) with; A and E (0.1% methanol-vehicle), B and F CPT as positive control, C 
and G, 32µM LPV/r and D and H 80µM LPV/r.   
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Figure C4.3: MRC-5 cells apoptosis statistical analysis using ANOVA and Tukey’s multiple 
comparison tests. The apoptosis percentage (%) increases with increasing LPV/r 
concentrations.  
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LPV/r apoptotic effects in A549 cells 
 
Figure C4.4: A549 cells apoptosis FACS analysis.  The cells were treated for 24h (A-D) and 
48h (E-H) with; A and E (0.1% methanol-vehicle), B and F CPT as positive control, C and G, 
32µM LPV/r and D and H 80µM LPV/r.    
 
Figure C4.5: A549 cells apoptosis FACS analysis.  The cells were treated for 24h (A-D) and 
48h (E-H) with; A and E (0.1% methanol-vehicle), B and F CPT as positive control, C and G, 
32µM LPV/r and D and H 80µM LPV/r.   
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Figure C4.6: A549 cells apoptosis statistical analysis using ANOVA and Tukey’s multiple 
comparison tests. The apoptosis percentage (%) increases with increasing LPV/r treatment.  
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C5) PCR (Gene) Arrays appendices  
 
Well Gene Symbol GenBank Gene name 
A01 ABL1 NM_005157 C-abl oncogene 1, non-receptor tyrosine kinase 
A02 ANAPC2 NM_013366 Anaphase promoting complex subunit 2 
A03 ATM NM_000051 Ataxia telangiectasia mutated 
A04 ATR NM_001184 Ataxia telangiectasia and Rad3 related 
A05 AURKA NM_003600 Aurora kinase A 
A06 AURKB NM_004217 Aurora kinase B 
A07 BCCIP NM_016567 BRCA2 and CDKN1A interacting protein 
A08 BCL2 NM_000633 B-cell CLL/lymphoma 2 
A09 BIRC5 NM_001168 Baculoviral IAP repeat containing 5 
A10 BRCA1 NM_007294 Breast cancer 1, early onset 
A11 BRCA2 NM_000059 Breast cancer 2, early onset 
A12 CASP3 NM_004346 Caspase 3, apoptosis-related cysteine peptidase 
B01 CCNA2 NM_001237 Cyclin A2 
B02 CCNB1 NM_031966 Cyclin B1 
B03 CCNB2 NM_004701 Cyclin B2 
B04 CCNC NM_005190 Cyclin C 
B05 CCND1 NM_053056 Cyclin D1 
B06 CCND2 NM_001759 Cyclin D2 
B07 CCND3 NM_001760 Cyclin D3 
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B08 CCNE1 NM_001238 Cyclin E1 
B09 CCNF NM_001761 Cyclin F 
B10 CCNG1 NM_004060 Cyclin G1 
B11 CCNG2 NM_004354 Cyclin G2 
B12 CCNH NM_001239 Cyclin H 
C01 CCNT1 NM_001240 Cyclin T1 
C02 CDC16 NM_003903 Cell division cycle 16 homolog (S. cerevisiae) 
C03 CDC20 NM_001255 Cell division cycle 20 homolog (S. cerevisiae) 
C04 CDC25A NM_001789 Cell division cycle 25 homolog A (S. pombe) 
C05 CDC25C NM_001790 Cell division cycle 25 homolog C (S. pombe) 
C06 CDC34 NM_004359 Cell division cycle 34 homolog (S. cerevisiae) 
C07 CDC6 NM_001254 Cell division cycle 6 homolog (S. cerevisiae) 
C08 CDK1 NM_001786 Cyclin-dependent kinase 1 
C09 CDK2 NM_001798 Cyclin-dependent kinase 2 
C10 CDK4 NM_000075 Cyclin-dependent kinase 4 
C11 CDK5R1 NM_003885 Cyclin-dependent kinase 5, regulatory subunit 1 
(p35) 
C12 CDK5RAP1 NM_016408 CDK5 regulatory subunit associated protein 1 
D01 CDK6 NM_001259 Cyclin-dependent kinase 6 
D02 CDK7 NM_001799 Cyclin-dependent kinase 7 
D03 CDK8 NM_001260 Cyclin-dependent kinase 8 
D04 CDKN1A NM_000389 Cyclin-dependent kinase inhibitor 1A (p21, 
Cip1) 
D05 CDKN1B NM_004064 Cyclin-dependent kinase inhibitor 1B (p27, 
Kip1) 
D06 CDKN2A NM_000077 Cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) 
D07 CDKN2B NM_004936 Cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) 
D08 CDKN3 NM_005192 Cyclin-dependent kinase inhibitor 3 
D09 CHEK1 NM_001274 CHK1 checkpoint homolog (S. pombe) 
D10 CHEK2 NM_007194 CHK2 checkpoint homolog (S. pombe) 
D11 CKS1B NM_001826 CDC28 protein kinase regulatory subunit 1B 
D12 CKS2 NM_001827 CDC28 protein kinase regulatory subunit 2 
E01 CUL1 NM_003592 Cullin 1 
E02 CUL2 NM_003591 Cullin 2 
E03 CUL3 NM_003590 Cullin 3 
E04 E2F1 NM_005225 E2F transcription factor 1 
E05 E2F4 NM_001950 E2F transcription factor 4, p107/p130-binding 
E06 GADD45A NM_001924 Growth arrest and DNA-damage-inducible, 
alpha 
E07 GTSE1 NM_016426 G-2 and S-phase expressed 1 
E08 HUS1 NM_004507 HUS1 checkpoint homolog (S. pombe) 
E09 KNTC1 NM_014708 Kinetochore associated 1 
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E10 KPNA2 NM_002266 Karyopherin alpha 2 (RAG cohort 1, importin 
alpha 1) 
E11 MAD2L1 NM_002358 MAD2 mitotic arrest deficient-like 1 (yeast) 
E12 MAD2L2 NM_006341 MAD2 mitotic arrest deficient-like 2 (yeast) 
F01 MCM2 NM_004526 Minichromosome maintenance complex 
component 2 
F02 MCM3 NM_002388 Minichromosome maintenance complex 
component 3 
F03 MCM4 NM_005914 Minichromosome maintenance complex 
component 4 
F04 MCM5 NM_006739 Minichromosome maintenance complex 
component 5 
F05 MDM2 NM_002392 Mdm2 p53 binding protein homolog (mouse) 
F06 MKI67 NM_002417 Antigen identified by monoclonal antibody Ki-
67 
F07 MNAT1 NM_002431 Menage a trois homolog 1, cyclin H assembly 
factor (Xenopus laevis) 
F08 MRE11A NM_005590 MRE11 meiotic recombination 11 homolog A 
(S. cerevisiae) 
F09 NBN NM_002485 Nibrin 
F10 RAD1 NM_002853 RAD1 homolog (S. pombe) 
F11 RAD17 NM_002873 RAD17 homolog (S. pombe) 
F12 RAD51 NM_002875 RAD51 homolog (S. cerevisiae) 
G01 RAD9A NM_004584 RAD9 homolog A (S. pombe 
G02 RB1 NM_000321 Retinoblastoma 1 
G03 RBBP8 NM_002894 Retinoblastoma binding protein 8 
G04 RBL1 NM_002895 Retinoblastoma-like 1 (p107) 
G05 RBL2 NM_005611 Retinoblastoma-like 2 (p130) 
G06 SERTAD1 NM_013376 SERTA domain containing 1 
G07 SKP2 NM_005983 S-phase kinase-associated protein 2 (p45) 
G08 STMN1 NM_005563 Stathmin 1 
G09 TFDP1 NM_007111 Transcription factor Dp-1 
G10 TFDP2 NM_006286 Transcription factor Dp-2 (E2F dimerization 
partner 2) 
G11 TP53 NM_000546 Tumor protein p53 
G12 WEE1 NM_003390 WEE1 homolog (S. pombe) 
H01 ACTB NM_001101 Actin, beta 
H02 B2M NM_004048 Beta-2-microglobulin 
H03 GAPDH NM_002046 Glyceraldehyde-3-phosphate dehydrogenase 
H04 HPRT1 NM_000194 Hypoxanthine phosphoribosyltransferase 1 
H05 RPLP0 NM_001002 Ribosomal protein, large, P0 
H06 HGDC SA_00105 Human Genomic DNA Contamination 
H07 RTC SA_00104 Reverse Transcription Control 
H08 RTC SA_00104 Reverse Transcription Control 
RM. Marima: PhD Thesis 
192 
 
H09 RTC SA_00104 Reverse Transcription Control 
H10 PPC SA_00103 Positive PCR Control 
H11 PPC SA_00103 Positive PCR Control 
H12 PPC SA_00103 Positive PCR Control  
 
 Figure C5.1: The layout of the human cell-cycle PCR Array, each well representing an 
individual gene. There are 84 genes across the array (A1 to G12), with the H row comprising 
of the quality controls which include HKG, HGDC, as well as the RTC and PPC. The 
accession numbers corresponding to the gene names (full) and abbreviations are provided 
here.  
 
Table C5.1: Gene expression in fold changes in untreated A549 vs MRC-5  
Position Gene Symbol UniGene GenBank Fold Change 
A01 ABL1 Hs.431048 NM_005157 -2.87 
A02 ANAPC2 Hs.533262 NM_013366 -2.64 
A03 ATM Hs.367437 NM_000051 1.07 
A04 ATR Hs.271791 NM_001184 1.55 
A05 AURKA Hs.250822 NM_003600 4.44 
A06 AURKB Hs.442658 NM_004217 14.12 
A07 BCCIP Hs.370292 NM_016567 2.06 
A08 BCL2 Hs.150749 NM_000633 1.95 
A09 BIRC5 Hs.728893 NM_001168 3.61 
A10 BRCA1 Hs.194143 NM_007294 3.84 
A11 BRCA2 Hs.34012 NM_000059 4 
A12 CASP3 Hs.141125 NM_004346 -3.73 
B01 CCNA2 Hs.58974 NM_001237 3.01 
B02 CCNB1 Hs.23960 NM_031966 7.62 
B03 CCNB2 Hs.194698 NM_004701 14.62 
B04 CCNC Hs.430646 NM_005190 1.21 
B05 CCND1 Hs.523852 NM_053056 -10.7 
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B06 CCND2 Hs.376071 NM_001759 -3541.14 
B07 CCND3 Hs.534307 NM_001760 2.38 
B08 CCNE1 Hs.244723 NM_001238 3.68 
B09 CCNF Hs.1973 NM_001761 4.08 
B10 CCNG1 Hs.79101 NM_004060 -11.63 
B11 CCNG2 Hs.13291 NM_004354 -3.23 
B12 CCNH Hs.292524 NM_001239 -1.13 
C01 CCNT1 Hs.279906 NM_001240 -1.88 
C02 CDC16 Hs.374127 NM_003903 -4.41 
C03 CDC20 Hs.524947 NM_001255 2.95 
C04 CDC25A Hs.437705 NM_001789 1.31 
C05 CDC25C Hs.656 NM_001790 3.97 
C06 CDC34 Hs.514997 NM_004359 -1.22 
C07 CDC6 Hs.405958 NM_001254 5.03 
C08 CDK1 Hs.334562 NM_001786 3.76 
C09 CDK2 Hs.19192 NM_001798 -1.57 
C10 CDK4 Hs.95577 NM_000075 -1.39 
C11 CDK5R1 Hs.500015 NM_003885 1.93 
C12 CDK5RAP1 Hs.435952 NM_016408 -1.53 
D01 CDK6 Hs.119882 NM_001259 -2.16 
D02 CDK7 Hs.184298 NM_001799 -1.65 
D03 CDK8 Hs.382306 NM_001260 -1.16 
D04 CDKN1A Hs.370771 NM_000389 -16.11 
D05 CDKN1B Hs.238990 NM_004064 1.4 
D06 CDKN2A Hs.512599 NM_000077 -891.44 
D07 CDKN2B Hs.72901 NM_004936 -64.45 
D08 CDKN3 Hs.84113 NM_005192 7.46 
D09 CHEK1 Hs.24529 NM_001274 1.85 
D10 CHEK2 Hs.291363 NM_007194 4.23 
D11 CKS1B Hs.374378 NM_001826 1.73 
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D12 CKS2 Hs.83758 NM_001827 1.64 
E01 CUL1 Hs.146806 NM_003592 -1.12 
E02 CUL2 Hs.82919 NM_003591 -3.23 
E03 CUL3 Hs.372286 NM_003590 1.66 
E04 E2F1 Hs.654393 NM_005225 2.81 
E05 E2F4 Hs.108371 NM_001950 1.61 
E06 GADD45A Hs.80409 NM_001924 -10.7 
E07 GTSE1 Hs.386189 NM_016426 3.58 
E08 HUS1 Hs.152983 NM_004507 -8.11 
E09 KNTC1 Hs.300559 NM_014708 4.96 
E10 KPNA2 Hs.594238 NM_002266 1.21 
E11 MAD2L1 Hs.591697 NM_002358 1.84 
E12 MAD2L2 Hs.19400 NM_006341 2.83 
F01 MCM2 Hs.477481 NM_004526 1.97 
F02 MCM3 Hs.179565 NM_002388 3.07 
F03 MCM4 Hs.460184 NM_005914 4.29 
F04 MCM5 Hs.517582 NM_006739 3.51 
F05 MDM2 Hs.484551 NM_002392 -1.25 
F06 MKI67 Hs.689823 NM_002417 3.39 
F07 MNAT1 Hs.509523 NM_002431 1.35 
F08 MRE11A Hs.192649 NM_005590 1.78 
F09 NBN Hs.492208 NM_002485 1.09 
F10 RAD1 Hs.531879 NM_002853 -4.79 
F11 RAD17 Hs.16184 NM_002873 -2.71 
F12 RAD51 Hs.631709 NM_002875 1.01 
G01 RAD9A Hs.655354 NM_004584 4.89 
G02 RB1 Hs.408528 NM_000321 -2.1 
G03 RBBP8 Hs.546282 NM_002894 -1.13 
G04 RBL1 Hs.207745 NM_002895 3.46 
G05 RBL2 Hs.513609 NM_005611 -1.06 
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G06 SERTAD1 Hs.269898 NM_013376 -4.5 
G07 SKP2 Hs.23348 NM_005983 -3.48 
G08 STMN1 Hs.209983 NM_005563 -1.06 
G09 TFDP1 Hs.79353 NM_007111 -1.13 
G10 TFDP2 Hs.379018 NM_006286 1.16 
G11 TP53 Hs.654481 NM_000546 4.32 
G12 WEE1 Hs.249441 NM_003390 1.11 
 
Table C5.2: Gene expression fold changes in MRC-5 cells treated with EFV 
Position Gene Symbol UniGene GenBank Fold Change 
A01 ABL1 Hs.431048 NM_005157 1.39 
A02 ANAPC2 Hs.533262 NM_013366 1.01 
A03 ATM Hs.367437 NM_000051 2.68 
A04 ATR Hs.271791 NM_001184 2.57 
A05 AURKA Hs.250822 NM_003600 1.57 
A06 AURKB Hs.442658 NM_004217 -1.02 
A07 BCCIP Hs.370292 NM_016567 2.36 
A08 BCL2 Hs.150749 NM_000633 1.84 
A09 BIRC5 Hs.728893 NM_001168 1.72 
A10 BRCA1 Hs.194143 NM_007294 2.4 
A11 BRCA2 Hs.34012 NM_000059 1.09 
A12 CASP3 Hs.141125 NM_004346 -1.45 
B01 CCNA2 Hs.58974 NM_001237 1.02 
B02 CCNB1 Hs.23960 NM_031966 2.73 
B03 CCNB2 Hs.194698 NM_004701 1.01 
B04 CCNC Hs.430646 NM_005190 1.09 
B05 CCND1 Hs.523852 NM_053056 -1.09 
B06 CCND2 Hs.376071 NM_001759 3.97 
B07 CCND3 Hs.534307 NM_001760 1.37 
B08 CCNE1 Hs.244723 NM_001238 1.35 
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B09 CCNF Hs.1973 NM_001761 1.01 
B10 CCNG1 Hs.79101 NM_004060 -1.12 
B11 CCNG2 Hs.13291 NM_004354 8.76 
B12 CCNH Hs.292524 NM_001239 7.95 
C01 CCNT1 Hs.279906 NM_001240 -1.93 
C02 CDC16 Hs.374127 NM_003903 1.59 
C03 CDC20 Hs.524947 NM_001255 1.46 
C04 CDC25A Hs.437705 NM_001789 1.41 
C05 CDC25C Hs.656 NM_001790 1.22 
C06 CDC34 Hs.514997 NM_004359 1.53 
C07 CDC6 Hs.405958 NM_001254 1.4 
C08 CDK1 Hs.334562 NM_001786 -1.32 
C09 CDK2 Hs.19192 NM_001798 -1.47 
C10 CDK4 Hs.95577 NM_000075 1.09 
C11 CDK5R1 Hs.500015 NM_003885 1.03 
C12 CDK5RAP1 Hs.435952 NM_016408 1.53 
D01 CDK6 Hs.119882 NM_001259 2.13 
D02 CDK7 Hs.184298 NM_001799 3.16 
D03 CDK8 Hs.382306 NM_001260 1.77 
D04 CDKN1A Hs.370771 NM_000389 1.89 
D05 CDKN1B Hs.238990 NM_004064 1.19 
D06 CDKN2A Hs.512599 NM_000077 1.18 
D07 CDKN2B Hs.72901 NM_004936 4.2 
D08 CDKN3 Hs.84113 NM_005192 -1.19 
D09 CHEK1 Hs.24529 NM_001274 2.28 
D10 CHEK2 Hs.291363 NM_007194 1.05 
D11 CKS1B Hs.374378 NM_001826 -1.11 
D12 CKS2 Hs.83758 NM_001827 -1.07 
E01 CUL1 Hs.146806 NM_003592 1.42 
E02 CUL2 Hs.82919 NM_003591 1.36 
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E03 CUL3 Hs.372286 NM_003590 1.36 
E04 E2F1 Hs.654393 NM_005225 1.77 
E05 E2F4 Hs.108371 NM_001950 1.34 
E06 GADD45A Hs.80409 NM_001924 1.3 
E07 GTSE1 Hs.386189 NM_016426 1.28 
E08 HUS1 Hs.152983 NM_004507 2.13 
E09 KNTC1 Hs.300559 NM_014708 1.23 
E10 KPNA2 Hs.594238 NM_002266 1.19 
E11 MAD2L1 Hs.591697 NM_002358 -1.13 
E12 MAD2L2 Hs.19400 NM_006341 -1.84 
F01 MCM2 Hs.477481 NM_004526 -1.03 
F02 MCM3 Hs.179565 NM_002388 2.51 
F03 MCM4 Hs.460184 NM_005914 1.83 
F04 MCM5 Hs.517582 NM_006739 1.35 
F05 MDM2 Hs.484551 NM_002392 3.92 
F06 MKI67 Hs.689823 NM_002417 1.16 
F07 MNAT1 Hs.509523 NM_002431 1.51 
F08 MRE11A Hs.192649 NM_005590 1.02 
F09 NBN Hs.492208 NM_002485 1.36 
F10 RAD1 Hs.531879 NM_002853 -1.2 
F11 RAD17 Hs.16184 NM_002873 1.29 
F12 RAD51 Hs.631709 NM_002875 2.11 
G01 RAD9A Hs.655354 NM_004584 1.74 
G02 RB1 Hs.408528 NM_000321 1.39 
G03 RBBP8 Hs.546282 NM_002894 -1.19 
G04 RBL1 Hs.207745 NM_002895 2.85 
G05 RBL2 Hs.513609 NM_005611 1.42 
G06 SERTAD1 Hs.269898 NM_013376 1.88 
G07 SKP2 Hs.23348 NM_005983 1.67 
G08 STMN1 Hs.209983 NM_005563 -1.12 
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G09 TFDP1 Hs.79353 NM_007111 1.34 
G10 TFDP2 Hs.379018 NM_006286 1.27 
G11 TP53 Hs.654481 NM_000546 1.27 
G12 WEE1 Hs.249441 NM_003390 1.26 
 
 
Figure C5.2: The heat map (left) indicating GE in 13µM EFV treated MRC-5 cells. The heat 
map represents fold changes Fold changes in gene expression are represented between EFV 
treated vs untreated MRC-5 cells. The value of ±3.13 indicates the minimum and maximum 
change in gene expression across the array. The abundance of the red blocks denotes the up-
regulation.    
Scatter plot (right) representing gene expression (GE) in 13µM EFV treated MRC-5 cells 
relative to the untreated control. The scatter plot illustrates the normalized expression of every 
gene on the array between the treated and untreated groups. The black data points clustered in 
the region of the solid line show the genes with relatively unchanged expression levels. The 
up-regulated genes are shown in yellow in the upper left quadrant. No significantly down-
regulated genes are depicted in this scatter plot. 
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Table C5.3: Gene expression fold changes in A549 cells treated with EFV 
Position Gene Symbol UniGene GenBank Fold Change 
A01 ABL1 Hs.431048 NM_005157 -1.1 
A02 ANAPC2 Hs.533262 NM_013366 -1.28 
A03 ATM Hs.367437 NM_000051 -1.13 
A04 ATR Hs.271791 NM_001184 -3.07 
A05 AURKA Hs.250822 NM_003600 1.02 
A06 AURKB Hs.442658 NM_004217 -4.28 
A07 BCCIP Hs.370292 NM_016567 1.28 
A08 BCL2 Hs.150749 NM_000633 1.29 
A09 BIRC5 Hs.728893 NM_001168 -1.35 
A10 BRCA1 Hs.194143 NM_007294 2.33 
A11 BRCA2 Hs.34012 NM_000059 -1.12 
A12 CASP3 Hs.141125 NM_004346 2.74 
B01 CCNA2 Hs.58974 NM_001237 -1.05 
B02 CCNB1 Hs.23960 NM_031966 -1.27 
B03 CCNB2 Hs.194698 NM_004701 -2.71 
B04 CCNC Hs.430646 NM_005190 -1.15 
B05 CCND1 Hs.523852 NM_053056 1.45 
B06 CCND2 Hs.376071 NM_001759 1.04 
B07 CCND3 Hs.534307 NM_001760 -1.21 
B08 CCNE1 Hs.244723 NM_001238 1.11 
B09 CCNF Hs.1973 NM_001761 -1.15 
B10 CCNG1 Hs.79101 NM_004060 2.57 
B11 CCNG2 Hs.13291 NM_004354 3.32 
B12 CCNH Hs.292524 NM_001239 1.07 
C01 CCNT1 Hs.279906 NM_001240 -1.05 
C02 CDC16 Hs.374127 NM_003903 1.76 
C03 CDC20 Hs.524947 NM_001255 2.13 
C04 CDC25A Hs.437705 NM_001789 1.03 
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C05 CDC25C Hs.656 NM_001790 1.12 
C06 CDC34 Hs.514997 NM_004359 1.25 
C07 CDC6 Hs.405958 NM_001254 -1.32 
C08 CDK1 Hs.334562 NM_001786 -1.43 
C09 CDK2 Hs.19192 NM_001798 -1.03 
C10 CDK4 Hs.95577 NM_000075 2.43 
C11 CDK5R1 Hs.500015 NM_003885 -1.08 
C12 CDK5RAP1 Hs.435952 NM_016408 3.14 
D01 CDK6 Hs.119882 NM_001259 -1.12 
D02 CDK7 Hs.184298 NM_001799 1.32 
D03 CDK8 Hs.382306 NM_001260 1.86 
D04 CDKN1A Hs.370771 NM_000389 1.66 
D05 CDKN1B Hs.238990 NM_004064 2.57 
D06 CDKN2A Hs.512599 NM_000077 1.04 
D07 CDKN2B Hs.72901 NM_004936 1.04 
D08 CDKN3 Hs.84113 NM_005192 1.35 
D09 CHEK1 Hs.24529 NM_001274 1.17 
D10 CHEK2 Hs.291363 NM_007194 -2 
D11 CKS1B Hs.374378 NM_001826 1.18 
D12 CKS2 Hs.83758 NM_001827 -1.05 
E01 CUL1 Hs.146806 NM_003592 -1.15 
E02 CUL2 Hs.82919 NM_003591 2.32 
E03 CUL3 Hs.372286 NM_003590 1.03 
E04 E2F1 Hs.654393 NM_005225 -1.12 
E05 E2F4 Hs.108371 NM_001950 -1.93 
E06 GADD45A Hs.80409 NM_001924 1.78 
E07 GTSE1 Hs.386189 NM_016426 -1.23 
E08 HUS1 Hs.152983 NM_004507 2.21 
E09 KNTC1 Hs.300559 NM_014708 -1.33 
E10 KPNA2 Hs.594238 NM_002266 -1.25 
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E11 MAD2L1 Hs.591697 NM_002358 -1.31 
E12 MAD2L2 Hs.19400 NM_006341 -5.85 
F01 MCM2 Hs.477481 NM_004526 -1.33 
F02 MCM3 Hs.179565 NM_002388 -1.25 
F03 MCM4 Hs.460184 NM_005914 -3.65 
F04 MCM5 Hs.517582 NM_006739 -1.2 
F05 MDM2 Hs.484551 NM_002392 1.26 
F06 MKI67 Hs.689823 NM_002417 1.11 
F07 MNAT1 Hs.509523 NM_002431 1.18 
F08 MRE11A Hs.192649 NM_005590 1.04 
F09 NBN Hs.492208 NM_002485 3.42 
F10 RAD1 Hs.531879 NM_002853 2.29 
F11 RAD17 Hs.16184 NM_002873 3.3 
F12 RAD51 Hs.631709 NM_002875 1.15 
G01 RAD9A Hs.655354 NM_004584 1.41 
G02 RB1 Hs.408528 NM_000321 -1.05 
G03 RBBP8 Hs.546282 NM_002894 1.13 
G04 RBL1 Hs.207745 NM_002895 -3.52 
G05 RBL2 Hs.513609 NM_005611 1.3 
G06 SERTAD1 Hs.269898 NM_013376 2.76 
G07 SKP2 Hs.23348 NM_005983 2.21 
G08 STMN1 Hs.209983 NM_005563 -1.08 
G09 TFDP1 Hs.79353 NM_007111 1.03 
G10 TFDP2 Hs.379018 NM_006286 -1.36 
G11 TP53 Hs.654481 NM_000546 1.02 
G12 WEE1 Hs.249441 NM_003390 1.12 
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Figure C5.3: The heat map (left) denoting changes in GE in 13µM EFV treated A549 cells 
relative to untreated. A549 cells. The ±2.547 up/down-regulation indicates the lowest and 
highest fold changes. The green, red and grey range indicators represent under-expressed, 
over-expressed and non-detected genes, respectively 
The scatter plot (right) representing GE in 13µM EFV treated A549 cells. Unchanged gene 
expression remains across the solid line in the middle, while the up-regulated and the down-
regulated genes fall above (up) and below (down) the dotted lines. Fewer genes are shown to 
be down-regulated in this scatter plot.   
 
 
Table C5.4: Gene expression fold changes in MRC-5 cells treated with LPV/r 
Position Gene Symbol UniGene GenBank Fold Change 
A01 ABL1 Hs.431048 NM_005157 -2.53 
A02 ANAPC2 Hs.533262 NM_013366 -10.78 
A03 ATM Hs.367437 NM_000051 1.06 
A04 ATR Hs.271791 NM_001184 -1.1 
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A05 AURKA Hs.250822 NM_003600 -12.82 
A06 AURKB Hs.442658 NM_004217 -11.96 
A07 BCCIP Hs.370292 NM_016567 -1.49 
A08 BCL2 Hs.150749 NM_000633 1.79 
A09 BIRC5 Hs.728893 NM_001168 -20.68 
A10 BRCA1 Hs.194143 NM_007294 -3.03 
A11 BRCA2 Hs.34012 NM_000059 -1.21 
A12 CASP3 Hs.141125 NM_004346 -4.29 
B01 CCNA2 Hs.58974 NM_001237 -17.15 
B02 CCNB1 Hs.23960 NM_031966 -21.41 
B03 CCNB2 Hs.194698 NM_004701 -17.75 
B04 CCNC Hs.430646 NM_005190 1.1 
B05 CCND1 Hs.523852 NM_053056 -8.82 
B06 CCND2 Hs.376071 NM_001759 -2.77 
B07 CCND3 Hs.534307 NM_001760 -8.22 
B08 CCNE1 Hs.244723 NM_001238 -2.83 
B09 CCNF Hs.1973 NM_001761 -14.52 
B10 CCNG1 Hs.79101 NM_004060 -3.61 
B11 CCNG2 Hs.13291 NM_004354 -2.04 
B12 CCNH Hs.292524 NM_001239 1.11 
C01 CCNT1 Hs.279906 NM_001240 -1.91 
C02 CDC16 Hs.374127 NM_003903 -2.19 
C03 CDC20 Hs.524947 NM_001255 -95.67 
C04 CDC25A Hs.437705 NM_001789 -3.73 
C05 CDC25C Hs.656 NM_001790 -14.32 
C06 CDC34 Hs.514997 NM_004359 -2.22 
C07 CDC6 Hs.405958 NM_001254 1.51 
C08 CDK1 Hs.334562 NM_001786 -27.1 
C09 CDK2 Hs.19192 NM_001798 -24.25 
C10 CDK4 Hs.95577 NM_000075 -1.52 
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C11 CDK5R1 Hs.500015 NM_003885 1.09 
C12 CDK5RAP1 Hs.435952 NM_016408 -4.41 
D01 CDK6 Hs.119882 NM_001259 -3.23 
D02 CDK7 Hs.184298 NM_001799 -1.99 
D03 CDK8 Hs.382306 NM_001260 -2.08 
D04 CDKN1A Hs.370771 NM_000389 -1.11 
D05 CDKN1B Hs.238990 NM_004064 -2.71 
D06 CDKN2A Hs.512599 NM_000077 -2.66 
D07 CDKN2B Hs.72901 NM_004936 5.17 
D08 CDKN3 Hs.84113 NM_005192 -10.13 
D09 CHEK1 Hs.24529 NM_001274 -3.68 
D10 CHEK2 Hs.291363 NM_007194 -3.46 
D11 CKS1B Hs.374378 NM_001826 -5.66 
D12 CKS2 Hs.83758 NM_001827 -5.58 
E01 CUL1 Hs.146806 NM_003592 1.09 
E02 CUL2 Hs.82919 NM_003591 -1.58 
E03 CUL3 Hs.372286 NM_003590 1.01 
E04 E2F1 Hs.654393 NM_005225 -4.17 
E05 E2F4 Hs.108371 NM_001950 -3.18 
E06 GADD45A Hs.80409 NM_001924 -1.02 
E07 GTSE1 Hs.386189 NM_016426 34.3 
E08 HUS1 Hs.152983 NM_004507 -2.23 
E09 KNTC1 Hs.300559 NM_014708 -3.73 
E10 KPNA2 Hs.594238 NM_002266 -12.73 
E11 MAD2L1 Hs.591697 NM_002358 -9.71 
E12 MAD2L2 Hs.19400 NM_006341 -9.71 
F01 MCM2 Hs.477481 NM_004526 -40.79 
F02 MCM3 Hs.179565 NM_002388 -14.32 
F03 MCM4 Hs.460184 NM_005914 -9.06 
F04 MCM5 Hs.517582 NM_006739 -12.3 
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F05 MDM2 Hs.484551 NM_002392 1.26 
F06 MKI67 Hs.689823 NM_002417 -27.28 
F07 MNAT1 Hs.509523 NM_002431 -2.28 
F08 MRE11A Hs.192649 NM_005590 -3.84 
F09 NBN Hs.492208 NM_002485 -1.09 
F10 RAD1 Hs.531879 NM_002853 -2.33 
F11 RAD17 Hs.16184 NM_002873 -1.21 
F12 RAD51 Hs.631709 NM_002875 -11.08 
G01 RAD9A Hs.655354 NM_004584 -2.22 
G02 RB1 Hs.408528 NM_000321 -1.96 
G03 RBBP8 Hs.546282 NM_002894 1.12 
G04 RBL1 Hs.207745 NM_002895 -3.48 
G05 RBL2 Hs.513609 NM_005611 -1.08 
G06 SERTAD1 Hs.269898 NM_013376 -10.78 
G07 SKP2 Hs.23348 NM_005983 -9.38 
G08 STMN1 Hs.209983 NM_005563 -18 
G09 TFDP1 Hs.79353 NM_007111 -5.94 
G10 TFDP2 Hs.379018 NM_006286 -2.75 
G11 TP53 Hs.654481 NM_000546 1.26 
G12 WEE1 Hs.249441 NM_003390 -3.36 
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Figure C5.4: The heat map (left) illustrating GE in 32µM LPV/r treated MRC-5 cells relative 
to untreated MRC5 cells. The log2 value of ±6.58 represents the minimum and the maximum 
fold changes. The abundance of green blocks indicates the under-expression of most of the 
genes in response to LPV/r, across the array.  
The scatter plot (right) demonstrating GE in 32µM LPV/r treated MRC-5 cells, compared to 
untreated MRC-5 cells. As reflected in the heat map above, most genes are down-regulated, 
with data points occurring below the dotted line on the lower right. Genes with unaltered 
expression are plotted on the solid line in the middle. The dotted lines (upper and lower) 
represent the ±2 cut-off for the significantly up/down-regulated genes 
Table C5.5: Gene expression fold changes in A549 cells treated with LPV/r  
Position Gene Symbol UniGene GenBank Fold Change 
A01 ABL1 Hs.431048 NM_005157 -1 
A02 ANAPC2 Hs.533262 NM_013366 1 
A03 ATM Hs.367437 NM_000051 4.1 
A04 ATR Hs.271791 NM_001184 1.9 
A05 AURKA Hs.250822 NM_003600 -3.74 
A06 AURKB Hs.442658 NM_004217 -13.3 
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A07 BCCIP Hs.370292 NM_016567 2.63 
A08 BCL2 Hs.150749 NM_000633 10.38 
A09 BIRC5 Hs.728893 NM_001168 -6.34 
A10 BRCA1 Hs.194143 NM_007294 -1.54 
A11 BRCA2 Hs.34012 NM_000059 -4.18 
A12 CASP3 Hs.141125 NM_004346 2.34 
B01 CCNA2 Hs.58974 NM_001237 -23 
B02 CCNB1 Hs.23960 NM_031966 -45.69 
B03 CCNB2 Hs.194698 NM_004701 -44.13 
B04 CCNC Hs.430646 NM_005190 1.12 
B05 CCND1 Hs.523852 NM_053056 1.17 
B06 CCND2 Hs.376071 NM_001759 2.18 
B07 CCND3 Hs.534307 NM_001760 -8.02 
B08 CCNE1 Hs.244723 NM_001238 -3 
B09 CCNF Hs.1973 NM_001761 -6.61 
B10 CCNG1 Hs.79101 NM_004060 2.42 
B11 CCNG2 Hs.13291 NM_004354 3.55 
B12 CCNH Hs.292524 NM_001239 4.71 
C01 CCNT1 Hs.279906 NM_001240 2.52 
C02 CDC16 Hs.374127 NM_003903 1.98 
C03 CDC20 Hs.524947 NM_001255 -13.03 
C04 CDC25A Hs.437705 NM_001789 -3.47 
C05 CDC25C Hs.656 NM_001790 -36.6 
C06 CDC34 Hs.514997 NM_004359 1.31 
C07 CDC6 Hs.405958 NM_001254 -4.94 
C08 CDK1 Hs.334562 NM_001786 -20.31 
C09 CDK2 Hs.19192 NM_001798 -3.96 
C10 CDK4 Hs.95577 NM_000075 3.17 
C11 CDK5R1 Hs.500015 NM_003885 -1.07 
C12 CDK5RAP1 Hs.435952 NM_016408 4.52 
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D01 CDK6 Hs.119882 NM_001259 1.16 
D02 CDK7 Hs.184298 NM_001799 1.61 
D03 CDK8 Hs.382306 NM_001260 1.62 
D04 CDKN1A Hs.370771 NM_000389 3.15 
D05 CDKN1B Hs.238990 NM_004064 3.13 
D06 CDKN2A Hs.512599 NM_000077 3.24 
D07 CDKN2B Hs.72901 NM_004936 1.11 
D08 CDKN3 Hs.84113 NM_005192 -9.34 
D09 CHEK1 Hs.24529 NM_001274 -2.61 
D10 CHEK2 Hs.291363 NM_007194 -4.61 
D11 CKS1B Hs.374378 NM_001826 -1.5 
D12 CKS2 Hs.83758 NM_001827 -3.85 
E01 CUL1 Hs.146806 NM_003592 1.7 
E02 CUL2 Hs.82919 NM_003591 4.1 
E03 CUL3 Hs.372286 NM_003590 3.13 
E04 E2F1 Hs.654393 NM_005225 -14.97 
E05 E2F4 Hs.108371 NM_001950 1.99 
E06 GADD45A Hs.80409 NM_001924 40.12 
E07 GTSE1 Hs.386189 NM_016426 -47.3 
E08 HUS1 Hs.152983 NM_004507 23.36 
E09 KNTC1 Hs.300559 NM_014708 -4.24 
E10 KPNA2 Hs.594238 NM_002266 -1.52 
E11 MAD2L1 Hs.591697 NM_002358 -9.34 
E12 MAD2L2 Hs.19400 NM_006341 -4.84 
F01 MCM2 Hs.477481 NM_004526 -5.22 
F02 MCM3 Hs.179565 NM_002388 -4.61 
F03 MCM4 Hs.460184 NM_005914 -15.93 
F04 MCM5 Hs.517582 NM_006739 -14.66 
F05 MDM2 Hs.484551 NM_002392 1.59 
F06 MKI67 Hs.689823 NM_002417 -13.12 
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F07 MNAT1 Hs.509523 NM_002431 -1.78 
F08 MRE11A Hs.192649 NM_005590 -1.25 
F09 NBN Hs.492208 NM_002485 1.81 
F10 RAD1 Hs.531879 NM_002853 3.26 
F11 RAD17 Hs.16184 NM_002873 5.45 
F12 RAD51 Hs.631709 NM_002875 -6.61 
G01 RAD9A Hs.655354 NM_004584 -1.03 
G02 RB1 Hs.408528 NM_000321 1.59 
G03 RBBP8 Hs.546282 NM_002894 1.87 
G04 RBL1 Hs.207745 NM_002895 -2.8 
G05 RBL2 Hs.513609 NM_005611 2.88 
G06 SERTAD1 Hs.269898 NM_013376 3.4 
G07 SKP2 Hs.23348 NM_005983 -1.25 
G08 STMN1 Hs.209983 NM_005563 -15.71 
G09 TFDP1 Hs.79353 NM_007111 1.1 
G10 TFDP2 Hs.379018 NM_006286 -1.09 
G11 TP53 Hs.654481 NM_000546 3.4 
G12 WEE1 Hs.249441 NM_003390 -1.41 
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Figure C5.5: The heat map (left) denoting GE in 32µM LPV/r treated A549 cells vs untreated 
A549 cells. Undetectable genes are/is in the grey blocks, while green and red blocks denote 
down and up-regulated genes, respectively. The log2 value of ±5.564 represents the fold 
change magnitude.   
The scatter plot (right) illustrating GE in 32µM LPV/r treated A549 cells relative to untreated 
A549 cells. Genes’ whose expression remains unchanged are located on the solid middle line, 
while up and down-regulated genes are positioned above and below the upper and lower 
dotted lines, which represent the ±2 fold cut-off in expression levels.  
 
C6) RT-qPCR appendices 
Table C6.1: The descriptive details of the selected target genes.  
Gene symbol Description Accession number 
(GenBank) 
1. MAD2L2 MAD2 mitotic arrest 
deficient-like 2 (yeast) 
NM_006341 
2. CASP3 Caspase 3, apoptosis-related NM_004346 
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cysteine peptidase 
3. AURKB Aurora kinase B NM_004217 
4. GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
NM_002046  
 
In this study, all four genes (three targets and one HKG control) were profiled on 12 cDNA 
samples, MRC-5: 0.1% methanol at 24h and 48h, 13µM EFV treatment at 24h and 48h, 32µM 
LPV/r at 24h and 48h. The same was done for A549 cells.   
 
 
Figure C6.1: MAD2L2 PCR products. MAD2L2 inserts represented in lanes 3-6, run 
parallel to a 100bp molecular weight marker in lane 1. 
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Figure C6.2: CASP3 PCR products. CASP3 PCR products illustrated in lanes 3-5, run in 
parallel to a 100bp molecular weight marker in lane1.  
 
 
Figure C6.3: AURKB PCR products. AURKB amplicons as shown in lanes 3-5, run parallel 
to a 100bp molecular weight marker in lane1.  
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Figure C6.4: GAPDH PCR products. GAPDH PCR products as demonstrated in lanes 3-6, 
run parallel to a 100bp molecular weight marker in lane 1.  
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Figure C6.5: The Melt curves of target genes. Single peaks show primer specificity, with 
MAD2L2 (84.2 °C), CASP3 (85.7 °C), AURKB (81.4 °C) and GAPDH (81 °C) melting 
temperatures. No template controls lack any amplification peaks.  
 
RM. Marima: PhD Thesis 
215 
 
 
Figure C6.6: Target gene expression level in fold change in untreated A549 vs MRC-5 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in cancer vs normal 
cells at 24h and 48h 
 
Figure C6.7: Target gene expression level in fold change in untreated A549 vs MRC-5 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in cancer vs normal 
cells at 24h and 48h.   
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Figure C6.8: Target gene expression level in fold change in EFV treated MRC-5 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in EFV treated vs 
untreated cells at 24h and 48h.   
 
Figure C6.9: Target gene expression level in fold change in EFV treated MRC-5 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in EFV treated vs 
untreated cells at 24h and 48h.   
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Figure C6.10: Target gene expression level in fold change in EFV treated A549 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in EFV treated vs 
untreated cells at 24h and 48h.   
 
 
Figure C6.11: Target gene expression level in fold change in EFV treated A549 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in EFV treated vs 
untreated cells at 24h and 48h.   
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Figure C6.12: Target gene expression level in fold change in LPV/r treated MRC-5 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in LPV/r treated vs 
untreated cells at 24h and 48h.   
 
Figure C6.13: Target gene expression level in fold change in LPV/r treated MRC-5 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in LPV/r treated vs 
untreated cells at 24h and 48h.   
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Figure C6.14: Target gene expression level in fold change in LPV/r treated A549 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in LPV/r treated vs 
untreated cells at 24h and 48h. 
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Figure C6.15: Target gene expression level in fold change in LPV/r treated A549 cells. 
MAD2L2, CASP3 and AURKB gene expression levels were determined in LPV/r treated vs 
untreated cells at 24h and 48h. 
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